Multivalent degraders

Multivalent PROTACs targeting multiple E3 ligases effectively degrade BET proteins, addressing resistance issues and enhancing anti-tumor activity by optimizing linker designs and attachment vectors for specific protein targeting.

WO2024241046A1PCT designated stage expired Publication Date: 2024-11-28UNIVERSITY OF DUNDEE

Patent Information

Application Number
PCT/GB2024/051314
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-22
Filing Date
2024-05-21
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Current PROTAC degraders face challenges in efficiently targeting BET family proteins due to resistance mechanisms, such as dysregulation of the ubiquitin proteasome system, and competition for binding sites, leading to reduced anti-tumor activity.

Method used

Development of multivalent PROTACs that simultaneously target multiple E3 ligases, specifically heterotrivalent and heterotetravalent designs that incorporate different E3 ligase ligands and a BET protein warhead, optimizing linker lengths and attachment vectors to minimize off-target degradation and enhance specificity.

Benefits of technology

The multivalent PROTACs demonstrate potent and selective degradation of BET proteins, maintaining a high selectivity window over off-target E3 ligases, thereby overcoming resistance mechanisms and improving anti-tumor efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure GB2024051314_28112024_PF_FP_ABST
    Figure GB2024051314_28112024_PF_FP_ABST
Patent Text Reader

Abstract

This invention particularly relates to hetero-multivalent PROTACs of formula (I) as described herein which bind to a protein within the Bromo- and Extra-Terminal (BET) family of proteins, and especially to hetero-multivalent PROTACs including different small molecule E3 ubiquitin ligase protein binding ligand compounds, which induce degradation of the BRD2, BRD3 and BRD4 proteins within the bromodomain of the BET family of proteins. (Formula (I).
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Multivalent Degraders

[0002] Field of the Invention

[0003] This invention relates to novel small molecule Proteolysis Targeted Chimeras (PROTACs) that induce proximity between two different E3 ubiquitin ligase proteins and their target protein of interest. This invention particularly relates to hete rotrival ent and heterotetravalent PROTACs which bind to a protein within the Bromo- and Extra-Terminal (BET) family of proteins, and especially to PROTACs including small molecule E3 ubiquitin ligase protein binding ligand compounds which induce degradation of the BRD2, BRD3 and BRD4 protein within the bromodomain of the BET family of proteins.

[0004] Background of the Invention

[0005] Targeted degradation compounds, conventionally classified as either PROTACs or molecular glues depending on whether bivalent or monovalent for binding, have shown great promise as a new class of chemical probes to study biology and therapeutics for treatment of disease1.

[0006] Degraders form a ternary complex, bringing together the target protein and an E3 ubiquitin ligase component, resulting in ubiquitination and subsequent degradation of the target protein via the proteasome.

[0007] PROTACs are traditionally conceived as bifunctional, i.e. composed of two ligands joined by a linker, and as a result can engage the target or E3 component separately in binary complexes, or both target and E3 component simultaneously to form a ternary complex. This design feature allows PROTACs a wide target scope and the ability to standardize design with the use of established E3 ligase binders. Indeed, potent PROTAC degraders have been developed to most commonly recruit either the von Hippel-Lindau (VHL) or cereblon (CRBN) E3 ligase against a wide spectrum of protein targets including nuclear, and cytoplasmic.

[0008] One of the main advantages presented by PROTAC degraders over inhibitors is their event-driven mode of action (MOA), whereby PROTACs initiate the catalytic cascade of ternary complex formation, ubiquitination and subsequent proteasomal degradation of a protein target. This offers an alternative to the occupancy-driven pharmacology presented by small molecule inhibitors, historically developed for high affinity inhibition of an active or allosteric site on a particular protein drug target, to block the protein’s function.1 3Although this is an effective strategy in drug discovery, occupancy-based therapeutic strategies may require high treatment concentrations to elicit a desired effect in vivo,4increasing the risk of off-target effects and drug resistance.5The event-driven MOA of PROTACs means that they do not require the inhibition of an active site on a protein to elicit a pharmacological effect, allowing forthe removal altogether of the target protein, including previously undrugged or “undruggable” proteins.6 Due to their complex mode of action via the ternary complex, PROTACs have shown unexpected advantages compared to the inhibitors they are composed. For example, PROTACs can discriminate amongst highly homologues targets, and can exhibit much greater potencies than expected, due to a catalytic mechanism of action, which can compensate for low binary binding affinities or poor cellular permeability, and allow for use of weak, non-functional inhibitors to serve as warhead ligands.

[0009] Furthermore, PROTACs can impact proteins in complexes even though not directly engaged by the degrader via either bystander ubiquitination or destabilization. Despite the aforementioned advantages and remarkable successes demonstrated, it can be challenging to design PROTACs efficiently, often requiring extensive chemical optimization.

[0010] Drug resistance mechanisms of small molecule inhibitors in cancers involve multiple mechanisms: for example, drug inactivation, decreasing the amount of free drug available through metabolism; alterations to the drug target, including changes in protein expression level or mutations; and drug efflux, for instance driven by overexpression of transmembrane transporter proteins such as multi-drug resistant protein 1 (MDR1).5 7PROTACs can offer an alternative strategy and help to overcome some of these resistance mechanisms. Their catalytic MOA can counteract mechanisms involving overexpression of the target, providing that the rate of degradation is faster than the rate of protein synthesis.8Typically missense resistance mutations that develop for inhibitor-based drugs involve mutations that weaken ligand binding in such a way that it is no longer possible to maintain an effective drug concentration to achieve the same level of target occupancy as in the case of wild-type / non- resistance tumours.9’10This is not the same for PROTAC degraders due to them being able to compensate and overcome significant losses in binary binding affinity, and still effectively and efficiently degrade the target protein for which the binding affinity has been weakened, through ternary complex stability and enhanced PPIs.11 15

[0011] Although PROTACs can offer a potential solution to the drug resistance presented by traditional small molecule inhibitors, there is growing evidence that cancer cells still find ways to be resistant to PROTAC degraders after extended treatment. For instance, recent studies have shown that after prolonged treatment of several BET-targeting degraders in cancer cell lines, instead of more conventional resistant mechanisms of mutations of the target protein, PROTAC induced resistance occurred via dysregulation of components of the ubiquitin proteasome system, including the hijacked E3 ligand machinery.9’16 19Resistance to different CRBN-recruiting PROTACs was a result from the loss of activity and expression of the gene encoding for CRBN and the E2 ubiquitin conjugating enzyme, UBE2G1.16’17’19Moreover, resistance to different VHL-recruiting PROTACs was a result from the loss of the VHL E3 ligase scaffolding protein CUL2.16’17’19Interestingly, Shirasaki and colleagues found that when sequentially or simultaneously treating cancer cells with CRBN-based BET-degrader, dBET6,20and then with VHL- based BET-degraders MZ121or ARV-771 ,22there was a lack in cross resistance. However, simultaneous treatment led to an attenuation in the anti-tumour activity of the compounds, potentially contributed by each degrader competing for the same BET protein binding site.17 The finding that there was a lack of resistance when simultaneously or sequentially treating with degraders which target the same oncoproteins, but recruit different E3 ligases, is an encouraging outcome and motivates the discovery of new PROTACs which target new E3 ligases.

[0012] It is an object of the present invention to mitigate or address at least some of these problems and to find alternative multivalent PROTACs which target more than one E3 ligase at the same time.

[0013] Summary of the Invention

[0014] In a first aspect of the invention, there is provided a compound of formula (I) : wherein m, n and o are each independently selected from 0, 1 , 2, 3, 4, 5 and 6; wherein R is selected from H, Me; wherein G is selected from H, Me; wherein W is selected from wherein X is selected from wherein Z is selected from H, F; wherein Y is selected from -NH- and -O-; wherein U is selected from H, Me, Et, Pr, and iPr; wherein Ti and T2 are each independently selected from H and OH; and wherein X is attached to the thalidomide-derivative of the compound at the 3-C or 4-C position; or a pharmaceutically acceptable, salt, enantiomer, stereoisomer, hydrate, solvate, or polymorph thereof.

[0015] The compound of formula (I) , may have a formula (IA): wherein m, n and 0 are each independently selected from 0, 1 , 2, 3, 4, 5 and 6; wherein R is selected from H, Me; wherein W is selected from wherein X is selected from wherein Z is selected from H, F; wherein Y is selected from -NH- and-O-; wherein U is selected from H, Me, Et, Pr, and iPr; wherein Ti and T2 are each independently selected from H and OH; and wherein X is attached to the thalidomide-derivative of the compound at the 3-C or 4-C position; or a pharmaceutically acceptable, salt, enantiomer, stereoisomer, hydrate, solvate, or polymorph thereof.

[0016] In other words, in the compound of formula (I), G may be H.

[0017] The compound of formula (I) may have a formula (IB):

[0018] wherein m, and n are each independently selected from 0, 1 , 2, 3, 4, 5 and 6; wherein X is selected from wherein R is selected from wherein Z is selected from H and F; wherein Y is selected from -NH- and-O-; wherein U is selected from H, Me, Et, Pr, and iPr; wherein Ti and T2 are each independently selected from H and OH; and wherein X is attached to the thalidomide-derivative of the compound at the 3-C or 4-C position; or a pharmaceutically acceptable, salt, enantiomer, stereoisomer, hydrate, solvate, or polymorph thereof.

[0019] In other words, in the compound of Formula (I), W may be Me.

[0020] The compound of formula (I) may have a formula (IC):

[0021] wherein m, n and o are each independently selected from 0, 1 , 2, 3, 4, 5 and 6; wherein X is selected from wherein R is selected from H and Me; wherein Z is selected from H and F; wherein Y is selected from -NH- and-O-; wherein U is selected from H, Me, Et, Pr, and iPr; wherein Ti and T2 are each independently selected from H and OH; and wherein X is attached to the thalidomide-derivative of the compound at the 3-C or 4-C position; or a pharmaceutically acceptable, salt, enantiomer, stereoisomer, hydrate, solvate, or polymorph thereof.

[0022] In other words, in the compound of formula (I), W may

[0023] In the compound of formula (I), (IA), (IB), or (IC) as defined herein, X may be attached to the thalidomide-derivative of the compound at the 3-C position. In other embodiments, X may be attached to the thalidomide-derivative of the compound at the 4-C position. In the compound of formula (I), (IA), (IB), or (IC) as defined herein, m and n may each be independently selected from 2 or 3. For example, both m and n may be 3; or m may be 3 and n may be 2; or m may be 2 and n may be 3; or both m and n may be 2; or both m and n may be 1 ; or both m and n may be 3.

[0024] In some embodiments of the compound of formula (I), (IA), (IB), or (IC) as defined herein, Y may be- O-. In other embodiments of compound of formula (I), (IA), (IB), or (IC) as defined herein, Y may be - NH-. Preferably, Y may be-O-.

[0025] In some embodiments of the compound of formula (I), (IA), (IB), or (IC) as defined herein, R may be H, and in other embodiments R may be Me. Preferably, R may be H.

[0026] In some embodiments of the compound of formula (I), (IA), (IB) or (IC) as defined herein, X may be . , . ,

[0027] In some embodiments of the compound of formula (I), (IA), (IB), or (IC) as defined herein, Ti may be selected from H and OH. In some embodiments of the compound of formula (I), (IA), (IB), or (IC) as defined herein, T2 may be selected from H and OH. In preferred embodiments of the compound of formula (I), (IA), (IB), or (IC) as defined herein, T1 may be OH and T2 may be H.

[0028] In some embodiments of the compound of formula (I), (IA), (IB), or (IC) as defined herein, U may be selected from H, Me, Et, Pr, and iPr. In preferred embodiments of the compound of formula (I), (IA), (IB), or (IC) as defined herein, U may be selected from H and Et.

[0029] In some embodiments of the compounds of formula (I) or (IA) or (IC) in which W is may be selected from 2 or 3. Preferably, 0 may be 3.

[0030] Preferred compounds of formula (I), (IA), (IB) or (IC) as defined herein may be selected from:

[0031]

[0032]

[0033]

[0034]

[0035] or a pharmaceutically acceptable, salt, enantiomer, stereoisomer, hydrate, solvate, or polymorph thereof.

[0036] In otherwords, preferred compounds of formula (I), (IA), or (IB) as defined herein may be selected from:

[0037] (2S,4 / ?)-1-((20S)-20-(fert-butyl)-1-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-

[0038] / ][1 ,2,4]triazolo[4,3-a][1 ,4]diazepin-6-yl)-14-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxoisoindolin-4- yl)amino)ethoxy)ethoxy)ethoxy)methyl)-14-methyl-2,18-dioxo-6,9,12,16-tetraoxa-3,19- diazahenicosan-21-oyl)-4-hydroxy- / V-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide

[0039] (MN666) (1);

[0040] (2S,4 / ?)-1-((17S)-17-(fert-butyl)-1-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-

[0041] / ][1 ,2,4]triazolo[4,3-a][1 ,4]diazepin-6-yl)-11-((2-(2-((2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxoisoindolin-4- yl)amino)ethoxy)ethoxy)methyl)-11-methyl-2,15-dioxo-6,9,13-trioxa-3,16-diazaoctadecan-18-oyl)-4- hydroxy- / V-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (MN675) (2);

[0042] (17S)-11-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxoisoindolin-4- yl)amino)ethoxy)ethoxy)ethoxy)methyl)-17-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5- yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-1 1 ,18,18-trimethyl-15-oxo-3,6,9,13-tetraoxa-16- azanonadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f|[1 ,2,4]triazolo[4,3- a][1 ,4]diazepin-6-yl)acetate (AB3062) (23); (17S)-11-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxoisoindolin-4- yl)amino)ethoxy)ethoxy)ethoxy)methyl)-17-((2S,4 / ?)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5- yl)phenyl)ethyl)carbamoyl)pyrrolidine-1-carbonyl)-1 1 , 18,18-trimethyl-15-oxo-3, 6,9,13-tetraoxa-16- azanonadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2- / ][1 ,2,4]triazolo[4,3- a][1 ,4]diazepin-6-yl)acetate (AB3066) (24);

[0043] (14S)-8-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxoisoindolin-4- yl)amino)ethoxy)ethoxy)ethoxy)methyl)-14-((2S,4 / ?)-4-hydroxy-2-((4-(4-methylthiazol-5- yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-8,15,15-trimethyl-12-oxo-3,6,10-trioxa-13-azahexadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2- / ][1 ,2,4]triazolo[4,3-a][1 ,4]diazepin-6-yl)acetate (AB3064) (25);

[0044] (17S)-11-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1 ,3-dioxoisoindolin-5- yl)amino)ethoxy)ethoxy)ethoxy)methyl)-17-((2S,4 / ?)-4-hydroxy-2-((4-(4-methylthiazol-5- yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-1 1 ,18,18-trimethyl-15-oxo-3,6,9,13-tetraoxa-16- azanonadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2- / ][1 ,2,4]triazolo[4,3- a][1 ,4]diazepin-6-yl)acetate (AB3063) (26);

[0045] (17S)-11 -((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1 ,3-dioxoisoindolin-5- yl)amino)ethoxy)ethoxy)ethoxy)methyl)-17-((2S,4 / ?)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5- yl)phenyl)ethyl)carbamoyl)pyrrolidine-1-carbonyl)-1 1 , 18,18-trimethyl-15-oxo-3, 6,9,13-tetraoxa-16- azanonadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2- / ][1 ,2,4]triazolo[4,3- a][1 ,4]diazepin-6-yl)acetate (AB3067) (27);

[0046] (14S)-8-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1 ,3-dioxoisoindolin-5- yl)amino)ethoxy)ethoxy)ethoxy)methyl)-14-((2S,4 / ?)-4-hydroxy-2-((4-(4-methylthiazol-5- yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-8,15,15-trimethyl-12-oxo-3,6,10-trioxa-13-azahexadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2- / ][1 ,2,4]triazolo[4,3-a][1 ,4]diazepin-6-yl)acetate

[0047] (AB3065) (28);

[0048] (17S)-11-((2-(2-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1 ,3-dioxoisoindolin-5- yl)amino)ethoxy)ethoxy)methyl)-17-((2S,4 / ?)-4-hydroxy-2-((4-(4-methylthiazol-5- yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-1 1 ,18,18-trimethyl-15-oxo-3,6,9,13-tetraoxa-16- azanonadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2- / ][1 ,2,4]triazolo[4,3- a][1 ,4]diazepin-6-yl)acetate (AB3126) (29);

[0049] (14S)-8-((2-(2-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1 ,3-dioxoisoindolin-5- yl)amino)ethoxy)ethoxy)methyl)-14-((2S,4 / ?)-4-hydroxy-2-((4-(4-methylthiazol-5- yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-8,15,15-trimethyl-12-oxo-3,6,10-trioxa-13-azahexadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2- / ][1 ,2,4]triazolo[4,3-a][1 ,4]diazepin-6-yl)acetate

[0050] (AB3125) (30);

[0051] (17S)-11-((2-(2-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxoisoindolin-4-yl)piperazin-1- yl)ethoxy)ethoxy)ethoxy)methyl)-17-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5- yl)benzyl)carbamoyl)pyrrolidine-1 -carbonyl)-1 1 ,18,18-trimethyl-15-oxo-3,6,9,13-tetraoxa-16- azanonadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f|[1 ,2,4]triazolo[4,3- a][1 ,4]diazepin-6-yl)acetate (AB3029) (106) (31);

[0052] (17S)-11-((2-(2-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1 ,3-dioxoisoindolin-5-yl)piperazin-1- yl)ethoxy)ethoxy)ethoxy)methyl)-17-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5- yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-1 1 ,18,18-trimethyl-15-oxo-3,6,9,13-tetraoxa-16- azanonadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f|[1 ,2,4]triazolo[4,3- a][1 ,4]diazepin-6-yl)acetate (AB3030) (32);

[0053] 11-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1 ,3-dioxoisoindolin-5- yl)amino)ethoxy)ethoxy)ethoxy)methyl)-11-((2-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5- yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)methyl)- 3,6,9, 13,16, 19-hexaoxahenicosane-1 ,21 -diyl bis(2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H- thieno[3,2- / ][1 ,2,4]triazolo[4,3-a][1 ,4]diazepin-6-yl)acetate) (AB3124) (86);

[0054] (17S)-11-((2-(2-(2-((6-fluoro-2-(1-methyl-2,6-dioxopiperidin-3-yl)-1 ,3-dioxoisoindolin-5- yl)amino)ethoxy)ethoxy)ethoxy)methyl)-17-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5- yl)phenyl)ethyl)carbamoyl)pyrrolidine-1-carbonyl)-1 1 , 18,18-trimethyl-15-oxo-3, 6,9,13-tetraoxa-16- azanonadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f|[1 ,2,4]triazolo[4,3- a][1 ,4]diazepin-6-yl)acetate (neg-AB3067) (93);

[0055] (17S)-11-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1 ,3-dioxoisoindolin-5- yl)amino)ethoxy)ethoxy)ethoxy)methyl)-17-((2S,4S)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5- yl)phenyl)ethyl)carbamoyl)pyrrolidine-1-carbonyl)-1 1 , 18,18-trimethyl-15-oxo-3, 6,9,13-tetraoxa-16- azanonadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f|[1 ,2,4]triazolo[4,3- a][1 ,4]diazepin-6-yl)acetate (C / S-AB3067) (94);

[0056] (17S)-11-((2-(2-(2-((6-fluoro-2-(1-methyl-2,6-dioxopiperidin-3-yl)-1 ,3-dioxoisoindolin-5- yl)amino)ethoxy)ethoxy)ethoxy)methyl)-17-((2S,4S)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5- yl)phenyl)ethyl)carbamoyl)pyrrolidine-1-carbonyl)-1 1 , 18,18-trimethyl-15-oxo-3, 6,9,13-tetraoxa-16- azanonadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f|[1 ,2,4]triazolo[4,3- a][1 ,4]diazepin-6-yl)acetate (neg-c / s-AB3067) (95);

[0057] (17S)-11-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1 ,3-dioxoisoindolin-5- yl)amino)ethoxy)ethoxy)ethoxy)methyl)-17-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5- yl)phenyl)ethyl)carbamoyl)pyrrolidine-1-carbonyl)-1 1 , 18,18-trimethyl-15-oxo-3, 6,9,13-tetraoxa-16- azanonadecyl (2R)-2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f|[1 ,2,4]triazolo[4,3- a][1 ,4]diazepin-6-yl)butanoate (AB3145) (97). or a pharmaceutically acceptable, salt, enantiomer, stereoisomer, hydrate, solvate, or polymorph thereof.

[0058] Further preferred compounds of formula (I), (IA), (IB), or (IC) as defined herein may be selected from:

[0059]

[0060] or a pharmaceutically acceptable, salt, enantiomer, stereoisomer, hydrate, solvate, or polymorph thereof.

[0061] In other words, further preferred compounds of formula (I), (IA), (IB), or (IC) as defined herein may be selected from:

[0062] (2S,4 / ?)-1-((20S)-20-(fert-butyl)-1-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-

[0063] / ][1 ,2,4]triazolo[4,3-a][1 ,4]diazepin-6-yl)-14-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxoisoindolin-4- yl)amino)ethoxy)ethoxy)ethoxy)methyl)-14-methyl-2,18-dioxo-6,9,12,16-tetraoxa-3,19- diazahenicosan-21-oyl)-4-hydroxy- / V-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide

[0064] (MN666) (1);

[0065] (2S,4 / ?)-1-((17S)-17-(fert-butyl)-1-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-

[0066] / ][1 ,2,4]triazolo[4,3-a][1 ,4]diazepin-6-yl)-11-((2-(2-((2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxoisoindolin-4- yl)amino)ethoxy)ethoxy)methyl)-11-methyl-2,15-dioxo-6,9,13-trioxa-3,16-diazaoctadecan-18-oyl)-4- hydroxy- / V-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (MN675) (2);

[0067] (17S)-11-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxoisoindolin-4- yl)amino)ethoxy)ethoxy)ethoxy)methyl)-17-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5- yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-11 ,18,18-trimethyl-15-oxo-3,6,9,13-tetraoxa-16- azanonadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f|[1 ,2,4]triazolo[4,3- a][1 ,4]diazepin-6-yl)acetate (AB3062) (23); (17S)-11-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxoisoindolin-4- yl)amino)ethoxy)ethoxy)ethoxy)methyl)-17-((2S,4 / ?)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5- yl)phenyl)ethyl)carbamoyl)pyrrolidine-1-carbonyl)-1 1 , 18,18-trimethyl-15-oxo-3, 6,9,13-tetraoxa-16- azanonadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2- / ][1 ,2,4]triazolo[4,3- a][1 ,4]diazepin-6-yl)acetate (AB3066) (24);

[0068] (14S)-8-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxoisoindolin-4- yl)amino)ethoxy)ethoxy)ethoxy)methyl)-14-((2S,4 / ?)-4-hydroxy-2-((4-(4-methylthiazol-5- yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-8,15,15-trimethyl-12-oxo-3,6,10-trioxa-13-azahexadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2- / ][1 ,2,4]triazolo[4,3-a][1 ,4]diazepin-6-yl)acetate (AB3064) (25);

[0069] (17S)-11-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1 ,3-dioxoisoindolin-5- yl)amino)ethoxy)ethoxy)ethoxy)methyl)-17-((2S,4 / ?)-4-hydroxy-2-((4-(4-methylthiazol-5- yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-1 1 ,18,18-trimethyl-15-oxo-3,6,9,13-tetraoxa-16- azanonadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2- / ][1 ,2,4]triazolo[4,3- a][1 ,4]diazepin-6-yl)acetate (AB3063) (26);

[0070] (17S)-11 -((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1 ,3-dioxoisoindolin-5- yl)amino)ethoxy)ethoxy)ethoxy)methyl)-17-((2S,4 / ?)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5- yl)phenyl)ethyl)carbamoyl)pyrrolidine-1-carbonyl)-1 1 , 18,18-trimethyl-15-oxo-3, 6,9,13-tetraoxa-16- azanonadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2- / ][1 ,2,4]triazolo[4,3- a][1 ,4]diazepin-6-yl)acetate (AB3067) (27);

[0071] (14S)-8-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1 ,3-dioxoisoindolin-5- yl)amino)ethoxy)ethoxy)ethoxy)methyl)-14-((2S,4 / ?)-4-hydroxy-2-((4-(4-methylthiazol-5- yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-8,15,15-trimethyl-12-oxo-3,6,10-trioxa-13-azahexadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2- / ][1 ,2,4]triazolo[4,3-a][1 ,4]diazepin-6-yl)acetate

[0072] (AB3065) (28);

[0073] (17S)-11-((2-(2-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1 ,3-dioxoisoindolin-5- yl)amino)ethoxy)ethoxy)methyl)-17-((2S,4 / ?)-4-hydroxy-2-((4-(4-methylthiazol-5- yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-1 1 ,18,18-trimethyl-15-oxo-3,6,9,13-tetraoxa-16- azanonadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2- / ][1 ,2,4]triazolo[4,3- a][1 ,4]diazepin-6-yl)acetate (AB3126) (29);

[0074] (14S)-8-((2-(2-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1 ,3-dioxoisoindolin-5- yl)amino)ethoxy)ethoxy)methyl)-14-((2S,4 / ?)-4-hydroxy-2-((4-(4-methylthiazol-5- yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-8,15,15-trimethyl-12-oxo-3,6,10-trioxa-13-azahexadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2- / ][1 ,2,4]triazolo[4,3-a][1 ,4]diazepin-6-yl)acetate

[0075] (AB3125) (30);

[0076] (17S)-11-((2-(2-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxoisoindolin-4-yl)piperazin-1- yl)ethoxy)ethoxy)ethoxy)methyl)-17-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5- yl)benzyl)carbamoyl)pyrrolidine-1 -carbonyl)-1 1 ,18,18-trimethyl-15-oxo-3,6,9,13-tetraoxa-16- azanonadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f|[1 ,2,4]triazolo[4,3- a][1 ,4]diazepin-6-yl)acetate (AB3029) (31);

[0077] (17S)-11-((2-(2-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1 ,3-dioxoisoindolin-5-yl)piperazin-1- yl)ethoxy)ethoxy)ethoxy)methyl)-17-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5- yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-1 1 ,18,18-trimethyl-15-oxo-3,6,9,13-tetraoxa-16- azanonadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f|[1 ,2,4]triazolo[4,3- a][1 ,4]diazepin-6-yl)acetate (AB3030) (32);

[0078] 11-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1 ,3-dioxoisoindolin-5- yl)amino)ethoxy)ethoxy)ethoxy)methyl)-11-((2-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5- yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)methyl)-

[0079] 3,6,9, 13,16, 19-hexaoxahenicosane-1 ,21 -diyl bis(2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H- thieno[3,2- / ][1 ,2,4]triazolo[4,3-a][1 ,4]diazepin-6-yl)acetate) (AB3124) (86);

[0080] (17S)-11-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1 ,3-dioxoisoindolin-5- yl)amino)ethoxy)ethoxy)ethoxy)methyl)-17-((2S,4S)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5- yl)phenyl)ethyl)carbamoyl)pyrrolidine-1-carbonyl)-1 1 , 18,18-trimethyl-15-oxo-3, 6,9,13-tetraoxa-16- azanonadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f|[1 ,2,4]triazolo[4,3- a][1 ,4]diazepin-6-yl)acetate (C / S-AB3067) (94);

[0081] (17S)-11-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1 ,3-dioxoisoindolin-5- yl)amino)ethoxy)ethoxy)ethoxy)methyl)-17-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5- yl)phenyl)ethyl)carbamoyl)pyrrolidine-1-carbonyl)-1 1 , 18,18-trimethyl-15-oxo-3, 6,9,13-tetraoxa-16- azanonadecyl (2R)-2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f|[1 ,2,4]triazolo[4,3- a][1 ,4]diazepin-6-yl)butanoate (AB3145) (97). or a pharmaceutically acceptable, salt, enantiomer, stereoisomer, hydrate, solvate, or polymorph thereof.

[0082] Even further preferred compounds of formula (I), (IA), (IB), or (IC) as defined herein may be selected from:

[0083] or a pharmaceutically acceptable, salt, enantiomer, stereoisomer, hydrate, solvate, or polymorph thereof.

[0084] In otherwords, even further preferred compounds of formula (I), (IA), (IB) or (IC) as defined herein may be selected from:

[0085] 11-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1 ,3-dioxoisoindolin-5- yl)amino)ethoxy)ethoxy)ethoxy)methyl)-11-((2-(((S)-1-((2S,4 / ?)-4-hydroxy-2-((4-(4-methylthiazol-5- yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)methyl)-

[0086] 3,6,9, 13,16, 19-hexaoxahenicosane-1 ,21 -diyl bis(2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H- thieno[3,2-f|[1 ,2,4]triazolo[4,3-a][1 ,4]diazepin-6-yl)acetate) (AB3124) (86);

[0087] (17S)-11 -((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1 ,3-dioxoisoindolin-5- yl)amino)ethoxy)ethoxy)ethoxy)methyl)-17-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5- yl)phenyl)ethyl)carbamoyl)pyrrolidine-1-carbonyl)-1 1 , 18,18-trimethyl-15-oxo-3, 6,9,13-tetraoxa-16- azanonadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f|[1 ,2,4]triazolo[4,3- a][1 ,4]diazepin-6-yl)acetate (AB3067) (27);

[0088] (17S)-11-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1 ,3-dioxoisoindolin-5- yl)amino)ethoxy)ethoxy)ethoxy)methyl)-17-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5- yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-1 1 ,18,18-trimethyl-15-oxo-3,6,9,13-tetraoxa-16- azanonadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f|[1 ,2,4]triazolo[4,3- a][1 ,4]diazepin-6-yl)acetate (AB3063) (26);

[0089] (14S)-8-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1 ,3-dioxoisoindolin-5- yl)amino)ethoxy)ethoxy)ethoxy)methyl)-14-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5- yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-8,15,15-trimethyl-12-oxo-3,6,10-trioxa-13-azahexadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2- / ][1 ,2,4]triazolo[4,3-a][1 ,4]diazepin-6-yl)acetate

[0090] (AB3065) (28);

[0091] (17S)-11-((2-(2-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1 ,3-dioxoisoindolin-5- yl)amino)ethoxy)ethoxy)methyl)-17-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5- yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-1 1 ,18,18-trimethyl-15-oxo-3,6,9,13-tetraoxa-16- azanonadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f|[1 ,2,4]triazolo[4,3- a][1 ,4]diazepin-6-yl)acetate (AB3126) (29);

[0092] (17S)-11-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxoisoindolin-4- yl)amino)ethoxy)ethoxy)ethoxy)methyl)-17-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5- yl)phenyl)ethyl)carbamoyl)pyrrolidine-1-carbonyl)-1 1 , 18,18-trimethyl-15-oxo-3, 6,9,13-tetraoxa-16- azanonadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f|[1 ,2,4]triazolo[4,3- a][1 ,4]diazepin-6-yl)acetate (AB3066) (24);

[0093] (17S)-11-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1 ,3-dioxoisoindolin-5- yl)amino)ethoxy)ethoxy)ethoxy)methyl)-17-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5- yl)phenyl)ethyl)carbamoyl)pyrrolidine-1-carbonyl)-1 1 , 18,18-trimethyl-15-oxo-3, 6,9,13-tetraoxa-16- azanonadecyl (2R)-2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f|[1 ,2,4]triazolo[4,3- a][1 ,4]diazepin-6-yl)butanoate (AB3145) (97). or a pharmaceutically acceptable, salt, enantiomer, stereoisomer, hydrate, solvate, or polymorph thereof.

[0094] Most preferred compounds of formula (I), (IA), (IB) or (IC) as defined herein may be selected from: or a pharmaceutically acceptable, salt, enantiomer, stereoisomer, hydrate, solvate, or polymorph thereof.

[0095] In otherwords, most preferred compounds of formula (I), (IA), or (IB) as defined herein may be selected from:

[0096] 11-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1 ,3-dioxoisoindolin-5- yl)amino)ethoxy)ethoxy)ethoxy)methyl)-11-((2-(((S)-1-((2S,4 / ?)-4-hydroxy-2-((4-(4-methylthiazol-5- yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)methyl)- 3,6,9, 13,16, 19-hexaoxahenicosane-1 ,21 -diyl bis(2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H- thieno[3,2- / ][1 ,2,4]triazolo[4,3-a][1 ,4]diazepin-6-yl)acetate) (AB3124) (86); and

[0097] (17S)-11 -((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1 ,3-dioxoisoindolin-5- yl)amino)ethoxy)ethoxy)ethoxy)methyl)-17-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5- yl)phenyl)ethyl)carbamoyl)pyrrolidine-1-carbonyl)-1 1 , 18,18-trimethyl-15-oxo-3, 6,9,13-tetraoxa-16- azanonadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f|[1 ,2,4]triazolo[4,3- a][1 ,4]diazepin-6-yl)acetate (AB3067) (27); or a pharmaceutically acceptable, salt, enantiomer, stereoisomer, hydrate, solvate, or polymorph thereof.

[0098] For the avoidance of doubt, compounds of formula (I), (IA), (IB) and (IC) described herein may present any of the described features in different combinations or order.

[0099] In a second aspect of the invention there is provided a pharmaceutical composition comprising a compound of formula (I), (IA), (IB), or (IC) as defined herein and a pharmaceutically acceptable vehicle or diluent therefor.

[0100] In a third aspect of the invention there is provided a of formula (I), (IA), (IB), or (IC) as defined herein for use as a medicament.

[0101] In a fourth aspect of the invention there is provided a compound of formula (I), (IA), (IB), or (IC) as defined herein or a pharmaceutical composition as defined herein, for the prophylaxis or treatment of a disease or condition associated with deregulation of protein activity of one or more proteins within the Bromo- and Extra-terminal (BET) family of proteins BRD2, BRD3 and BRD4.

[0102] In a fifth aspect of the invention, there is provided compound of formula (I), (IA), (IB), or (IC) as defined herein or a pharmaceutical composition as defined herein, for the prophylaxis or treatment of a disease or condition associated with selective degradation of the BRD4 protein within the bromodomain of the BET family of proteins.

[0103] In a sixth aspect of the invention there is provided a compound of formula (I), (IA), (IB) or (IC) as defined herein or a pharmaceutical composition as defined herein, for the prophylaxis or treatment of a disease or condition associated with deregulation of BET protein activity.

[0104] Brief description of the figures

[0105] Figure 1 shows a schematic representation of the heterotrivalent PROTAC design rationale. (A) Active VHL-driven BET trivalent PROTAC, SIM1 (top), and bivalent PROTACs, MZ1 and MZ2 (middle right). Active CRBN-driven BET PROTAC, dBET54 (bottom). Inactive CRBN-VHL Heterobifunctional-E3 Ligase PROTACs, “Compounds 7a & 7b”, ZXH-4-135, CRBN-2-2-2-2-VHL and CRBN-2-2-2-5-VHL (middle left). VHL ligand, VH032 (orange), BET ligand, JQ1 (blue), and CRBN ligand, thalidomide (green) are highlighted. Black arrows indicate potential vectors for linker tethering. (8) Overlayed chemical structures of CRBN-2-2-2-2-VHL / CRBN-2-2-2-5-VHL and MZ1 / MZ2 to show target hetero- trivalent scaffold. Bonds shared by each compound are highlighted in bold.

[0106] Figure 2 shows the cellular evaluation of MN666 (1) and MN675 (2) .(A), (8) Degradation profiles of MN666 (1) and MN675 (2) from live cell kinetic profiles in HiBiT-Brd CRISPR knock-in HEK293 cells. Plots of percentage degradation or Dmax versus concentration of 1 (left) and 2 from live cell degradation kinetics in HiBiT-Brd CRISPR knock in HEK293 cells. Cells were treated with DMSO and a threefold serial dilution of 1 or 2 over a concentration range of (A) 12 nM - 3 pM in HiBiT-Brd2, HiBiT-Brd3 and HiBiT-Brd4 knock in cells or (8) 4 nM - 3 pM in HiBiT-Brd4 knock in cells with or without pre-treatment with 20 pM of either CRBN inhibitor pomalidomide, or VHL inhibitor VH298. Dmax so is tabulated.

[0107] Figure 3 shows Western blot evaluation of heterotrivalent PROTACs 23 - 32 in HEK293 cells. Western blot data for BET, CRBN and VHL protein levels monitored from 1 pM to 100 pM compound treatments over 6 h in HEK293 cells. Blots arranged with fluorinated compounds 23 - 25 and 31 on top, and nonfluorinated compounds 26 - 30 and 32 on bottom. Bands are normalised to tubulin and vehicle control (DMSO) to derive DCso values that enable rank order of each PROTAC.

[0108] Figure 4 shows degradation profiles of heterotrivalent PROTACs 23 - 32 from live cell kinetic profiles in HiBiT-Brd4 CRISPR knock-in HEK293 cells. Plots of (A) percentage degradation or Dmax and (8) rate constant A (IT1) versus concentration of 23 - 32 from live cell degradation kinetics in HiBiT-Brd4 CRISPR knock in HEK293 cells. Cells were treated with DMSO and a threefold serial dilution of 23 - 32 over a concentration range of (A) 5 pM - 3 pM or (8) 500 pM - 3 pM in HiBiT-Brd4 knock in cells.

[0109] Figure 5 shows the cellular evaluation of heterotetravalent PROTAC AB3124 (86). (A) Western blot data for BET, CRBN and VHL protein levels monitored after 1 pM to 100 pM treatments of 86 over 6 h in HEK293 cells. Bands are normalised to tubulin and vehicle control (DMSO) to derive DCso values that enable rank order of each PROTAC. (8) Plots of percentage degradation or Dmax versus concentration of 86 and 27 from live cell degradation kinetics in HiBiT-Brd4 CRISPR knock in HEK293 cells. Cells were treated with DMSO and a threefold serial dilution of 86 and 27 over a concentration range of 5 pM - 3 pM in HiBiT-Brd4 knock in cells. Data points > 333 pM for 86 were excluded from the data fitting due to appeared onset of hook-effect.

[0110] Figure 6 shows immunoblot and calculated degradation parameters of AB3145 (97) and AGB1 from concentration titrations performed in a homozygous HiBiT-BromoTag-BRD4 HEK293 cell line. (A) Western blotting data of BET protein levels monitored from 10 pM to 1 pM AB3145 and 1 pM to 0.001 pM AGB1 treatment over 4 h in a homozygous HiBiT-BromoTag-BRD4 HEK293 cell line. Representative of two independent repeats. (8) Data extracted from immunoblot of AB3145 and AGB1 concentration titration (A) was normalised to a vehicle control and linear regression curve fitting applied to produced degradation curves that were subsequently used to extract the Dc50 and DMAX for each BET protein. Error Bars calculated from the standard deviation of two independent repeats. (C) Table containing Dc50 and DMAX values for a 4-hour treatment of AB3145 or AGB1 in a homozygous HiBiT-BromoTag- BRD4 HEK293 model system. Detailed Description

[0111] The finding by Shirasaki and colleagues that there was a lack of resistance when simultaneously or sequentially treating with degraders which target the same oncoproteins, but recruit different E3 ligases20, is an encouraging outcome and motivates the discovery of new PROTACs which target new E3 ligases.

[0112] To try and leverage this finding, the inventors devised a research program for combining two different E3 ligase ligands in the same molecule, whilst also containing a target protein warhead into heterotrivalent degraders. The inventors recently showed that trivalency in the context of PROTAC degraders is possible. SIM1 is a trivalent PROTAC consisting of VH032 to recruit the VHL E3 ligase linked via a trifunctional linker to two molecules of JQ1 which target BET proteins.23SIM1 potently degrades BET proteins to sub-nanomolar DC50S, with a preference for Brd2. This preference for Brd2 was found to be due to the bivalent nature of SIM1 binding strongly, with high avidity, to both BD1 and BD2 of the same Brd2 protein.23

[0113] Heterotrivalent PROTAC design rationale

[0114] In the design of the hetero-trivalent PROTACs of the present invention, the inventors ensured that the linkage between VH032 and JQ1 would allow for VHL-driven BET degradation; and similarly, that the chemical nature of the linkage between thalidomide and JQ1 would allow for CRBN-driven BET degradation. In contrast, the linkage between VH032 and thalidomide was designed so as to minimise any cross-degradation between VHL and CRBN, by minimising the chance of forming productive ternary complex between CRBN:PROTAC:VHL.

[0115] To link VH032 with JQ1 , the inventors started with the linker lengths of active VHL recruiting trivalent, SIM1 ,23and bivalent, MZ121and MZ221(which differ by one PEG unit in the linker) BET degraders as scaffolds all of which have 15, 11 and 14 C / O atoms, respectively, between the terminal amide NH of VH032 and JQ1 (Figure 1A). To enable CRBN mediated degradation of BET proteins, the inventors chose to use the scaffold of dBET54,24an active CRBN recruiting BET degrader comprising of a 20 C / O atom long linker between the ether O tether to thalidomide and the amide NH of JQ1 . Lastly, to help best avoid degradation of either E3 ligase, the inventors opted to use the linker lengths of inactive / poor CRBN-VHL heterobifunctional-E3 ligase degraders, “Compounds 7a & 7b”,25ZXH-4- 135,28CRBN-2-2-2-2-VHL,27and CRBN-2-2-2-5-VHL,27(14, 20, 15, 11 and 14 C / O / N atoms, respectively, between VH032 amide NH, and the aniline NH tether to thalidomide) (Figure 1A).

[0116] When overlaying the structures of CRBN-2-2-2-2-VHL or CRBN-2-2-2-5-VHL with either MZ1 or MZ2, the inventors could envisage an optimal linker composition and length between thalidomide and JQ1 (15 - 21 C / O atoms) that would ensure both VHL and CRBN-driven degradation of BET proteins, while helping to avoid the degradation of either ligase (Figure 1 B). Initial heterotrivalent PROTACs

[0117] For “proof-of-concept”, the inventors initially synthesised two heterotrivalent compounds, MN666 (1) and MN675 (2) (shown below). The structure of 1 shares a scaffold much like that of SIM1 , differing only by a JQ1 ligand being substituted by thalidomide via an aniline tether. 2 is a smaller analogue of 1 , with a PEG unit removed from both VH032-JQ1 and VH032-thalidomide sides to the linker.

[0118] The inventors then evaluated the BET degradation profiles of PROTACs 1 and 2 in cell. To this end, they performed live cell kinetic degradation assay in HEK293 cells.30The inventors first knocked-in the 11-aminoacid HiBiT sequence using CRISPR to the N-termini of Brd2, Brd3 and Brd4, respectively, in a HEK293 cell line stably expressing an 18 kDa LgBiT protein. They then treated HiBiT-tagged Brd2, Brd3 and Brd4 HEK293 cells with varying concentrations of 1 and 2 ranging from 12 nM - 1 pM (Figure 2A).

[0119] The inventors then generated kinetic degradation profiles (Figure 2A) to determine the degradation potency of compounds 1 and 2 (Dmax so). Both 1 and 2 induced degradation of Brd2, Brd3 and Brd4, with Dmaxsos of 84 and 156 nM, respectively for Brd2; 23 and 21 nM, respectively for Brd3; and 37 and 55 nM respectively for Brd4.

[0120] To assess whether each E3 ligase ligand of 1 and 2 was able to drive degradation, the inventors ran a similar experiment by treating HiBiT-Brd4 HEK293 cells with 1 or 2 at concentrations ranging from 4 nM - 3 pM, with or without pre-treatmentwith 20 pM of either CRBN ligand pomalidomide,31or VHL inhibitor VH298 (Figure 2B).32When VHL binding is blocked by VH298, the degradation profiles of 1 and 2 are not drastically effected by the inability to recruit VHL when comparing to the vehicle control, with Dmax 50S of 34 and 58 nM, respectively, vs 32 and 38 nM, respectively (Figure 2B). In contrast, when CRBN recruitment was outcompeted by pomalidomide binding, the degradation potency dropped by 5.3-fold in the case of 1 (Dmax sos of 32 vs 166 nM), and by 3.6-fold in the case of 2 (Dmax sos of 38 vs 138 nM). This data suggests that although both 1 and 2 can degrade Brd4 in the absence of either VHL or CRBN, there is a strong preference for CRBN mediated degradation over VHL.

[0121] Taken together, the data show that while 1 and 2 can induce degradation of BET proteins by engaging either ligase. The inventors then sought to develop a larger and more diverse set of heterotrivalent PROTACs to expand the chemical space, and to improve on the characteristics presented by 1 and 2, in particular to try and decrease non-degrading component to the compound’s cellular activity.

[0122] Second generation heterotrivalent PROTACs

[0123] In order to improve the properties of the initial heterovalent degraders, 1 and 2, the inventors investigated the effect of replacing the amide linkage as JQ1 conjugation chemistry with an ester, a modification which the inventors have previously shown to be beneficial when optimising JQ1 -based BET degraders.33 34Next, they introduced diversity in the VHL binding ligand by adding a methyl group to the benzylic position of VH032, in order to enhance the binary binding affinity to VHL.33 35To gain a better understanding of the effects on linker length between each ligand, the inventors synthesised analogues which varied in the number of PEG units separating either JQ1 or thalidomide to the central quaternary carbon centre of the linker (Table 1). Finally, the inventors investigated the effect of modifying the linker attachment vector and functionality to thalidomide. Additionally to the anilines tethered at the 3-position of the phthalimide, the inventors synthesised some compounds with another linkage vector at the 4-position, a tethering site which has been used successfully in other CRBN- recruiting PROTACs.13’36 38Alongside the linkage vector at the 4-position, the inventors also investigated the effect of introducing a fluorine atom ortho to the aniline. A fluorine at the 4 / 5-position of the phthalimide of thalidomide has been seen to increase both binding affinity to CRBN and to help reduce off-target degradation of neo-substrates, Aiolos (IKZF3) and CK1 a.39Finally, the inventors synthesised two compounds which would be attached to thalidomide via a piperazine at either the 3- or 4-position of the phthalimide. This functionality can improve solubility of CRBN-recruiting degraders (Table 1).37’38’4°-42

[0124] Table 1. Second generation heterotrivalent PROTAC library (compounds 23 - 32). Compound R X Z n m

[0125] Vector

[0126] AB3062 (23) H 3-C -NH- H 3 3

[0127] AB3066 (24) Me 3-C -NH- H 3 3

[0128] AB3064 (25) H 3-C -NH- H 3 2

[0129] AB3063 (26) H 4-C -NH- F 3 3

[0130] AB3067 (27) Me 4-C -NH- F 3 3

[0131] AB3065 (28) H 4-C -NH- F 3 2

[0132] AB3126 (29) H 4-C -NH- F 2 3

[0133] AB3125 (30) H 4-C -NH- F 2 2

[0134] To synthesise linkers which would enable orthogonal trifunctionality, the inventors adapted the approach seen in Scheme 1 and previously reported to make the linker for SIM1.23The linker design consisted of the following functionalities: a carboxylic acid, to allow for facile amide coupling to VHL ligands; an amine masked as an azide, to enable future SNAr attachment to thalidomide; an alcohol protected by an acid labile acetal, to allow for esterification to JQ1 , and also to allow for mesylation and subsequent nucleophilic substitution of piperazine substituted derivatives of thalidomide (see Scheme 2 in the Materials and Methods section). Cellular evaluation of second generation heteromultivalent PROTACs

[0135] BET degradation profiles in cells after treatment of compounds 23 - 32. HEK293 cells were treated with 1 pM to 100 pM of compounds 23 - 32. Cells were then harvested, and the subsequent lysate was analysed via western blot, monitoring intracellular levels of on-target Brd2, Brd3 and Brd4 (short and long isoforms) degradation, and off-target CRBN and VHL protein degradation (Figure 3, Table 2).

[0136] Table 2. Quantification of the degradation profile of heterotrivalent PROTACs 23 - 32 against BET proteins and CRBN in HEK293 cells. pDCsoa

[0137] Compound Brd4Lon9 Brd4ShortBrd3 Brd2 CRBN

[0138] AB3062 (23) 8.3 ± 0.3 8.0 ± 0.2 8.2 ± 0.2 7.3 ± 0.2 6.5 ± 0.3

[0139] AB3066 (24) 8.3 ± 0.1 8.2 ± 0.3 8.4 ± 0.3 7.5 ± 0.1 7.1 ± 0.1

[0140] AB3064 (25) 8.0 ± 0.2 7.8 ± 0.1 7.6 ± 0.02 7.2 ± 0.2 7.4 ± 0.6

[0141] AB3029 (31) 7.9 ± 0.2 7.8 ± 0.1 7.9 ± 0.1 7.4 ± 0.05 6.4 ± 0.4

[0142] AB3063 (26) 9.1 ± 0.03 8.5 ± 0.1 8.6 ± 0.1 7.9 ± 0.1 6.8 ± 0.1

[0143] AB3067 (27) 8.7 ± 0.1 8.6 ± 0.1 8.7 ± 0.2 7.8 ± 0.1 7.1 ± 0.1

[0144] AB3065 (28) 7.9 ± 0.1 8.0 ± 0.2 8.2 ± 0.1 7.7 ± 0.2 6.7 ± 0.4

[0145] AB3126 (29) 8.4 ± 0.5b8.2 ± 0.7b8.6 ± 0.4b7.6 ± 0.3b6.4 ± n / ac

[0146] AB3125 (30) 8.5 ± 0.3b8.3 ± 0.2b8.2 ± 0.04b7.4 ± 0.4b5.9 ± 0.02b

[0147] AB3030 (32) 8.2 ± 0.1 8.1 ± 0.2 8.3 ± 0.2 7.6 ± 0.1 6.4 ± 0.3aCalculated as mean (± S.E) from three independent biological experiments.bCalculated as mean (± S.E) from two independent biological experiments.cValue from one experiment.

[0148] The inventors treated HEK293 cells with 1 pM to 100 pM of compounds. Cells were then harvested, and the lysate was analysed via western blot, monitoring intracellular levels of on-target Brd2, Brd3 and Brd4 (short and long isoforms) degradation, and off-target CRBN and VHL protein degradation (Figure 3). To assess compound effects, relative protein levels were quantified, normalized with the means of the bands from DMSO treatment (100%), and relative to housekeeping protein standard (Tubulin).

[0149] Gratifyingly, all compounds were able to potently degrade each BET protein, each showing a preference for Brd4 (long and short isoforms) and Brd3 over Brd2. There was no observed degradation of VHL, however, each compound displayed degradation of CRBN to varying extents at the top treatment concentration of 1 pM, and in some cases also at 100 nM. Strikingly, compounds which were tethered to 5-fluorothalidomide at the 4-position of the phthalimide ring (26 - 28 and 32) were an average of 3- fold more potent at degrading each BET protein when compared to their nonfluorinated matched pairs (23 - 25 and 31), tethered to thalidomide at the 3-position of the phthalimide ring (26 vs 23, 27 vs 24, 28 vs 25, and 32 vs 31 , respectively).

[0150] Out of the entire series, compounds AB3063 (26) and AB3067 (27), were the most potent degraders of each BET protein with DCso values of 0.8 nM and 2.2 nM for Brd4Lon9; 3.0 nM and 2.6 nM for Brd4Short; 2.4 nM and 1 .9 nM, for Brd3; and, 13 nM and 17 nM, for Brd2, respectively (Table 2). 26 and 27 were an average of 3-fold more potent than their 3-position tethered counterparts AB3062 (23) and AB3066 (24), respectively, with DCso values of 4.7 nM and 5.6 nM for Brd4Lon9; 9.8 nM and 5.6 nM for Brd4Short; 6.3 nM and 4.1 nM for Brd3; and, 53 nM and 34 nM, for Brd2, respectively (Table 2). Interestingly, the additional methyl group on the benzylic position of VH032 present in 27 and 24 had no significant effect on BET degradation when comparing to their non-methylated matched pairs 26 and 23 respectively, however, the modification did lead to an unfavourable 2.2 to 3.6-fold increase, respectively, in CRBN degradation (DCso = 73 vs 164 nM, and 87 vs 311 nM, respectively).

[0151] Effect of long vs short linker lengths between each ligand

[0152] When investigating the changes in linker length between each of the three ligands, the inventors observed that there was an overall preference for a longer linker between both E3 ligase ligands, VH032 and thalidomide, to the BET ligand (JQ1) for BET degradation. Removing a PEG unit from each of the VH032-JQ1 and thalidomide- VH032 (and therefore, thalidomide-JQ1) linkers from 26 to form AB3125 (30), results in a 4.2-fold decrease in Brd4Lon9degradation (DCso = 0.8 vs 3.5 nM); a 1.5-fold decrease in Brd4Shortdegradation (DCso = 3.0 vs 4.5 nM); and a 2.7-fold decrease in the degradation of both Brd3 (DCso = 2.4 vs 6.4 nM) and Brd2 (DCso = 13 vs 36 nM). However, 30 also had a favourable 7.5-fold decrease in CRBN degradation vs 26 (DCso = 1224 vs 164 nM), making it also an attractive compound, meeting the criteria for dialling out potential E3 ligase degradation.

[0153] Effects of subtly changing linker lengths one at a time

[0154] A more subtle change by removing one PEG (polyethylene glycol) unit in the VH032-JQ1 linker (and therefore, thalidomide-JQ1) from 26 to form AB3065 (28), whilst keeping the thalidomide- VH032 linker the same, the inventors observed that there is a 1.5 to 15-fold decrease in BET degradation for 28 compared to 26, with DCsoS of 13 vs 0.8 nM for Brd4Lon9; 9.2 vs 3.0 nM for Brd4Short; 6.5 vs 2.4 for Brd3; and 20 vs 13 for Brd2, respectively, whilst having no significant effect on CRBN degradation (DCso = 192 vs 164 nM).

[0155] Similarly, when comparing 26 and 28, to the non-fluorinated counterparts 23 and AB3064 (25), respectively, there is a 1 .3 to 4.4-fold decrease in BET degradation for the shorter VH032 / thalidomide- JQ1 linker of 25 compared to the longer linker of 23, with DCsoS of 9.9 vs 4.7 nM for Brd4Lon9; 18 vs 9.8 nM for Brd4Short; 28 vs 6.3 for Brd3; and 69 vs 53 for Brd2, respectively, whilst also having an unfavourable 7.8-fold increase in CRBN degradation (DCso = 40 vs 311 nM).

[0156] Alternatively, one can compare 26 to AB3126 (29), a compound which has one PEG unit removed from the thalidomide-JQ1 linker (and therefore, thalidomide-VH032), whilst sharing the same VH032-JQ1 linker length as 26. The inventors observed no change in the degradation of Brd3 (DCsoS = ~2.5 nM), but a >2-fold decrease in the degradation of Brd4Lon9(DC50 = 0.8 vs 3.8 nM), Brd4Short(DC50 = 3.0 vs 6.4 nM), and Brd2 (DC50 = 13 vs 27 nM). However, 29 also had a favourable 2.6-fold decrease in CRBN degradation vs 26 (DC50 = 432 vs 164 nM) (Table 2).

[0157] Interestingly, comparing 28, which has a longer thalidomide-VH032 linker with a shorter VH032-JQ1 linker, to 29, the inventors observed a small decrease in the degradation of Brd2 (DC50 = 20 vs 27 nM), but a 1 .4 to 3.4-fold increase in the degradation of Brd4Lon9(DC50 = 13 vs 3.8 nM), Brd4Short(DC50 = 9.2 vs 6.4 nM), and Brd3 (DC50 = 6.5 vs 2.5 nM). While sharing the same thalidomide-JQ1 linker length, there is a preference for a shorter thalidomide- VH032 linker with a longer VH032-JQ1 linker of 29, than a longer thalidomide-VH032 linker with a shorter VH032-JQ1 linker of 28. This is likely a combined result of a 2.2-fold decrease in CRBN degradation for 29 vs 28 (DC50 = 432 vs 192 nM) and the preferential longer VH032-JQ1 linker length of 29 vs 28.

[0158] Effects of piperazinyl vs aniline linker tether to thalidomide

[0159] Comparing the 3- and 4-position piperazinyl tether of AB3029 (31) and AB3030 (32), respectively, with their direct aniline tethered matched pairs 23 and 26, respectively, the inventors observed that 31 and 32 were 2.8 to 8.1 -fold weaker at degrading Brd4Lon9(DC50 = 13 vs 4.7 nM, and 6.7 vs 0.8 nM); 1 .5 to 2.9-fold weaker at degrading Brd4Short(DC50 = 15 vs 9.8 nM, and 8.5 vs 3.0 nM); and 2.1 to 2.4-fold weaker at degrading Brd3 (DC50 = 13 vs 6.3 nM, and 5.6 vs 2.4 nM) than 23 and 26, respectively. 31 and 32 were however, 1.3 to 2.5-fold favourably weaker at degrading CRBN (DC50 = 414 vs 311 nM, and 417 vs 164 nM). Interestingly, 4-piperazinyl tethered 32 was also 1 .7-fold weaker at degrading Brd2 (DC50 = 23 vs 13 nM) than 4-aniline tethered 26, whereas 3-piperazinyl tethered 31 was slightly better at degrading Brd2 (DC50 = 41 vs 53 nM) than 3-aniline tethered 23. It is also interesting to see that 31 and 32 degrade CRBN to the same extent (DC50 = ~415 nM) even when switching thalidomide tethering vector, deviating from the trend previously seen with some aniline tethered matched pairs (c.f. 23 vs 26, 24 vs 27, Table 2). It is important to note that 31 and 32 have the longest thalidomide-VH032 / JQ1 linkers of the entire series, differing to thalidomide-VH032 / JQ1 linkers of 23 and 26 by just two methylene groups in length.

[0160] Further biological evaluation of second generation heterotrivalent PROTACs 23 - 32

[0161] Next, the inventors employed the same live cell kinetic degradation assay set up as described above to evaluate Brd4 degradation profiles (Dmaxsos) of compounds 23 - 32 in HiBiT-Brd4 HEK293 cell line, to provide an orthogonal degradation assay to western blot, and to allow for comparison with the initial compounds 1 and 2 (Figure 4A, Table 3). They also evaluated degradation rate, A (h1), of each compound to reach Dmax at varying concentrations (Figure 4B). Table 3. Quantification of the degradation profile of heterotrivalent PROTACs 1, 2 and 23 - 32 against Brd4 in HiBiT-Brd4 knock-in HEK293 cells (Figure 4A). pDmax 50

[0162] Compound Brd4 95% Cl

[0163] MN666 (1) 7.4 7.5 to 7.3

[0164] MN675 (2) 7.3 7.4 to 7.0

[0165] AB3062 (23) 8.0 8.0 to 7.9

[0166] AB3066 (24) 8.5 8.6 to 8.5

[0167] AB3064 (25) 7.5 7.6 to 7.4

[0168] AB3029 (31) 7.8 7.9 to 7.8

[0169] AB3063 (26) 8.5 8.6 to 8.5

[0170] AB3067 (27) 9.2 9.3 to 9.1

[0171] AB3065 (28) 8.5 8.6 to 8.5

[0172] AB3126 (29) 8.4 8.4 to 8.3

[0173] AB3125 (30) 8.1 8.1 to 8.0

[0174] AB3030 (32) 8.1 8.3 to 8.0

[0175] Reassuringly, the Dmax so values (Table 3) correlated well with DCso values (Table 3) from western blot analysis. Compound 27 was shown to be the most potent degrader of Brd4 out of the series, giving a sub-nanomolar Dmax so value of 600 pM. This directly correlates with 27 also having the greater degradation rate of Brd4 with the highest Amax of ~2.5 IT1of the compound series, as well as the highest degradation rate at any compound concentration tested (Figure 4B). Encouragingly, all second generation heterotrivalent PROTACs performed 1.2 to 59-fold, and 1.8 to 86-fold better at degrading Brd4 than 1 and 2, respectively (Table 3). The benefit of the amide-to-ester switch in the linker attachment point to JQ1 is evident when comparing molecular matched pairs, amide 1 and ester 23.

[0176] Ester 23 gave a 3.5-fold increase in the degradation of Brd4 than amide 1 (Dmax so = 11 vs 37 nM, respectively) (Table 3). Brd4 degradation was increased by a further 3.6-fold when further switching from the 3-position tethering to thalidomide of 23 to the 4-position tethering of 5-fluorothalidomide in 26 (Dmax so = 11 vs 3.0 nM, respectively), showing that there is a positive combinatory effect of applying each modification to the parent 1. A similar combinatory effect is seen when applying both amide-to- ester substitution and 4-position tethering of 5-fluorothalidomide to 2, to give molecular matched pair 30, a compound which degrades Brd4 6.6-fold more than 2 (Dmax so = 8.2 vs 55 nM, respectively). The degradation profiles from both western blot and live cell HiBiT assay indicate that compounds 26 and 27 are the most potent BET degraders of the series.

[0177] Design, synthesis, and characterisation of a heterotetravalent PROTAC

[0178] With the encouraging results presented by the heterotrivalent PROTAC series, the inventors wanted to further investigate the chemical space and synthesise a compound which would more closely resemble SIM1 by aiming to retain the avidity and BET bivalency displayed by SIM1 ,23but now adding the ability to recruit two instead of just one E3 ligase. The so-called “heterotetravalent PROTAC” would be a combination of heterotrivalent PROTAC AB3063 (26) and BET-bivalent, trivalent PROTAC SIM1 . The inventors functionalised SIM1 from the methyl group of the central quaternary carbon present in the linker of SIM1 as a potential vector to recruit CRBN by adding another linker to tethered to thalidomide. The inventors chose to synthesise a linker which would again allow for: simple amide coupling to the VH032; future SNArto a fluoro-thalidomide derivative; and di-esterification to JQ1 (Scheme 5, Materials and Methods section).

[0179] Next, the inventors assessed the degradation profile of the heterotetravalent PROTAC AB3124 (86) by western blot and by live cell kinetics. First, they treated HEK293 cells with 1 pM to 100 pM of 86 and monitored intracellular levels of on-target Brd2, Brd3 and Brd4 (short and long isoforms), and off-target CRBN and VHL protein degradation (Figure 5A, Table 4).

[0180] Table 4. Quantification of the degradation profile of heterotetravalent PROTAC AB3124 (86) and heterotrivalent PROTACs AB3063 (26) and AB3067 (27) against BET proteins and CRBN in HEK293 cells.

[0181] HiBiT Western Blot pDCsoapDmax 50

[0182] Compound Brd4Lon9Brd4ShortBrd3 Brd2 CRBN Brd4

[0183] AB3124 (86) 8.8 ± 0.05 8.6 ± 0.2 8.9 ± 0.2 9.3 ± 0.2 5.9 ± 0.02 9.0

[0184] AB3063 (26) 9.1 ± 0.03 8.5 ± 0.1 8.6 ± 0.1 7.9 ± 0.1 6.8 ± 0.1 8 5

[0185] AB3067 (27) 8.7 ± 0.1 8.6 ± 0.1 8.7 ± 0.2 7.8 ± 0.1 7.1 ± 0.1 9.2aCalculated as mean (± S.E) from two / three independent biological experiments.

[0186] Compound 86 was able to potently degrade all BET proteins, with DCso values of 1 .7 nM for Brd4Lon9; 2.4 nM for Brd4Short; 1.4 nM for Brd3; and 0.4 nM for Brd2. Similarly, to the heterotrivalent PROTAC series, 86 showed no observed degradation of VHL, and also degradation of CRBN (DCso = 1.2 pM). Strikingly, 86 gave the largest selectivity window between on-target BET and off-target CRBN degradation of the entire hetero-multivalent PROTAC series of between 500 to 2600-fold (c.f. AB3125 (30), Table 2). In contrast with heterotrivalent PROTACs 23 - 32, 86 showed potent and preferential degradation for Brd2, albeit incomplete (Dmax ~80%) and showing an earlier onset of the hook effect at 1 pM (Figure 5A). This hook effect can also be seen to a smaller extent in Brd4Lon9blot (Figure 5A). The earlier onset of the hook effect is likely due to 86 inhibiting Brd2 and Brd4 more due to its extra linkage to a second JQ1 molecule and potential BET bivalency. The switch in BET protein preference and increase in potency that 86 has for degrading Brd2 compared with the heterotrivalent compounds is also likely because of the extra JQ1 “arm”. Trivalent PROTAC SIM1 , also shows preferential degradation of Brd2 by simultaneously engaging both BD1 and BD2 of the same Brd2 protein with high avidity, forming a stable 1 :1 :1 (Brd2BD1 BD2:SIM1 :VHL) ternary complex with VHL.23This is likely the reason for the observed switch in selectivity, especially when comparing heterotetravalent PROTAC 86 to its heterotrivalent matched pair 26 (Table 4).

[0187] Design, synthesis, and characterisation of a heterotrivalent BromoTag PROTAC AB3145 (97)

[0188] Finally, to show general applicability of our heterotrivalent PROTAC strategy, we designed an AB3067(27)-like compound for targeting BromoTag.21BromoTag is our recently reported inducible degradation system that leverages an engineered Leu-Ala version of Brd4-BD2 as universal tag for targeted protein degradation.21We designed and synthesized compound AB3145 (97), which (analogously to VHL-based bifunctional degrader AGB1) bears an ethyl-“bump” into the BET ligand, allowing for exguisite selectivity towards the BromoTag while sparingly degrading of endogenous BET proteins (Figure 6). Western blot degradation assays in homozygous CRISPR knock-in BromoTag-Brd4 HEK293 cell lines evidence highly potent degradation activity of 97 on the BromoTag-Brd4 protein (DC50: 120-140 pM; Dmax: 85-86%), maintaining a 250- and 6000-fold selectivity window over Brd3 (DC50: 33 nM; Dmax: 79%) and Brd2 (DC50: 770 nM; Dmax: 50%) respectively (Figure 6). Crucially, 97 proved to be 10-100 fold more potent than the current BromoTag degrader AGB1 , evidencing the advantage of the heterotrivalent strategy in augmenting protein degradation fitness for proteins of interest.

[0189] Further biological characterisation of AB3067 (27)

[0190] After profiling all heterotrivalent (23 - 32) and heterotetravalent (86) compounds in various biological assays, the inventors established AB3067 (27) as the most suitable hetero-multivalent compound to take forward for further study.

[0191] The inventors next sought to synthesise a series of control compounds which should complement data in CRBN KO and or VHL KO cell lines and allow them to gain a better understanding of the contributions from each ligase and enable control compounds in cancer cell resistance experiments. To this end, they synthesised control compounds neg-AB3067 (93), structurally identical to 27, but with the glutarimide nitrogen of the CRBN ligand methylated, a modification well known to block CRBN binding;45c / s-AB3067 (94), a diastereomer of 27 bearing the cis- instead of frans-hydroxyproline group to abrogate binding to VHL;21and neg-c / s-AB3067 (95), a diastereomer of 93, which has both the glutarimide methylated and the c / 's-hydroxyproline, to prevent both CRBN and VHL binding and provide a completely non-degrader control compound (Scheme 7, Materials and Methods section).

[0192] In summary, the inventors have devised a series of heterotrivalent PROTACs which have demonstrated degradation of BET proteins to varying extents, each with a preference for Brd4 and Brd3 over Brd2. By utilising the amide-to-ester substitution, the inventors have increased the potency of the initial amide heterotrivalent compounds MN666 (1) and MN675 (2). Furthermore, the inventors have discovered that all compounds which use the 4-position tethering of 5-fluorothalidomide were better at degrading BET proteins than their 3-position tethered non-fluorothalidomide counterparts.

[0193] The inventors have identified AB3067 (27) as their best heterotrivalent PROTAC due to showing the fastest and most potent degradation of BET proteins, especially Brd4 (Amax = 2.3 h1, Dmaxso = 0.6 nM), whilst maintaining a 35-fold selectivity window over off-target CRBN degradation. AB3067 (27) can engage and form ternary complexes with both VHL and CRBN and has been shown to be effective even in VHL and CRBN KO cell lines. AB3067 (27) mediated degradation of Brd4 is driven through contributions of each ligase, while showing a bigger dependency for CRBN-driven degradation over VHL-driven degradation.

[0194] The inventors have also synthesised the first heterotetravalent PROTAC, AB3124 (86), which was able to potently degrade BET proteins and showed potent antiproliferative effects in BET sensitive cells lines. AB3124 (86) displayed a contrasting preference for degrading Brd2 compared with heterotrivalent compounds, a preference similarly seen with trivalent PROTAC SIM1 which also has BET bivalency. AB3124 (86) gave the largest selectivity window between on-target BET and off-target CRBN degradation of the entire hetero-multivalent PROTAC series of between 500 to 2600-fold. Although AB3124 (86) showed potent degradation, the degradation was incomplete with DmaxS of <80% displaying a strong and early onset of the hook effect. This hook effect suggests that AB3124 (86) is a potent BET inhibitor.

[0195] Materials and Methods

[0196] Biology methods

[0197] Cell Culture

[0198] All cell lines employed in this study were obtained from ATCC. HEK293 was cultured in Dulbecco’s modified Eagle’s medium (Gibco, 31966021) supplemented with 10% fetal bovine serum (FBS) and 1 % Pen / Strep. All cell lines were maintained in a humidified incubator at 37 °C and 5% CO2.

[0199] For compound 97 only, HEK293 was cultured in DMEM supplemented with 10% (v / v) fetal bovine serum (FBS), 1 % L-glutamate and 1 % (v / v) penicillin / streptomycin (pen / strep) at 37°C, 5% CO2, and 95% humidity.

[0200] Development of eGFP-IRES-HiBiT-BromoTaq-BRD4 HEK293 cell line

[0201] To perform the single gRNA Cas9 CRISPR KI of BromoTag into BRD4 in HEK293. HEK293 cells were plated at a density of 5 x 105 cells into individual wells of a six-well plate in 1 mL of DMEM and left overnight to adhere to the plate. The cells were subsequently transfected the following day using GeneJuice lipofectamine reagent simultaneously with a custom donor vector pMK-RQ containing 500bp BRD4 homology arms on either side of an eGFP-IRES-HiBiT-BromoTag and two individual pBABED vector harbouring U6-sgRNA and puromycin expression cassettes containing two BRD4 targeting gRNA sequences: GTGGGATCACTAGCATGTCTG and GACTAGCATGTCTGCGGAGAG. The construction of these plasmids was performed by Thomas Macartney of the MRC-PPU CRISPR services. The following day cells were washed with PBS before fresh DMEM media was applied cells were left to recover in DMEM for a further 4 days. Cells were subsequently FACS sorted for GFP expression and expanded from single cells. HEK293 clones were validated for eGFP-IRES-HiBIT- BromoTag-BRD4 integration via WB, junction PCR and sequencing.

[0202] Western Blot Analysis

[0203] Cells were seeded (HEK293: 1 x 105cells / well) in 12-well plates. Following compound treatment, cells were lysed on ice with RIPA lysis and extraction buffer (Thermo Fisher Scientific, 89901) supplemented with protease inhibitor cocktail (Merck, 11697498001) and Benzonase Nuclease (Sigma-Aldrich, E1014). Protein concentration was determined using the BCA assay (Thermo Fisher Scientific, 23225). Samples were then prepared and loaded onto NuPAGE 4-12% Bis-Tris Midi gels (Thermo Fisher Scientific, WG1403A) followed by the transfer of the proteins onto nitrocellulose membranes (EMD Millipore). The membranes were blocked for 1 h prior to incubation with the primary antibodies using 5% Milk TBST. Membranes were probed for Brd2 (Abeam, Ab139690, 1 :1000), Brd3 (Abeam, Ab50818, 1 :4000), and Brd4 (Abeam, Ab128874, 1 :1000). Following overnight incubation with the primary antibodies at 4 °C, the membranes were incubated with secondary antibodies (Anti-rabbit, Abeam AB216773, 1 :5000 or antimouse, Abeam AB216774, 1 :5000) and hFAB Rhodamine Anti-Tubulin Antibody (Bio-Rad, 12004165, 1 :10 000) for 1 h and then imaged with a Bio-Rad imager (LI-COR Biosciences). All Western blots were analyzed for band intensities using Image Lab from Bio-Rad (LI- COR Biosciences). The data extracted from these blots were then subsequently plotted and analyzed using Prism (v. 8.2.1 , GraphPad).

[0204] Kinetic degradation and quantitation.

[0205] HEK293 cells (ATCC) stably expressing LgBiT (Promega) were edited using CRISPR / Cas9 to endogenously HiBiT tag the N-terminal genomic loci of BRD2, BRD3 or BRD4. For kinetic degradation assays, cells were plated in quadruplicate in white 96-well tissue culture plates at a density of 2 x 1OA4 cells per well in 100 pl of growth medium and incubated overnight at 37 °C with 5% CO2. The following day, medium was replaced with CO2-independent medium (Gibco) containing a 1 :100 dilution of Endurazine (Promega) and incubated at 37 °C in 5% CO2 for 2.5 h before addition of a threefold serial dilution of the indicated concentrations of compounds. Plates retaining lids were placed into the GloMax Discover microplate reader (Promega) set to 37 °C, and continuous luminescent measurements with readings every 5-15 min were made over a 22- to 24-h period. The degradation rate (A), Amax and Dmax were calculated from the above-determined kinetic degradation profiles. Briefly, the degradation portion of each kinetic concentration curve was fitted to a single exponential equation where A = degradation rate in units of h-1. The degraded fraction, Dmax, was calculated as 1 - plateau. For each curve, the data points before onset of degradation were excluded from the fits. The Dmax was then plotted against concentration to determine Dmax 50 values. Kinetic degradation Profiles and Dmaxso

[0206] Kinetic degradation profiles were generated by monitoring luminescence in 5 min continuous intervals over a 24 h period. This allowed for the determination of Dmax (compound concentration which achieves maximal degradation) at each concentration which could then be plotted to calculate Dmaxso (compound concentration which achieves 50% of maximal degradation). Dmax so can provide a more accurate representation of degradation potency (DCso) than standard dose-response curves, due to Dmax so factoring in the time it takes for a compound at a given concentration to reach maximal degradation, which can also vary with concentration.30

[0207] To assess whether each E3 ligase ligand of 1 and 2 was able to drive degradation, a similar experiment was run by treating HiBiT-Brd4 HEK293 cells with 1 or 2 at concentrations ranging from 4 nM - 3 pM, with orwithout pre-treatmentwith 20 pM of either CRBN ligand pomalidomide,31or VHL inhibitor VH298 (Figure 3B).32

[0208] Dose-Response Degradation Assay for compound 97

[0209] Compound 97 dose-response degradation assay was performed on the genotype verified eGFP-IRES- HiBIT-BromoTag-BRD4 homozygous HEK293 cell lines. The cells were plated at a density of 5 x 105 cells per well of a six well plate a day prior to initiation of the experiment. 97 was dissolved into a 10 mM concentrated stock solution in DMSO from which 97 was further diluted to a working concentration range of 10 pM to 10 pM in DMEM and was subseguently added to cells. Additional controls including, vehicle, AGB1 1 pM and cis-AGB1 1 pM were similarly added to cells alongside 97 treatments. Cells were left to incubate with compound for 4 hours at 37°C, 5% CO2, and 95% humidity. Cells were then subseguently washed twice with PBS before being harvested in RIPA buffer supplemented with protease inhibitor cocktail and Benzonase® Nuclease before being store at -20°C.

[0210] Western Blotting Analysis of 97 Dose-Response Degradation Assay

[0211] Total protein guantity was determined using the BCA protein assay. Protein concentration was determined using the BCA assay. Samples were then prepared in LDS buffer and subseguently loaded onto NuPAGETM 4-12% Bis-Tris Midi gels, followed by the transfer of the proteins onto nitrocellulose membranes. The membranes were blocked for 1 hour prior to incubation with the primary antibodies using 5% Milk TBST. Membranes were incubated at 4°C in either BRD4(Ab128874), BRD3(Ab50818) or BRD2(Ab139690) primary antibody overnight. Following overnight incubation, the membranes were incubated with complimentary IRDye® 800CW secondary antibodies and a hFAB™ Rhodamine Anti- Tubulin Primary Antibody (loading control) for 1 h and then imaged with a Bio-Rad imager. All western blots were analysed for band intensities using Image Lab (Bio-Rad). The data extracted from these blots were then plotted and analysed using Prism (v. 10.2.2, GraphPad). All western blotting figures were developed in Adobe illustrator.

[0212] Cellular evaluation of second generation heterotrivalent PROTACs 23 - 32

[0213] BET degradation profiles in cells after treatment of compounds 23 - 32. HEK293 cells were treated with 1 pM to 100 pM of compounds 23 - 32. Cells were then harvested, and the subseguent lysate was analysed via western blot, monitoring intracellular levels of on-target Brd2, Brd3 and Brd4 (short and long isoforms) degradation, and off-target CRBN and VHL protein degradation (Figure 3, Table 2).

[0214] Chemical synthesis and Characterisation

[0215] General Synthesis of compounds MN666 (1) and MN675 (2)

[0216] Using a similar route described by Imaide et al. for the synthesis of SIM1 ,23alcohol 3 was first alkylated with allyl bromide in a solution of potassium hydroxide and tetrabutylammonium bromide (TBAB) in toluene and water to give allyl ether 4 (Scheme 1 , Materials and Methods). The acetonide of 3 was hydrolysed with trifluoroacetic acid (TFA) in methanol and water to yield diol 5. Next, diol 5 was dideprotonated using 4 equivalents (4 eq.) of sodium hydride at 0°C in dimethylformamide (DMF), before the addition of azido mesylates 6 and 7 and heating to 60°C to yield dialkylated allyl ethers 8 and 9, respectively. Next, alkenes 8 and 9 were oxidatively cleaved with sodium periodate, 2,6-lutidine and a catalytic amount of osmium tetroxide in dioxane and water to yield aldehydes 10 and 11. Then, aldehydes 10 and 11 underwent a Pinnick oxidation by treating them with 2-methyl-2-butene, monobasic sodium phosphate and sodium chlorite in fe / Y-butanol and water to yield carboxylic acids 12 and 13 (Scheme 1).

[0217] With the trifunctional linkers in hand, the next step was to couple acids 12 and 13 with the terminal amine of VHL ligand, VH032 (14, synthesised through literature procedures28 29) via standard amide coupling conditions with 1-[bis(dimethylamino)methylene]-1 / 7-1 ,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (HATU) and diisopropylethylamine (DIPEA) in dimethylformamide (DMF) to yield amides 15 and 16. A Staudinger reduction was then employed to reduce a single azide of diazides 15 and 16 by slow addition with 1 eq. of triphenylphosphine in ethyl acetate and 1 .0 M aqueous hydrochloric acid to yield mono-amines 17 and 18. Next, amines 17 and 18 underwent nucleophilic aromatic substitution (SNAQ with CRBN ligand, 3-fluorothalidomide (19), by heating with DIPEA in / V-methyl-2- pyrrolidone (NMP) between 100-120°C to yield 3-substituted anilines 20 and 21. Finally, the azides of 20 and 21 were reduced with a suspension of 10% palladium on carbon (Pd / C) in methanol, under an atmosphere of hydrogen gas. The intermediate amines were immediately coupled to the acid of BET ligand, JQ1 (22) using HATU and DIPEA in DMF to yield the amides of hete rotrival ent PROTACs MN666 (1) and MN675 (2) (Scheme 1). Scheme 1. Synthesis of initial heterotrivalent PROTACs MN666 (1) and MN675 (2) aReaction conditions: (a) allyl bromide, KOH, TBAB, toluene, H2O, r.t., 16 h; (b) TFA, MeOH, H2O, r.t., 3 h; (c) i) NaH, DMF, 0°C, 30 min, ii) 6 or 7, DMF, 60°C, 16 h; (d) OsO4, NalO4, 2,6-lutidine, dioxane, H2O, r.t., 16 h; (e) 2-methyl-2-butene, NaH2PO4, NaCIO2, f-BuOH, H2O, r.t., 16 h; (f) VH032-amine (14), HATU, DIPEA, DMF, r.t., 2 h; (g) PPh3, EtOAc, 1.0 M HCI (aq); (h) 19, DIPEA, NMP, 100-120°C, 4 h; (i) i) H2, 10% Pd / C, MeOH, r.t., 16 h, ii) (+)-JQ1-acid (22), HATU, DIPEA, DMF, r.t., 2 h. Scheme 2. Synthesis of trifunctional linkers 53 — 57’ aReaction conditions: (a) MEMCI or MOMBr, DIPEA, DCM, r.t., 16 h; (b) MsCI, DIPEA, DCM, r.t., 3 h;

[0218] (c) i) NaH, DMF, 0°C, 30 min, ii) 6 or 7, DMF, 60°C, 16 h; (d) i) NaH, DMF, 0°C, 30 min, ii) 39 or 40, DMF, 60°C, 16 h; (e) i) NaH, DMF, 0°C, 30 min, ii) 38, DMF, 60°C, 16 h; (f) OsC , NaIC , 2,6-lutidine, dioxane, H2O, r.t., 16 h; (h) 2-methyl-2-butene, NaH2PC>4, NaCIC>2, f-BuOH, H2O, r.t., 16 h.bProducts 43 - 47 formed through step (f) then (g).cProduct 47 formed directly from step (e).

[0219] To make linkers which would ultimately result in a primary alcohol required for later esterification to JQ1 , acetal protecting groups, methoxyethoxymethyl (MEM) and methoxymethyl (MOM), were selected to mask the alcohol functionality. Firstly, triethylene (33) and diethylene (34) glycols were treated with either methoxyethoxymethyl chloride (MEMCI) or methoxymethyl bromide (MOMBr) in DIPEA and dichloromethane (DCM) to afford mono-MEM protected alcohols 35 and 36, and mono-MOM protected alcohol 37, respectively. Then, alcohols 35 - 37 were treated with methanesulfonyl chloride (MsCI) with DIPEA in DCM to yield mesylates 38 - 40 (Scheme 2). To build the trifunctional scaffold, diol 5 was carefully deprotonated using 1 .2 eq. of sodium hydride at 0°C in DMF, before addition of azido mesylates 6 and 7 with heating at 60°C to yield mono-alkylated products 41 and 42, respectively. This alkylation step was repeated by deprotonation of the alcohols of 41 and 42, using 1.5 eq. of sodium hydride at 0°C, before heating to 60°C with acetal-protected mesylates 40 and 39 to afford dialkylated allyl ethers 43 - 46. Diol 5 was also subjected to di- deprotonation with 4 eq. of sodium hydride at 0°C before quenching with 4 eq. MEM-protected mesylate 38 and heating to 60°C to yield dialkylated allyl ether 47. Next, the alkenes of 43 - 47 were oxidatively cleaved with sodium periodate, 2,6-lutidine and a catalytic amount of osmium tetroxide in dioxane and water to yield aldehydes 48 - 52. Finally, aldehydes 48 - 52 underwent a Pinnick oxidation by treating them with 2-methyl-2-butene, monobasic sodium phosphate and sodium chlorite in fe / Y-butanol and water to yield carboxylic acids 53 - 57 (Scheme 2).

[0220] General Synthesis of aniline tethered heterotrivalent PROTACs 23 - 30

[0221] The final part for the synthesis involved attachment of the trifunctional linker to the respective VHL, CRBN and BET ligands (Scheme 3).

[0222] Carboxylic acid 53 was coupled to both VH032-amine (14) and Me-VH032-amine (58, synthesised through literature procedures22) using HATU and DIPEA in DMF to yield amides 59 and 60, respectively. The remaining acids 54 - 57 were coupled to VH032-amine (14) only using the same conditions to yield amides 61 - 64. Next, the azides of 59 - 63 were reduced with a suspension of 10% Pd / C in methanol, under an atmosphere of hydrogen gas. The intermediate amines subsequently underwent an SNAr reaction with 3-fluoro 19 and 4,5-difluoro 65 derivatives of thalidomide, by heating with DIPEA in DMSO at 90°C to yield 3-substituted anilines 66 - 68 and 4-substituted-5-fluoro anilines 69 - 73. Finally, MOM / MEM protecting groups of 66 - 73 were hydrolysed with 4 N hydrochloric acid in dioxane and methanol. The subsequent primary alcohols were immediately conjugated to an intermediate acid chloride (22*), formed after treating (+)-JQ1-acid (22) with thionyl chloride in DCM, to afford the esters of aniline tethered heterotrivalent PROTACs 23 - 30 (Scheme 3).

[0223] Scheme 3. Synthesis of aniline tethered heterotrivalent PROTACs 23 - 30 aReaction conditions: (a) HATU, DIPEA, DMF, r.t., 2 h; (b) i) 59 - 64, H2, 10% Pd / C, MeOH, r.t., 16 h, ii) 19 or 65, DIPEA, DMSO, 90°C, 16 h; (c) SOCI2, DCM, r.t., 3 h; (d) i) 4N HCI in dioxane, MeOH, r.t., 3 h, ii) 22*, DIPEA, DCM, r.t., 16 h.bProduct used further in Scheme 4.

[0224] General Synthesis of piperazinyl tethered heterotrivalent PROTACs 31 and 32

[0225] To synthesise heterotrivalent PROTACs whose linkers are tethered via a piperazine to the CRBN ligand, thalidomide, the inventors required two masked alcohols in the linker to allow for esterification to JQ1 , and also for mesylation and subsequent amination with piperazine substituted thalidomide derivatives (Scheme 4). Scheme 4. Synthesis of piperazinyl tethered heterotrivalent PROTACs 31 & 32 aReaction conditions: (a) i) 4N HCI in dioxane, MeOH, r.t., 1 h, ii) 22*, DIPEA, DCM, r.t., 16 h; (b) i) MsCI, DIPEA, DCM, 0°C, 20 min, ii) r.t., 1 h; (c) 1-Boc-piperazine, DIPEA, DMSO, 90°C, 16 h; (d) i) 76 or 77, 4 N HCI in dioxane, DCM, r.t., 16 h, ii) 75, DIPEA, DMF, 80°C, 16 h.

[0226] Firstly, both MEM groups of compound 64 (synthesised in Scheme 3), were hydrolysed with 4 N hydrochloric acid in dioxane and methanol. The intermediate diol was reacted with sub-stoichiometric amounts (0.8 eq.) of the acid chloride 22* (synthesised in Scheme 3) to afford mono-ester 74. The remaining primary alcohol of 74 was mesylated by careful addition of MsCI in DCM at 0°C to yield mesylate 75. Careful addition is required due to the observed formation of a di-mesylated product, where another mesyl group is attached to the secondary alcohol present on the hydroxyproline of the VH032 ligand, a group usually inert in other reactions. Next step was to functionalise thalidomide derivatives 19 and 65 by heating them at 90°C with 1-Boc-piperazine and DIPEA in DMSO to give Boc- protected 3-piperazinyl (76) and 4-piperazinyl-5-fluoro (77) substituted thalidomide. The Boc groups of 76 and 77 were then hydrolysed using 4 N hydrochloric acid in dioxane and DCM. The intermediate hydrogen chloride salts were then alkylated by heating to 80°C with mesylate 75 and DIPEA in DMSO to yield the tertiary amine present in piperazine tethered heterotrivalent PROTACs 31 and 32. General Synthesis of heterotetravalent PROTAC AB3124 (86)

[0227] Scheme 5. Synthesis of heterotetravalent PROTAC AB3124 (86)a aReaction conditions: (a) i) NaH, DMF, 0°C, 15 min, ii) allyl bromide, r.t., 16 h; (b) i) NaH, DMF, r.t., 30 min, ii) 7, DMF, 60°C, 16 h; (c) i) NaH, DMF, r.t., 30 min, ii) 40, DMF, 60°C, 16 h; (d) OsO4, NaIC , 2,6- lutidine, dioxane, H2O, r.t., 16 h; (e) 2-methyl-2-butene, NaH2PC>4, NaCIC>2, f-BuOH, H2O, r.t., 16 h; (f) 14, HATU, DIPEA, DMF, r.t., 2 h; (g) i) H2, 10% Pd / C, MeOH, r.t., 16 h, ii) 65, DIPEA, DMSO, 90°C, 16 h; (h) i) 4N HCI in dioxane, MeOH, r.t., 3 h, ii) 22*, DIPEA, DCM, r.t., 16 h.

[0228] The synthesis follows a very similar route to the one used for heterotrivalent PROTACs (Schemes 2 & 3). Firstly, the tetrafunctional, penta erythritol (78) was mono-alkylated by first deprotonating with sodium hydride in DMF, followed by the addition of allyl bromide to yield the allyl ether triol 79. Triol 79 was then carefully deprotonated with sodium hydride in DMF, before heating to 60°C with azido mesylate 7 to yield ether 80. Di-deprotonation of diol 80 with excess sodium hydride in DMF at 0°C before subsequent addition of mesylate 119 and heating at 60°C to yield 81. Subsequently, alkene 81 was oxidatively cleaved with sodium periodate, 2,6-lutidine and a catalytic amount of osmium tetroxide in dioxane and water to yield aldehyde 82. Aldehyde 82 subsequently underwent a Pinnick oxidation by treating with 2-methyl-2-butene, monobasic sodium phosphate and sodium chlorite in fe / Y-butanol and water to yield carboxylic acid 83 in quantitative yields. Next, acid 83 was coupled to VH032-amine (14) with HATU and DIPEA in DMF to yield amide 84. Then, the azide of 84 was reduced with a suspension of 10% Pd / C in methanol, under an atmosphere of hydrogen gas. The intermediate amine subsequently underwent an SNAr reaction with 4,5-difluoro thalidomide 65, by heating with DIPEA in DMSO at 90°C to yield 4-substituted-5-fluoro aniline 85. Finally, MOM protecting groups of 85 were hydrolysed with 4 N hydrochloric acid in dioxane and methanol. The subsequent diol was immediately conjugated to an intermediate acid chloride (22*, synthesised in Scheme 3), formed after treating (+)-JQ1-acid (22) with thionyl chloride in DCM, to afford the di-ester of the heterotetravalent PROTAC AB3124 (86) (Scheme 5).

[0229] General synthesis of heterotrivalent BromoTag PROTAC AB3145 (97)

[0230] To make the heterotrivalent BromoTag PROTAC, we followed a similar synthesis to 27 (c.f. Scheme 3), but now using BromoTag ligand ET-JQ1-OH (96)34’46instead of endogenous BET ligand JQ1 (22) (Scheme 6).

[0231] Scheme 6. Synthesis of heterotrivalent BromoTag PROTAC AB3145 (97)a aReaction conditions: (a) SOCI2, DCM, r.t., 3 h; (b) i) 4N HCI in dioxane, MeOH, r.t., 3 h, ii) 96*, DIPEA, DCM, r.t., 16 h.

[0232] Firstly, the MOM protecting group of 70 was hydrolysed with 4 N hydrochloric acid in dioxane and methanol. The subsequent primary alcohol was immediately conjugated to an intermediate acid chloride (96*), formed after treating ET-JQ1-OH (96, synthesised through literature procedures46) with thionyl chloride in DCM, to afford the ester of heterotrivalent BromoTag PROTAC AB3145 (97) (Scheme 6).

[0233] General synthesis of control compounds 93 - 95 The synthetic route for the control compounds 93 - 95 was similar to that of 27 (Schemes 2 & 3). Firstly, glutarimide 65 was methylated by treating with potassium carbonate and methyl iodide in DMF to yield methylated di-fluorothalidomide 87. Next, carboxylic acid 53 was coupled to both Me-VH032-amine (58) and c / s-Me-VH032-amine (88, synthesised according to literature procedures22) using HATU and DIPEA in DMF to yield amides 60 and 89. Next, the azides of 60 and 89 were reduced with a suspension of 10% Pd / C in methanol, under an atmosphere of hydrogen gas. The intermediate amines subsequently underwent an SNAr reaction with 4,5-difluoro thalidomide derivatives 87 and 65, by heating with DIPEA in DMSO at 90°C 4-substituted-5-fluoro anilines 90 - 91. Finally, the MOM protecting groups of 90 - 92 were hydrolysed with 4 N hydrochloric acid in dioxane and methanol. The subsequent primary alcohols were immediately conjugated to an intermediate acid chloride (22*, synthesised in Scheme 3), formed aftertreating (+)-JQ1-acid (22) with thionyl chloride in DCM, to afford the esters of control compounds 93 - 95 (Scheme 7).

[0234] Scheme 7. Synthesis of AB3067 (27) control compounds, 93 - 95 aReaction conditions: (a) Mel, K2CO3, DMF, 0°C - r.t., 5.5 h; (b) HATU, DIPEA, DMF, r.t., 2 h; (b) i) H2, 10% Pd / C, MeOH, r.t., 16 h, ii) 87 or 65, DIPEA, DMSO, 90°C, 16 h; (c) i) 4N HCI in dioxane, MeOH, r.t., 3 h, ii) 22*, DIPEA, DCM, r.t., 16 h.

[0235] Experimental

[0236] Synthesis. Chemicals, commercially available, were purchased from Apollo Scientific, Sigma-Aldrich, Fluorochem, or Manchester Organics and used without any further purification. All reactions were carried out using anhydrous solvents. Reactions were monitored using either: an Agilent Technologies 1200 series analytical HPLC (High Performance Liquid Chromatography) connected to an Agilent Technologies 6130 quadrupole LC / MS containing an Agilent diode array detector and a Waters XBridge C18 column (50 mm x 2.1 mm, 3.5 pm particle size). Samples were eluted with a 3 min gradient of 5% to 95% MeCN:water containing 0.1 % HCOOH at a flow rate of 0.7 mL / min; or a Shimadzu HPLC / MS 2020 with photodiode array detector and a Hypersil Gold column (1 .9 pm 50 x 2.1 mm). Samples were eluted with a 3 min gradient of 5% to 95% MeCN:water containing 0.1 % HCOOH at a flow rate of 0.8 mL / min. Intermediates were purified by flash column chromatography using a Teledyne Isco Combiflash Rf or Rf200i, with Normal Phase RediSep Rf Disposable Columns or with Reverse Phase RediSep Rf Gold C18 Reusable Columns. Final compounds were purified by HPLC using a Gilson Preparative HPLC System equipped with a Waters X-Bridge C18 column (100 mm x 19 mm; 5 pm particle size) using a gradient from 5% to 95% of MeCN in water containing 0.1 % HCOOH or ammonia over 10 min at a flow rate of 25 mL / min unless stated otherwise. Compound characterization using NMR was performed either on a Bruker 500 Ultrashield or Bruker Ascend 400 spectrometers. The proton (1H) and carbon (13C) reference solvents used were as follows: di-Chloroform - CDCh (bH = 7.26 ppm / bC = 77.15 ppm), C / 4-CD3OD (bH = 3.31 ppm I bC = 49.00 ppm), de-(CD3)2SO (bH = 2.50 ppm I bC = 39.52 ppm) Signal patterns are described as singlet (s), doublet (d), triplet (t), quartet (q), quintet (quint.), multiplet (m), broad (br.), or a combination of the listed splitting patterns. Coupling constants (J) are measured in Hertz (Hz). NMR spectra for all compounds were processed using Bruker TopSpin 4.1 .1 . High resolution mass spectrometry (HRMS) data was performed on a Bruker MicrOTOF II focus ESI Mass Spectrometer connected in parallel to Dionex Ultimate 3000 RSLC system with diode array detector and a Waters XBridge C18 column (50mm x 2.1 , 3.5 pm particle size). Samples were eluted with a 6 min gradient of 5% to 95% MeCN: water containing 0.1 % HCOOH at a flow rate of 0.6 mL / min. All compounds are >95% pure by HPLC.

[0237] General Procedure A. Alcohol / d iol (1 .0 eq.) was dissolved in DMF (2.4 mL / mmol) under N2 and cooled to 0°C. 60% NaH in paraffin oil (1 .2 - 4.0 eq.) was carefully added and the flask was left to stir at 0°C for 30 min. A solution of mesylate (1 .0 - 3.0 eq.) in DMF (0.5 - 0.8 mL / mmol) was then added to the flask dropwise and the reaction was left to stir at 60°C for 16 h. The mixture was then filtered through PTFE filters or celite and concentrated in vacuo and purified.

[0238] General Procedure B. To a solution of alkene (1.0 eq.) in dioxane (18 mL / mmol) and water (4.6 mL / mmol) was added NalO4 (4.0 eq.), 2,6-lutidine (2.0 eq.) and 4% OsO4 in water (0.01 eq.). The reaction was left to stir at r.t. for 16 h. The resulting white suspension was quenched with saturated Na2SO3solution, extracted with DCM (4 x 10 mL), dried with MgSO4, and concentrated in vacuo. The residue is then purified by flash column chromatography using a linear gradient of 0% to 10% MeOH in DCM to yield aldehydes as colourless oils.

[0239] General Procedure C. To a solution of aldehyde (1.0 eq.) in f-BuOH (18 mL / mmol) and water (5.9 mL / mmol) was added NaH2PO4 (1 .0 eq.), NaCIO2 (3.95 eq.) followed by 2 M 2-methyl-2-butene in THF (5.0 eq.), and the reaction left to stir at r.t. for 16 h. The reaction was diluted with 2 M NaOH (aq) solution (1 mL) and then carefully neutralised 2 M HCI (1 mL). The mixture was extracted with DCM (4 x 10 mL), dried with MgSO4 and concentrated in vacuo to yield carboxylic acids as colourless oils without the need for further purification.

[0240] General Procedure D. To a solution of carboxylic acid (1.0 eq.) in DMF (7.7 mL / mmol) was added DIPEA (4.0 eq.). HATU (1.1 eq.) was then added, and the reaction was stirred at r.t. for 5 min. VH032- amine (14 synthesised according to literature1’2), Me-VH032-amine (58, synthesised according to literature3) or c / s-Me-VH032-amine (88, synthesised according to literature3) (1.1 eq.) was then added and the reaction left to stir at r.t. for 2 h. The reaction is then concentrated under vacuum and purified by reverse phase flash column chromatography (C18 gold column) using a linear gradient from 0% to 100% MeCN in 0.1 % HCOOH in water to afford amides as colourless oils.

[0241] General Procedure E. (Step 1) MOM / MEM protected compound (1.0 eq.) was dissolved in MeOH (26 mL / mmol). 4N HCI in dioxane (13 mL / mmol) was then added and the reaction was left to stir for at r.t. for 2 h. The reaction was then concentrated under vacuum to quantitatively yield alcohols without the need for purification. (Step 2) In a separate flask was dissolved (+)-JQ1 carboxylic acid (22) or ET-JQ1- OH (96, synthesised through literature procedures46) (1.5 - 3.0 eq.) in anhydrous DCM (9.4 mL / mmol) under an atmosphere of N2. Neat SOCI2 (22.5 - 45 eq.) was then added and left to stir at r.t. Conversion to the acid chloride was monitored by LC-MS by dissolving a sample in MeOH and observing the mass of the methyl ester of JQ1 (calc, for C20H20CIN4O2S [M+H]+415.9) or ET-JQ1-OH (calc, for C22H24CIN4O2S [M+H]+443.1). Complete conversion was observed after 1.5 h and the mixture was concentrated in vacuo. (Step 3) The acid chloride intermediate (1.5 - 3 eq) was re-dissolved in anhydrous DCM (9.6 mL / mmol) and added to a N2 purged flask containing alcohol (1.0 eq., from Step 1). Anhydrous DIPEA was added (3.0 - 5.0 eq., or until pH 9.0) and left to stir at r.t. for 16 h. The mixtures were then concentrated in vacuo and the residues were purified by HPLC.

[0242] General Procedure F. To a N2 flushed flask containing a solution of triethylene (33) or diethylene glycol (34) (5.25 eq.) in DCM (0.5 mL / mmol), was added DIPEA (1 .1 eq.). MEMCI or MOMBr (1.0 eq.) were then added dropwise, and the reaction was left to stir at r.t. for 16 h. The mixture was then diluted with DCM (20 mL) and water (20 mL) and the organic layer separated. The aqueous phase was extracted with DCM (3 x 20 mL), and the combined organic layers were dried with MgSC and concentrated in vacuo. The residue was then purified by flash column chromatography to yield mono-MEM / MOM protected alcohols as colourless oils.

[0243] General Procedure G. To a solution of alcohol (1.0 eq.) is dissolved in anhydrous DCM (4.9 mL / mmol) was added DIPEA (3.0 eq.) before flushing the flask with N2 and cooling to 0°C. MsCI (3.0 eq.) was then added dropwise, and the reaction was left to stir at 0°C for 20 min before warming to r.t. and stirring for 2 h. The reaction mixture was concentrated in vacuo. The residue was then purified by flash column chromatography using a linear gradient from 0% to 100% EtOAc in heptane to yield mesylates as orange / red oils.

[0244] General Procedure H. Azide (1 .0 eq.) was dissolved in MeOH (58 mL / mmol). A catalytic amount of 10 wt.% Pd / C was added, and the reaction was stirred under an atmosphere of H2 for 16 h. The reaction mixture was then filtered through PTFE syringe filters and evaporated to dryness to obtain the desired amine quantitative yields. The resulting amine (1.0 eq.) was added to a solution of thalidomide derivatives 19, 65 or 87 (1 .0 eq.) and DIPEA (4.0 eq.) in DMSO (24 mL / mmol) and the reaction was left to stir in a sealed vial at 90°C for 4 h. the reaction was then purified by HPLC using a linear gradient of 5% to 95% MeCN in 0.1 % HCOOH in water over 10 min gradient unless otherwise stated. (2S,4 / ?)-1-((20S)-20-(tert-butyl)-1-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2- f][1 ,2,4]triazolo[4,3-a][1 ,4]diazepin-6-yl)-14-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1 ,3- dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)methyl)-14-methyl-2,18-dioxo-6,9,12,16- tetraoxa-3,19-diazahenicosan-21-oyl)-4-hydroxy-W-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2- carboxamide (MN666) (1).

[0245] Azide 20 (12 mg, 10.6 pmol) was dissolved in MeOH (600 pL). A catalytic amount of 10 wt.% Pd / C (3 mg) was added, and the reaction was stirred under an atmosphere of hydrogen for 24 h. The reaction mixture was then filtered through a PTFE syringe filter and evaporated to dryness to leave crude amine intermediate. The crude amine (8 mg, 7.2 pmol) was dissolved in DMF (100 pL) and added to a solution of (+)-JQ1-acid (22) (3 mg, 7.5 pmol), HATU (3 mg, 7.9 pmol) and DIPEA (5 pL, 28.7 pL) in DMF (400 pL) and stirred at r.t. for 2 h. After completion, the reaction was directly purified by HPLC using a linear gradient over 10 min from 25% to 95% MeCN in 0.1 % HCOOH in water. Yield: 5.4 mg (34%); Contains a mixture of four diastereomers;1H NMR (500 MHz, CDCh): 6 = 9.50-9.19 (m, 1 H), 8.73-8.71 (m, 1 H), 7.78-7.71 (m, 1 H), 7.49-7.31 (m, 10H), 7.23-7.17 (m, 1 H), 7.09-7.06 (m, 1 H), 6.92-6.88 (m, 1 H), 6.49 (s, 1 H), 4.89-4.45 (m, 6H), 4.35-4.24 (m, 1 H), 4.09-3.93 (m, 3H), 3.73-3.21 (m, 32H), 2.83-2.62 (m, 6H), 2.52-2.50 (m, 3H), 2.44-2.37 (m, 4H), 2.19-2.02 (m, 2H), 1.64 (s, 3H), 1.39-1.29 (m, 1 H), 1.21- 1.17 (m, 1 H), 0.98-0.95 (m, 9H), 0.90-0.88 ppm (m, 3H); LC-MS m / z calc, for C73H93CIN 12O16S2 [M+2H]2+746.3, found: 746.2.

[0246] (2S,4R)-1 -((17S)-17-(tert-butyl)-1 -((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2- f][1 ,2,4]triazolo[4,3-a][1 ,4]diazepin-6-yl)-11 -( ( 2-( 2-( ( 2-( 2 ,6-d ioxop i pe ri d i n -3-y I )-1 ,3- dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)methyl)-11 -methyl-2,15-dioxo-6,9,13-trioxa-3,16- diazaoctadecan-18-oyl)-4-hydroxy-W-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2 -carboxamide (MN675) (2).

[0247] Azide 21 (13 mg, 12.4 pmol) was dissolved in MeOH (600 pL). A catalytic amount of 10 wt.% Pd / C (3 mg) was added, and the reaction was stirred under an atmosphere of hydrogen for 24 h. The reaction mixture was then filtered through a PTFE syringe filter and evaporated to dryness to leave crude amine intermediate. The crude amine (13 mg, 12.4 pmol) was dissolved in DMF (100 pL) and added to a solution of (+)-JQ1-acid (22) (5 mg, 12.4 pmol), HATU (5 mg, 13.1 pmol) and DIPEA (10 pL, 57.4 pL) in DMF (400 pL) and stirred at r.t. for 2 h. After completion, the reaction was directly purified by HPLC using a linear gradient over 10 min from 25% to 95% MeCN in 0.1 % HCOOH in water. Yield: 10 mg (59%); Contains a mixture of four diastereomers;1H NMR (500 MHz, CDCI3): 6 = 9.89-9.55 (m, 1 H), 8.72 (s, 1 H), 7.93-7.79 (m, 1 H), 7.49-7.31 (m, 10H), 7.28-7.23 (m, 1 H), 7.07-7.05 (m, 1 H), 6.92-6.88 (m, 1 H), 6.50 (s, 1 H), 4.90-4.83 (m, 1 H), 4.78-4.47 (m, 5H), 4.32-4.27 (m, 1 H), 4.15-3.95 (m, 3H), 3.71-3.22 (m, 24H), 2.78-2.61 (m, 6H), 2.52-2.50 (m, 3H), 2.40-2.31 (m, 4H), 2.17-1.98 (m, 2H), 1.64 (s, 3H), 1.38-1.29 (m, 1 H), 1.21-1.16 (m, 1 H), 0.98-0.94 (m, 9H), 0.90-0.87 ppm (m, 3H); HRMS m / z calc, for C69H84CIN12O14S2 [M+H]+1403.5354, found: 1403.5402. 5-((allyloxy)methyl)-2,2,5-trimethyl-1 ,3-dioxane (4).

[0248] (2,2,5-trimethyl-1 ,3-dioxan-5-yl)methanol (3) (2.0 g, 12.5 mmol) was dissolved in toluene (12.5 mL). KOH (2.1 g, 37.5 mmol) was dissolved in H2O (2.1 mL) and added to the flask, followed by TBAB (403 mg, 1 .25 mmol) and allyl bromide (4.53 g, 37.5 mmol). The reaction was stirred vigorously at r.t. for 16 h. DCM (20 mL) was added, and the aqueous layer was extracted with DCM (3 x 20 mL), dried with MgSO4 and concentrated in vacuo. The residue was purified by flash column chromatography (40 g silica column) using a linear gradient from 0% to 50% EtOAc in heptane to afford 121 (4) as a colourless oil. Yield: 1 .4 g (54%); Analytics matched those reported in literature (ref.4);1H NMR (400 MHz, CDCh): 6 = 5.95-5.85 (m, 1 H), 5.27 (qd, J = 1 .7, 17.3 Hz, 1 H), 5.16 (qd, J = 1 .5, 10.4 Hz, 1 H), 4.00 (td, J = 1 .5,

[0249] 5.4 Hz, 2H), 3.72 (d, J = 12.0 Hz, 2H), 3.55 (d, J = 11 .9 Hz, 2H), 3.43 (s, 2H), 1 .43 (s, 3H), 1 .40 (s, 3H), 0.89 ppm (s, 3H);13C NMR (101 MHz, CDCh): 6 = 135.2, 116.5, 98.0, 73.3, 72.5, 66.8, 34.5, 26.5, 21.4, 18.5.

[0250] 2-((allyloxy)methyl)-2-methylpropane-1 ,3-diol (5).

[0251] 5-((allyloxy)methyl)-2, 2, 5-trimethyl-1 ,3-dioxane (4) (1.4 g, 6.99 mmol) was dissolved in MeOH (10 mL) and H2O (6 mL). TFA (600 pL) was then added, and the reaction was left to stir at r.t. for 3 h. The mixture was then evaporated to dryness and the residue was purified by flash column chromatography (24 g silica column) using a linear gradient from 0% to 20% MeOH in DCM to afford 5 as a colourless oil. Yield: 874 mg (78%); Analytics matched those reported in literature (ref.4);1H NMR (400 MHz, CDCh): 6 = 5.94-5.84 (m, 1 H), 5.26 (qd, J = 1 .6, 17.3 Hz, 1 H), 5.20 (qd, J = 1 .4, 10.4 Hz, 1 H), 3.99 (td, J = 1 .4, 5.5 Hz, 2H), 3.72 (d, J = 11 .0 Hz, 2H), 3.61 (d, J = 10.9 Hz, 2H), 3.45 (s, 2H), 2.39 (br. s, 2H), 0.84 ppm (s, 3H).

[0252] 11 -((allyloxy)methyl)-1 ,21 -diazido-11 -methyl-3,6,9,13,16,19-hexaoxahenicosane (8).

[0253] Follow General Procedure A, using 1.0 eq of diol 5, 4 eq. of NaH and 3 eq. of 2-(2-(2- azidoethoxy)ethoxy)ethyl methanesulfonate (6). Purified by reverse phase flash column chromatography (50 g C18 gold column) using a linear gradient over 11 min from 0% to 100% MeCN in 0.1 % HCOOH in water. Yield: 179 mg (60%); Analytics matched those reported in literature (ref.4);1H NMR (500 MHz, CDCh) 6 = 5.96-5.84 (m, 1 H), 5.26 (dd, J = 1.7, 17.2 Hz, 1 H), 5.15 (dd, J = 1.5,

[0254] 10.4 Hz, 1 H), 4.01-3.93 (m, 2H), 3.76 - 3.61 (m, 16H), 3.62-3.55 (m, 4H), 3.44-3.37 (m, 4H), 3.37 - 3.33 (m, 4H), 3.33-3.29 (m, 2H), 0.96 (s, 3H);13C NMR (126 MHz, CDCh) 6 = 135.3, 116.0, 74.0, 73.0, 72.3, 71.1 , 70.8, 70.7, 70.5, 70.0, 50.7, 41.0, 17.4.

[0255] 8-((allyloxy)methyl)-1 ,15-diazido-8-methyl-3,6,10,13-tetraoxapentadecane (9).

[0256] Follow General Procedure A, using 1.0 eq of diol 5, 4 eq. of NaH and 3 eq. of 2-(2-azidoethoxy)ethyl methanesulfonate (7). Purified by reverse phase flash column chromatography (50 g C18 gold column) using a linear gradient over 11 min from 0% to 100% MeCN in 0.1 % HCOOH in water. Yield: 507 mg (60%);1H NMR (500 MHz, CDCh): 6 = 5.93-5.84 (m, 1 H), 5.25 (qd, J = 1.7, 17.2 Hz, 1 H), 5.14 (qd, J = 1 .5, 10.4 Hz, 1 H), 3.94 (td, J = 1 .5, 5.3 Hz, 2H), 3.69-3.67 (m, 4H), 3.65-3.61 (m, 4H), 3.60-3.56 (m, 4H), 3.37 (t, J = 5.1 Hz, 4H), 3.35 (s, 4H), 3.31 (s, 2H), 0.96 ppm (s, 3H);13C NMR (126 MHz, CDCb): 6 = 135.4, 1 16.2, 74.2, 73.2, 72.4, 71.3, 70.7, 70.2, 51.0, 41.1 , 17.6.

[0257] 1 -azido-11 -((2-(2-(2-azidoethoxy)ethoxy)ethoxy)methyl)-11 -methyl-3,6,9,13-tetraoxapentadecan- 15-al (10).

[0258] Follow General Procedure B, using alkene 8. Yield: 16 mg (64 %); Analytics matched those reported in literature (ref.4);1H NMR (500 MHz, CDCb) 6 = 9.73 (s, 1 H), 4.02 (s, 2H), 3.74-3.52 (m, 20H), 3.46- 3.26 (m, 10H), 0.98 (s, 3H);13C NMR (126 MHz, CDCb) 6 = 202.2, 77.0, 74.7, 73.9, 71 .2, 70.9, 70.8, 70.7, 70.2, 50.9, 41.3, 17.5.

[0259] 2-(3-(2-(2-azidoethoxy)ethoxy)-2-((2-(2-azidoethoxy)ethoxy)methyl)-2- methylpropoxy)acetaldehyde (11).

[0260] Follow General Procedure B, using alkene 9. Yield: 83%;1H NMR (400 MHz, CDCb): 6 = 9.73 (t, J = 1 .0 Hz, 1 H), 4.02 (d, J = 1 .0 Hz, 2H), 3.70-3.55 (m, 12H), 3.44 (s, 2H), 3.40-3.33 (m, 8H), 0.99 ppm (s, 3H);13C NMR (101 MHz, CDCb): 6 = 202.1 , 77.0, 74.7, 73.9, 71.2, 70.7, 70.2, 50.9, 41 .3, 17.4.

[0261] 1 -azido-11 -((2-(2-(2-azidoethoxy)ethoxy)ethoxy)methyl)-11 -methyl-3,6,9,13-tetraoxapentadecan- 15-oic acid (12).

[0262] Follow General Procedure C, using aldehyde 10. Yield: 150 mg (97%); Analytics matched those reported in literature (ref.4); 1 H NMR (500 MHz, CDCb) 6 = 4.05 (s, 2H), 3.70-3.58 (m, 20H), 3.45- 3.33 (m, 10H), 0.95 (s, 3H);13C NMR (126 MHz, CDCb) 6 = 172.1 , 75.4, 74.7, 71.3, 70.9, 70.7, 70.4, 70.2, 68.8, 50.8, 40.8, 18.0.

[0263] 2-(3-(2-(2-azidoethoxy)ethoxy)-2-((2-(2-azidoethoxy)ethoxy)methyl)-2-methylpropoxy)acetic acid (13).

[0264] Follow General Procedure C, using aldehyde 11. Yield: 422 mg (95%);1H NMR (500 MHz, CDCb): 6 = 4.06 (s, 2H), 3.69-3.60 (m, 12H), 3.48-3.44 (m, 4H), 3.40 (d, J = 9.3 Hz, 2H), 3.39-3.35 (m, 4H), 0.97 ppm (s, 3H);13C NMR (126 MHz, CDCb): 6 = 171 .9, 75.7, 75.0, 71.4, 70.5, 70.2, 68.7, 50.9, 40.8, 18.0.

[0265] (2S,4R)-1 -((S)-1 -azido-11 -((2-(2-(2-azidoethoxy)ethoxy)ethoxy)methyl)-17-(tert-butyl)-11 -methyl- 15-oxo-3, 6,9,13-tetraoxa-16 -azaoctadecan-18-oyl)-4-hydroxy-A / -(4-(4-methylthiazol-5- yl)benzyl)pyrrolidine-2 -carboxamide (15).

[0266] Follow General Procedure D, using carboxylic acid 13 and VH032-amine (14, synthesised through literature procedures2 5). Yield: 55 mg (50 %); Analytics matched those reported in literature (ref.4); 1 H NMR (500 MHz, CDCb) 6 (ppm) = 8.68 (s, 1 H), 7.39-7.30 (m, 5H), 7.10 (d, J = 8.5 Hz, 1 H), 4.73 (t, J = 7.8 Hz, 1 H), 4.59-4.51 (m, 2H), 4.48 (d, J = 8.7 Hz, 1 H), 4.35 (dd, J = 5.5, 15.0 Hz, 1 H), 4.09 (d, J = 12.0 Hz, 1 H), 3.94 (dd, J = 15.4, 17.7 Hz, 2H), 3.71-3.53 (m, 21 H), 3.46-3.30 (m, 10H), 2.60-2.49 (m, 1 H), 2.51 (s, 3H), 2.16-2.08 (m, 1 H), 0.96 (s, 3H), 0.95 (s, 9H). 13C NMR (126 MHz, CDCb) 6 (ppm) = 171.5, 170.8, 170.7, 150.5, 148.6, 138.3, 131.8, 131.1 , 129.7, 128.3, 74.8, 74.2, 74.1 , 71 .2, 70.9, 70.8, 70.7, 70.6, 70.3, 70.2, 58.5, 57.2, 56.7, 50.8, 43.4, 41.1 , 35.9, 35.0, 26.5, 17.7, 16.2. LC-MS m / z calc, for C41H65N10O11S [M+H]+905.5, found 905.3. (2S,4R)-1 -((S)-15-azido-8-((2-(2-azidoethoxy)ethoxy)methyl)-2-(tert-butyl)-8-methyl-4-oxo-

[0267] 6.10.13-trioxa-3-azapentadecanoyl)-4-hydroxy-W-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2- carboxamide (16).

[0268] Follow General Procedure D, using carboxylic acid 13 and VH032-amine (14, synthesised through literature procedures2 5). Yield: 312 mg (77%);1H NMR (500 MHz, CDCh): 6 = 8.68 (s, 1 H), 7.39-7.30 (m, 5H), 7.12 (d, J = 8.3 Hz, 1 H), 4.75 (t, J = 7.9 Hz, 1 H), 4.60-4.51 (m, 2H), 4.45 (d, J = 8.5 Hz, 1 H), 4.34 (dd, J = 5.4, 15.0 Hz, 1 H), 4.14 (d, J = 11 .1 Hz, 1 H), 3.93 (s, 2H), 3.75-3.28 (m, 23H), 2.75 (s, 1 H), 2.64-2.57 (m, 1 H), 2.52 (s, 3H), 2.12 (dd, J = 7.9, 13.7 Hz, 1 H), 0.99 (s, 3H), 0.95 ppm (s, 9H); LCMS calc, for C37H57N10O9S [M+H]+is 817.4, found 817.9.

[0269] (2S,4R)-1 -((17S)-1 -amino-11 -((2-(2-(2-azidoethoxy)ethoxy)ethoxy)methyl)-17-(tert-butyl)-11 - methyl-15-oxo-3, 6,9,13-tetraoxa-16 -azaoctadecan-18-oyl)-4-hydroxy-JV-(4-(4-methylthiazol-5- yl)benzyl)pyrrolidine-2 -carboxamide (17).

[0270] Diazide 15 (148 mg, 0.163 mmol) was dissolved in a 4:1 :5 ratio of EtOAc (4.5 mL), THF (1.1 mL) and 1 M HCI (aq) solution (5.6 mL). PPI13 (43 mg, 0.163 mmol) was then dissolved in EtOAc (4.2 mL) and added dropwise over 3 h (0.5 mL / h) to the flask containing the diazide solution. The reaction was then left to stir vigourously at r.t. for 16 h. The reaction was then diluted with 2 M HCI (aq) solution (5 mL) and the aqueous layer was separated and concentrated in vacuo. The residue was then purified by HPLC using a linear gradient over 10 min from 5% to 95% MeCN in 0.1 % NH3 in water to afford mono amine 17. Yield: 51 mg (36%); Contains a mixture of two diastereomers; Analytics matched those reported in literature (ref.4);1H NMR (500 MHz, CDCh) 6 (ppm) = 8.67 (s, 1 H), 8.52 (br. s, 1 H), 7.38- 7.33 (m, 4H), 7.17 (m, 1 H), 4.67 (m, 1 H), 4.55-4.47 (m, 3H), 4.38 (m, 1 H), 4.07-3.94 (m, 4H), 3.70- 3.21 (m, 31 H), 2.98 (m, 2H), 2.51 (s, 3H), 2.31 (s, 1 H), 2.23 (s, 1 H), 1.02-0.93 (m, 12H);13C NMR (126 MHz, CDCh) 6 (ppm) = 171.4, 171.03, 170.98, 170.72, 170.65, 169.4, 150.2, 148.4, 138.51 , 138.47, 131.6, 130.67, 130.66, 129.36, 129.35, 127.97, 74.2, 74.1 , 74.0, 73.9, 73.1 , 71 .1 , 70.87, 70.84, 70.80, 71.72, 70.70, 70.62, 70.45, 70.42, 70.38, 70.34, 70.3, 70.2, 70.2, 70.0, 69.9, 68.6, 68.5, 59.0, 57.3, 57.0, 50.6, 43.0, 42.99, 41.03, 41.01 , 39.8, 37.07, 36.98, 35.17, 35.10, 26.4, 17.5, 16.0; LC-MS calc, for C41H67N8O11S [M+H]+879.5, found 879.5.

[0271] (2S,4R)-1 -((2S)-15-amino-8-((2-(2-azidoethoxy)ethoxy)methyl)-2-(tert-butyl)-8-methyl-4-oxo-

[0272] 6.10.13-trioxa-3-azapentadecanoyl)-4-hydroxy-JV-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2- carboxamide (18).

[0273] Diazide 16 (256 mg, 0.313 mmol) was dissolved in a 1 :1 ratio of EtOAc (2 mL) and 2 M HCI (aq) solution (2 mL). PPhs (82 mg, 0.313 mmol) was then dissolved in EtOAc (2 mL) and added dropwise over 3 h (0.5 mL / h) to the flask containing the diazide solution. The reaction was then left to stir at r.t. for 16 h. The reaction was then diluted with 2 M HCI (aq) solution (3 mL) and the aqueous layer was separated, neutralised with 7N NH3 in MeOH and then concentrated in vacuo. The residue was then purified by HPLC using a linear gradient over 10 min from 5% to 95% MeCN in 0.1 % HCOOH in water to afford amine 18. Yield: 120 mg (48%); Contains a mixture of two diastereomers;1H NMR (500 MHz, CDCh): 6 = 8.65 (s, 1 H), 8.44 (s, 1 H), 8.33-8.26 (m, 1 H), 7.36 (d, J = 8.1 Hz, 4H), 7.32 (d, J = 8.3 Hz, 4H), 7.20-7.14 (m, 1 H), 4.62 (t, J = 8.7 Hz, 1 H), 4.57-4.44 (m, 3H), 4.32 (dd, J = 5.3, 14.7 Hz, 1 H), 4.04- 3.99 (m, 3H), 3.69-3.22 (m, 22H), 3.01-2.86 (m, 2H), 2.50 (s, 3H), 2.24-2.12 (m, 2H), 1.01 (s, 9H), 0.96-0.92 ppm (m, 3H);13C NMR (126 MHz, CDCb): 6 = 171 .8, 171.02, 171 .00, 170.96, 170.9, 169.0, 150.3, 148.5, 139.01 , 138.99, 131.8, 130.7, 129.4, 128.1 , 74.7, 74.6, 74.5, 74.3, 73.5, 73.4, 71.31 , 71.26, 71.20, 71.16, 70.82, 70.77, 70.7, 70.5, 70.2, 70.1 , 67.3, 59.3, 57.6, 57.24, 57.21 , 50.9, 43.0, 41 .2, 39.6, 37.6, 35.4, 26.5, 17.81 , 17.78, 16.2; LC-MS calc, for C37H59N8O9S [M+H]+791 .4, found 879.5.

[0274] (2S,4R)-1 -((17S)-1 -azido-17-(tert-butyl)-11 -((2-(2-(2-((2-(2 ,6-d ioxo pi peri d i n-3-y l)-1 ,3- dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)methyl)-11 -methyl-15-oxo-3,6,9,13-tetraoxa- 16-azaoctadecan-18-oyl)-4-hydroxy-W-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2- carboxamide (20).

[0275] To a solution of amine 17 (17 mg, 19.3 pmol) and DIPEA (20 pL, 116 pmol) dissolved in NMP (300 pL) was added 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1 ,3-dione (19) (5.3 mg, 19.3 pmol). The reaction was left to stir in a sealed vial at 100°C for 4 h. the reaction was then purified by HPLC using a linear gradient of 5% to 95% MeCN in 0.1 % HCOOH in water over 10 min gradient. Yield: 12 mg (54%); Contains a mixture of four diastereomers;1H NMR (400 MHz, CDCb): 6 = 9.36-9.13 (m, 1 H), 8.68 (s, 1 H), 7.50-7.40 (m, 2H), 7.38-7.33 (m, 4H), 7.19-7.13 (m, 1 H), 7.09 (d, J = 6.7 Hz, 1 H), 6.92- 6.88 (m, 1 H), 6.53-6.48 (m, 1 H), 4.91-4.81 (m, 1 H), 4.73-4.68 (m, 1 H), 4.63-4.46 (m, 3H), 4.36-4.26 (m, 1 H), 4.11 (d, J = 11.5 Hz, 1 H), 3.98-3.88 (m, 2H), 3.73-3.25 (m, 32H), 2.87-2.61 (m, 3H), 2.56- 2.48 (m, 4H), 2.15-2.04 (m, 2H), 0.96-0.93 ppm (m, 12H);13C NMR (101 MHz, CDCb): 6 = 171.79, 171.76, 171.7, 171.5, 171.4, 171.0, 170.90, 170.85, 170.83, 170.78, 169.43, 169.38, 168.95, 168.90,

[0276] 168.8, 167.8, 150.4, 148.7, 148.6, 147.01 , 146.98, 138.5, 138.4, 136.1 , 132.7, 131.8, 131 .0, 129.6, 128.35, 128.29, 116.91 , 116.87, 11 1.8, 1 11.7, 1 10.6, 74.5, 74.11 , 74.06, 73.9, 73.8, 71.31 , 71.25, 71.2, 71.01 , 70.97, 70.9, 70.83, 70.78, 70.7, 70.6, 70.39, 70.37, 70.2, 69.6, 69.5, 58.75, 58.66, 57.2, 57.1 ,

[0277] 56.8, 50.9, 49.1 , 49.0, 43.4, 42.6, 42.6, 41 .1 , 36.2, 36.1 , 35.1 , 35.0, 31.6, 26.5, 22.9, 17.6, 16.2 LC-MS calc, for C54H76N10O15S [M+2H]2+is 568.3, found 568.4.

[0278] (2S,4R)-1 -((2S)-15-azido-2-(tert-butyl)-8-((2-(2-((2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxoisoindolin-4- yl)amino)ethoxy)ethoxy)methyl)-8-methyl-4-oxo-6,10,13-trioxa-3-azapentadecanoyl)-4-hydroxy- A / -(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2 -carboxamide (21).

[0279] To a solution of amine 18 (36 mg, 45.5 pmol) and DIPEA (50 pL, 287 pmol) dissolved in NMP (1 mL) was added 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1 ,3-dione (19) (15 mg, 54.3 pmol). The reaction was left to stir in a sealed vial at 120°C for 4 h. the reaction was then purified by HPLC using a linear gradient of 40% to 95% MeCN in 0.1 % HCOOH in water over 8 min gradient. Yield: 13 mg (28%); Contains a mixture of four diastereomers;1H NMR (400 MHz, CDCb): 6 = 8.67 (s, 1 H), 7.50- 7.40 (m, 2H), 7.40-7.29 (m, 4H), 7.20-7.11 (m, 1 H), 7.08 (d, J = 7.2 Hz, 1 H), 6.92-6.88 (m, 1 H), 6.55- 6.46 (m, 1 H), 4.93-4.83 (m, 1 H), 4.71 (t, J = 7.8 Hz, 1 H), 4.62-4.47 (m, 3H), 4.36-4.27 (m, 1 H), 4.09 (d, J = 11.6 Hz, 1 H), 3.98-3.82 (m, 2H), 3.75-3.27 (m, 23H), 2.86-2.61 (m, 3H), 2.54-2.46 (m, 4H), 2.19-2.02 (m, 2H), 0.98-0.93 ppm (m, 12H);13C NMR (101 MHz, CDCb): 6 = 172.30, 172.28, 172.09, 172.07, 171.5, 171.4, 171 .0, 170.85, 170.82, 169.4, 168.95, 168.91 , 168.8, 167.8, 150.4, 148.6, 147.0, 146.9, 138.4, 136.1 , 132.8, 132.7, 131.8, 131.7, 131.0, 129.6, 128.3, 1 16.9, 116.8, 111.72, 111 .69, 110.5, 74.65, 74.56, 74.54, 74.46, 74.0, 73.93, 73.86, 73.8, 71.31 , 71.27, 71.22, 71.17, 71.15, 70.8, 70.6, 70.4, 70.2, 69.67, 69.66, 69.59, 69.55, 58.82, 58.78, 58.76, 57.14, 57.1 1 , 57.0, 56.9, 56.8, 50.9, 49.1 , 49.0, 43.3, 42.7, 41 .1 , 36.2, 35.2, 35.0, 31 .6, 26.5, 22.9, 17.5, 16.2; LC-MS calc, for CsoHssN OisS [M+2H]2+is 524.3, found 524.3.

[0280] (17S)-11 -((2-(2-(2-((2-(2, 6-di oxopi pe ridi n-3-y l)-1 ,3-dioxoisoindolin-4- yl)amino)ethoxy)ethoxy)ethoxy)methyl)-17-((2S,4 / ?)-4-hydroxy-2-((4-(4-methylthiazol-5- yl)benzyl)carbamoyl)pyrrolidine-1 -carbonyl)-11 ,18,18-trimethyl-15-oxo-3,6,9,13-tetraoxa-16- azanonadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1 ,2,4]triazolo[4,3- a][1 ,4]diazepin-6-yl)acetate (AB3062) (23).

[0281] Follow General Procedure E, using compound 66 and 1.5 eq of JQ1-acid (22). Purified by HPLC using a linear gradient over 10 min from 25% to 95% MeCN in 0.1 % HCOOH in water. Yield: 2.0 mg (26%); Contains a mixture of four diastereomers;1H NMR (500 MHz, CDCh): 6 = 9.36-9.09 (m, 1 H), 8.76 (s, 1 H), 7.50-7.44 (m, 2H), 7.42-7.32 (m, 8H), 7.20-7.13 (m, 1 H), 7.09 (d, J = 7.0 Hz, 1 H), 6.91 (dd, J = 5.8, 8.0 Hz, 1 H), 6.52 (m, 1 H), 4.94-4.80 (m, 1 H), 4.73-4.69 (m, 1 H), 4.64-4.48 (m, 4H), 4.37-4.26 (m, 3H), 4.11 (d, J = 11.7 Hz, 1 H), 3.98-3.88 (m, 2H), 3.77-3.70 (m, 4H), 3.68-3.50 (m, 19H), 3.47-3.24 (m, 8H), 2.86-2.66 (m, 5H), 2.54-2.46 (m, 4H), 2.42 (s, 3H), 2.35-2.32 (m, 1 H), 2.16 (m, 1 H), 2.07 (m, 1 H), 1.69 (s, 3H), 0.99-0.94 ppm (m, 12H); HRMS m / z calc, for C73H91 CIN 11 O17S2 [M+H]+1492.5719, found: 1492.5341.

[0282] (17S)-11 -((2-(2-(2-((2-(2, 6-di oxopi pe ridi n-3-yl)-1 ,3-dioxoisoindolin-4- yl)amino)ethoxy)ethoxy)ethoxy)methyl)-17-((2S,4 / ?)-4-hydroxy-2-(((S)-1 -(4-(4-methylthiazol-5- yl)phenyl)ethyl)carbamoyl)pyrrolidine-1 -carbonyl)-11 ,18,18-trimethyl-15-oxo-3,6,9,13-tetraoxa- 16-azanonadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f|[1 ,2,4]triazolo[4,3- a][1 ,4]diazepin-6-yl)acetate (AB3066) (24).

[0283] Follow General Procedure E, using compound 67 and 1.5 eq of JQ1-acid (22). Purified by HPLC using a linear gradient over 10 min from 25% to 95% MeCN in 0.1 % HCOOH in water. Yield: 2.6 mg (25%); Contains a mixture of four diastereomers;1H NMR (500 MHz, CDCh): 6 = 9.07-8.90 (m, 1 H), 8.67 (s, 1 H), 7.50-7.36 (m, 8H), 7.32 (d, J = 8.3 Hz, 2H), 7.20-7.16 (m, 1 H), 7.09 (d, J = 6.9 Hz, 1 H), 6.91 (dd, J = 2.0, 8.6 Hz, 1 H), 6.52-6.49 (m, 1 H), 5.09 (dq, J = 7.2, 7.2 Hz, 1 H), 4.92-4.88 (m, 1 H), 4.73 (t, J = 7.6 Hz, 1 H), 4.60 (dd, J = 6.6, 7.4 Hz, 1 H), 4.56-4.50 (m, 2H), 4.34-4.26 (m, 2H), 4.12 (d, J = 10.9 Hz, 1 H), 3.95 (s, 2H), 3.76-3.70 (m, 4H), 3.68-3.54 (m, 19H), 3.47-3.29 (m, 8H), 2.87-2.65 (m, 6H), 2.53- 2.47 (m, 4H), 2.41 (s, 3H), 2.12-2.06 (m, 2H), 1 .69 (s, 3H), 1 .48 (d, J = 6.7 Hz, 3H), 1 .05 (s, 9H), 0.98- 0.95 ppm (m, 3H); HRMS m / z calc, for C74H93CIN11 O17S2 [M+H]+1506.5875, found: 1506.6133. ( 14S)-8-((2-(2-(2-((2-(2,6-dioxopi peridi n-3-y l)-1 ,3-dioxoisoindoli n-4- yl)amino)ethoxy)ethoxy)ethoxy)methyl)-14-((2S,4 / ?)-4-hydroxy-2-((4-(4-methylthiazol-5- yl)benzyl)carbamoyl)pyrrolidine-1 -carbonyl)-8,15,15-trimethyl-12-oxo-3,6,10-trioxa-13- azahexadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f|[1,2,4]triazolo[4,3- a][1,4]diazepin-6-yl)acetate (AB3064) (25).

[0284] Follow General Procedure E, using compound 68 and 1.5 eq of JQ1-acid (22). Purified by HPLC using a linear gradient over 10 min from 25% to 95% MeCN in 0.1% HCOOH in water. Yield: 2.0 mg (32%); Contains a mixture of four diastereomers;1H NMR (500 MHz, CDCh): 6 = 9.25-8.99 (m, 1 H), 8.69 (s, 1 H), 7.50-7.43 (m, 2H), 7.40 (d, J = 8.1 Hz, 2H), 7.37-7.34 (m, 4H), 7.33 (d, J = 8.1 Hz, 2H), 7.19-7.13 (m, 1 H), 7.09 (d, J = 6.9 Hz, 1 H), 6.91 (dd, J = 6.0, 8.4 Hz, 1 H), 6.55-6.48 (m, 1 H), 4.92-4.82 (m, 1 H), 4.76-4.71 (m, 1 H), 4.63-4.48 (m, 4H), 4.37-4.24 (m, 3H), 4.11 (d, J = 10.9 Hz, 1 H), 3.98-3.88 (m, 2H), 3.75-3.69 (m, 4H), 3.68-3.51 (m, 15H), 3.47-3.27 (m, 8H), 2.86-2.66 (m, 5H), 2.53-2.46 (m, 4H), 2.41 (s, 3H), 2.36-2.33 (m, 1 H), 2.19-2.14 (m, 1 H), 2.11-2.05 (m, 1 H), 1.69 (s, 3H), 0.97-0.93 ppm (m, 12H); HRMS m / z calc, for C71H87CIN11O16S2 [M+H]+1448.5457, found: 1448.5259.

[0285] (17S)-11 -((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1 ,3-dioxoisoindolin-5- yl)amino)ethoxy)ethoxy)ethoxy)methyl)-17-((2S,4 / ?)-4-hydroxy-2-((4-(4-methylthiazol-5- yl)benzyl)carbamoyl)pyrrolidine-1 -carbonyl)-11 ,18,18-trimethyl-15-oxo-3,6,9,13-tetraoxa-16- azanonadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3- a][1,4]diazepin-6-yl)acetate (AB3063) (26).

[0286] Follow General Procedure E, using compound 69 and 1.5 eq of JQ1-acid (22). Purified by HPLC using a linear gradient over 10 min from 25% to 95% MeCN in 0.1% HCOOH in water. Yield: 2.6 mg (25%); Contains a mixture of four diastereomers;1H NMR (500 MHz, CDCh): 6 = 8.68 (s, 1 H), 8.58-8.53 (m, 1 H), 7.46-7.38 (m, 8H), 7.35 (d, J = 2.2 Hz, 8H), 7.32 (d, J = 8.8 Hz, 2H), 7.17-7.13 (m, 1 H), 7.13-7.10 (m, 1 H), 5.28-5.23 (m, 1 H), 4.89 (dd, J = 5.1 , 12.5 Hz, 1 H), 4.72 (t, J = 7.9 Hz, 1 H), 4.62-4.52 (m, 3H), 4.51-4.47 (m, 1 H), 4.38-4.25 (m, 3H), 4.09 (d, J = 11.7 Hz, 1 H), 3.95-3.86 (m, 2H), 3.77-3.72 (m, 4H), 3.70-3.51 (m, 19H), 3.48-3.42 (m, 2H), 3.41-3.27 (m, 6H), 2.86 (d, J = 17.2 Hz, 1 H), 2.82-2.66 (m, 5H), 2.55-2.48 (m, 4H), 2.41 (s, 3H), 2.20-2.09 (m, 2H), 1.68 (s, 3H), 0.96-0.94 ppm (m, 12H);13C NMR (126 MHz, CDCh): 6 = 171.7, 171.4, 171.3, 171.0, 170.6, 170.5, 168.44, 168.40, 167.6, 164.0, 155.4, 153.99 (d, J C-F = 248.5 Hz), 150.5, 150.1 , 148.4, 142.89 (d, J C-F = 13.2 Hz), 138.5, 137.0, 136.7,

[0287] 132.3, 131.9, 131.1 , 131.0, 130.9, 130.6, 130.18 (d, J C-F = 2.2 Hz), 130.0, 129.59, 129.58, 128.8, 128.3, 118.70 (d, J C-F = 6.2 Hz), 110.4, 110.30 (d, J C-F = 21 .0 Hz), 106.02-105.96 (m), 74.52, 74.50, 74.48, 73.99, 73.98, 73.9, 73.83, 73.81 , 73.79, 71 .23, 71.19, 71 .1 , 70.9, 70.84, 70.81 , 70.75, 70.72, 70.6, 70.5,

[0288] 70.3, 69.21 , 69.18, 64.2, 58.8, 58.7, 57.1 , 57.05, 57.03, 56.8, 53.9, 49.4, 43.4, 43.1 , 41.1 , 36.9, 36.3, 35.2, 35.2, 31.6, 26.5, 22.9, 17.6, 16.1 , 14.6, 13.3, 11.9;19F{1H} NMR (471 MHz, CDCh) 6 = -127.25*, -127.28*, -127.30*, -127.33* (1 F); HRMS m / z calc, for C73H90CIFN11O17S2 [M+H]+1510.5625, found: 1510.5257. (17S)-11 -((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1 ,3-dioxoisoindolin-5- yl)amino)ethoxy)ethoxy)ethoxy)methyl)-17-((2S,4 / ?)-4-hydroxy-2-(((S)-1 -(4-(4-methylthiazol-5- yl)phenyl)ethyl)carbamoyl)pyrrolidine-1 -carbonyl)-11 ,18,18-trimethyl-15-oxo-3,6,9,13-tetraoxa- 16-azanonadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f|[1,2,4]triazolo[4,3- a][1,4]diazepin-6-yl)acetate (AB3067) (27).

[0289] Follow General Procedure E, using compound 70 and 1.5 eq of JQ1-acid (22). Purified by HPLC using a linear gradient over 10 min from 30% to 95% MeCN in 0.1% HCOOH in water. Yield: 2.4 mg (21%); Contains a mixture of four diastereomers;1H NMR (500 MHz, CDCh): 6 = 8.68 (s, 1 H), 8.64-8.58 (m, 1 H), 7.50-7.45 (m, 1 H), 7.41-7.35 (m, 7H), 7.32 (d, J = 8.6 Hz, 2H), 7.22-7.18 (m, 1 H), 7.11 (d, J H-F = 6.9 Hz, 1 H), 5.31-5.25 (m, 1 H), 5.08 (dq, J = 7.2, 7.2 Hz, 1 H), 4.90 (dd, J = 5.5, 12.4 Hz, 1 H), 4.72 (t, J = 7.9 Hz, 1 H), 4.60 (dd, J = 6.1 , 7.9 Hz, 1 H), 4.56-4.49 (m, 2H), 4.35-4.25 (m, 2H), 4.09 (d, J = 11 .0 Hz, 1 H), 3.95 (d, J = 15.9 Hz, 1 H), 3.92 (d, J = 16.4 Hz, 1 H), 3.77-3.71 (m, 4H), 3.67-3.54 (m, 19H), 3.48-3.30 (m, 8H), 2.90-2.70 (m, 3H), 2.66 (s, 3H), 2.52-2.45 (m, 4H), 2.41 (s, 3H), 2.14-2.07 (m, 2H), 1 .68 (s, 3H), 1 .49-1 .45 (m, 3H), 1 .05 (s, 9H), 0.98-0.96 ppm (m, 3H);13C NMR (126 MHz, CDCh): 6 =

[0290] 171.7, 171.49, 171.46, 171.38, 171.36, 170.7, 170.0, 168.54, 168.49, 167.6, 167.04, 167.02, 164.0,

[0291] 162.7, 155.4, 153.97 (d, J C-F = 248.7 Hz), 150.5, 150.1 , 148.5, 143.5, 142.87 (d, J C-F = 12.5 Hz), 136.9,

[0292] 136.7, 132.3, 131.8, 131.04, 131.02, 130.8, 130.6, 130.16 (d, J C-F = 2.1 Hz), 130.04, 130.00, 129.6,

[0293] 128.8, 126.6, 118.65 (d, C-F = 8.3 Hz), 110.28 (d, J C-F = 22.5 Hz), 105.96 (d, J C-F = 5.3 Hz), 74.5, 74.0, 73.9, 73.8, 72.7, 71.2, 71.1 , 70.9, 70.84, 70.76, 70.7, 70.6, 70.5, 70.2, 69.2, 69.11 , 69.09, 69.08,

[0294] 64.2, 58.64, 58.61 , 57.1 , 56.8, 53.8, 49.4, 49.0, 43.0, 41 .1 , 36.9, 35.8, 35.3, 31 .6, 26.6, 22.9, 22.4, 17.6,

[0295] 16.2, 14.5, 13.2, 11.9;19F{1H} NMR (471 MHz, CDCh) 6 = -127.22*, -127.26*, -127.26*, -127.29* (1 F); HRMS m / z calc, for C74H92CIFN11O17S2 [M+H]+1524.5781 , found: 1524.5363.

[0296] (14S)-8-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5- yl)amino)ethoxy)ethoxy)ethoxy)methyl)-14-((2S,4 / ?)-4-hydroxy-2-((4-(4-methylthiazol-5- yl)benzyl)carbamoyl)pyrrolidine-1 -carbonyl)-8,15,15-trimethyl-12-oxo-3,6,10-trioxa-13- azahexadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f|[1,2,4]triazolo[4,3- a][1,4]diazepin-6-yl)acetate (AB3065) (28).

[0297] Follow General Procedure E, using compound 71 and 1.5 eq of JQ1-acid (22). Purified by HPLC using a linear gradient over 10 min from 25% to 95% MeCN in 0.1% HCOOH in water. Yield: 3.1 mg (27%);1H NMR (500 MHz, CDCh): 6 = 8.67 (s, 1 H), 8.67-8.48 (m, 1 H), 7.45-7.38 (m, 4H), 7.37-7.34 (m, 4H), 7.32 (d, J = 8.4 Hz, 2H), 7.17-7.07 (m, 2H), 5.27-5.23 (m, 1 H), 4.89 (dd, J = 4.7, 12.3 Hz, 1 H), 4.74 (t, J = 8.1 Hz, 1 H), 4.62-4.47 (m, 4H), 4.40-4.24 (m, 3H), 4.10 (d, J = 12.4 Hz, 1 H), 3.94 (d, J = 15.1 Hz, 1 H), 3.89 (d, J = 15.0 Hz, 1 H), 3.75 (t, J = 5.2 Hz, 2H), 3.71 (t, J = 5.0 Hz, 2H), 3.69-3.54 (m, 15H), 3.47-3.30 (m, 8H), 2.88-2.66 (m, 5H), 2.53-2.47 (m, 4H), 2.41 (s, 3H), 2.38-2.34 (m, 1 H), 2.22-2.10 (m, 2H), 1.69 (s, 3H), 0.97-0.93 ppm (m, 12H);19F NMR (471 MHz, CDCh) 6 = -127.23— 127.34 (m, 1 F); HRMS m / z calc, for C71H86CIFN11O16S2 [M+H]+1466.5362, found: 1466.5249. (17S)-11 -((2-(2-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1 ,3-dioxoisoindolin-5- yl)amino)ethoxy)ethoxy)methyl)-17-((2S,4 / ?)-4-hydroxy-2-((4-(4-methylthiazol-5- yl)benzyl)carbamoyl)pyrrolidine-1 -carbonyl)-11 ,18,18-trimethyl-15-oxo-3,6,9,13-tetraoxa-16- azanonadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1 ,2,4]triazolo[4,3- a][1 ,4]diazepin-6-yl)acetate (AB3126) (29).

[0298] Follow General Procedure E, using compound 72 and 1.5 eq of JQ1-acid (22). Purified by HPLC using a linear gradient over 15 min from 10% to 95% MeCN in 0.1 % HCOOH in water. Yield: 3.1 mg (27%);1H NMR (500 MHz, CDCb): 6 = 8.68 (s, 1 H), 8.66-8.57 (m, 1 H), 7.49-7.44 (m, 1 H), 7.43-7.39 (m, 3H), 7.36 (s, 4H), 7.32 (d, J = 8.0 Hz, 2H), 7.17 (d, J = 7.9 Hz, 1 H), 7.14-7.10 (m, 1 H), 5.28-5.22 (m, 1 H), 4.89 (d, J = 12.1 Hz, 1 H), 4.73 (t, J = 7.8 Hz, 1 H), 4.63-4.47 (m, 4H), 4.39-4.27 (m, 3H), 4.11-4.08 (m, 1 H), 3.98-3.86 (m, 2H), 3.76-3.70 (m, 4H), 3.69-3.51 (m, 15H), 3.47-3.25 (m, 8H), 2.87-2.65 (m, 6H), 2.52-2.46 (m, 4H), 2.41 (s, 3H), 2.21-2.10 (m, 2H), 1.67 (s, 3H), 0.96 (s, 9H), 0.93 ppm (s, 3H);19F{1H} NMR (471 MHz, CDCb) 6 = -127.35*, -127.36*, -127.41*, -127.41* (1 F); HRMS m / z calc, for C71H86CIFN11O16S2 [M+H]+1466.5362, found: 1466.5441.

[0299] (14S)-8-((2-(2-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1 ,3-dioxoisoindolin-5- yl)amino)ethoxy)ethoxy)methyl)-14-((2S,4 / ?)-4-hydroxy-2-((4-(4-methylthiazol-5- yl)benzyl)carbamoyl)pyrrolidine-1 -carbonyl)-8,15,15-trimethyl-12-oxo-3,6,10-trioxa-13- azahexadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f|[1 ,2,4]triazolo[4,3- a][1 ,4]diazepin-6-yl)acetate (AB3125) (30).

[0300] Follow General Procedure E, using compound 73 and 1.5 eq of JQ1-acid (22). Purified by HPLC using a linear gradient over 15 min from 10% to 95% MeCN in 0.1 % HCOOH in water. Yield: 3.2 mg (44%);1H NMR (500 MHz, CDCb): 6 = 8.68 (s, 1 H), 8.61-8.52 (m, 1 H), 7.50-7.45 (m, 1 H), 7.43-7.34 (m, 7H), 7.32 (d, J = 8.7 Hz, 2H), 7.20-7.16 (m, 1 H), 7.14-7.1 1 (m, 1 H), 5.31-5.26 (m, 1 H), 4.92-4.87 (m, 1 H), 4.73 (t, J = 8.1 Hz, 1 H), 4.62-4.54 (m, 3H), 4.51-4.48 (m, 1 H), 4.37-4.29 (m, 2H), 4.28-4.23 (m, 1 H), 4.13-4.09 (m, 1 H), 3.96-3.86 (m, 2H), 3.74-3.69 (m, 4H), 3.69-3.54 (m, 11 H), 3.47-3.27 (m, 8H), 2.88-2.65 (m, 5H), 2.52-2.47 (m, 4H), 2.41 (s, 3H), 2.37-2.33 (m, 1 H), 2.22-2.16 (m, 1 H), 2.13-2.10 (m, 1 H), 1.68 (s, 3H), 0.96 (s, 9H), 0.94-0.91 ppm (m, 3H);19F{1H} NMR (471 MHz, CDCb) 6 = -127.34*, -127.34*, -127.39*, -127.40* (1 F); HRMS m / z calc, for C69H82CIFN11O15S2 [M+H]+1422.5100, found: 1422.5330.

[0301] (17S)-11 -((2-(2-(2-(4-(2-(2 ,6-d ioxo pi peri d i n-3-y l)-1 ,3-dioxoisoindolin-4-yl)piperazin-1 - yl)ethoxy)ethoxy)ethoxy)methyl)-17-((2S,4 / ?)-4-hydroxy-2-((4-(4-methylthiazol-5- yl)benzyl)carbamoyl)pyrrolidine-1 -carbonyl)-11 ,18,18-trimethyl-15-oxo-3,6,9,13-tetraoxa-16- azanonadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1 ,2,4]triazolo[4,3- a][1 ,4]diazepin-6-yl)acetate (AB3029) (31).

[0302] To solution of Boc-protected compound 76 (55 mg, 0.12 mmol) in DCM (2 mL), was added 4N HCI in dioxane (0.62 mL, 2.48 mmol) and the solution was left to stir at r.t. for 16 h. The reaction was then evaporated to dryness to quantitatively yield an amine intermediate as a HCI salt (46 mg, 0.12 mmol). The amine intermediate (3.4 mg, 9.1 pmol) was dissolved in DMF (100 pL) followed by the addition of DIPEA (5.4 pL, 30 pmol). This was then added to a solution containing mesylate 75 in DMF (200 pL) and stirred for 16 h at 80°C. The reaction was concentrated in vacuo and purified by HPLC using a linear gradient over 10 min from 5% to 95% MeCN in 0.1 % HCOOH in water. Yield: 4.0 mg (68%); Contains a mixture of four diastereomers;1H NMR (500 MHz, CDCh): 6 = 8.75-8.66 (m, 2H), 7.59 (t, J = in Hz, 1 H), 7.45-7.39 (m, 4H), 7.36 (s, 4H), 7.32 (d, J = 8.5 Hz, 2H), 7.18-7.15 (m, 2H), 4.96-4.91 (m, 1 H), 4.74-4.70 (m, 1 H), 4.62-4.49 (m, 4H), 4.39-4.26 (m, 3H), 4.09 (d, J = 11 .4 Hz, 1 H), 3.96 (d, J = 15.3 Hz, 1 H), 3.92 (d, J = 15.1 Hz, 1 H), 3.75-3.72 (m, 2H), 3.69-3.53 (m, 23H), 3.43-3.29 (m, 10H), 2.88-2.66 (m, 11 H), 2.54-2.48 (m, 4H), 2.41 (s, 3H), 2.19-2.13 (m, 1 H), 2.12-2.06 (m, 1 H), 1.69 (s, 3H), 0.98-0.96 ppm (m, 12H); HRMS m / z calc, for C77H98CIN12O17S2 [M+H]+1561.6297, found: 1561.6552.

[0303] (17S)-11 -((2-(2-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1 ,3-dioxoisoindolin-5-yl)piperazin-1 - yl)ethoxy)ethoxy)ethoxy)methyl)-17-((2S,4 / ?)-4-hydroxy-2-((4-(4-methylthiazol-5- yl)benzyl)carbamoyl)pyrrolidine-1 -carbonyl)-11 ,18,18-trimethyl-15-oxo-3,6,9,13-tetraoxa-16- azanonadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1 ,2,4]triazolo[4,3- a][1 ,4]diazepin-6-yl)acetate (AB3030) (32).

[0304] To solution of Boc-protected compound 77 (77 mg, 0.16 mmol) in DCM (1 .3 mL), was added 4N HCI in dioxane (0.84 mL, 3.3 mmol) and the solution was left to stir at r.t. for 16 h. The reaction was then evaporated to dryness to quantitatively yield an amine intermediate as a HCI salt (63 mg, 0.16 mmol). The amine intermediate (3.6 mg, 9.1 pmol) was dissolved in DMF (100 pL) followed by the addition of DIPEA (5.4 pL, 30 pmol). This was then added to a solution containing mesylate 75 in DMF (200 pL) and stirred for 16 h at 80°C. The reaction was concentrated in vacuo and purified by HPLC using a linear gradient over 10 min from 5% to 95% MeCN in 0.1 % HCOOH in water. Yield: 4.1 mg (68%); Contains a mixture of four diastereomers;1H NMR (500 MHz, CDCh): 6 = 8.68 (s, 1 H), 8.28 (d, J = 31 .3 Hz, 1 H), 7.49-7.36 (m, 9H), 7.32 (d, J = 8.6 Hz, 2H), 7.15 (d, J = 8.0 Hz, 1 H), 4.92 (dd, J = 5.2, 12.2 Hz, 1 H), 4.73 (t, J = 7.7 Hz, 1 H), 4.62-4.53 (m, 3H), 4.50 (d, J = 8.4 Hz, 1 H), 4.40-4.26 (m, 3H), 4.08 (d, J = 11.1 Hz, 1 H), 3.98-3.88 (m, 2H), 3.76-3.72 (m, 2H), 3.70-3.53 (m, 23H), 3.44-3.29 (m, 10H), 2.91-2.66 (m, 11 H), 2.51 (s, 4H), 2.41 (s, 3H), 2.20-2.12 (m, 2H), 1 .68 (s, 3H), 0.98-0.94 ppm (m, 12H);19F NMR (471 MHz, CDCh) 6 = -110.75—110.81 (m, 1 F); HRMS m / z calc, for

[0305] C77H97CIFN12O17S2 [M+H]+1579.6203, found: 1579.6462.

[0306] 2, 5, 7,10,13-pentaoxapentadecan-15-ol (35).

[0307] Follow General Procedure F, using triethylene glycol (33) and MEMCI. Purified by flash column chromatography (80 g silica column) using a linear gradient from 0% to 20% MeOH in DCM. Yield: 3.15 g (66%);1H NMR (500 MHz, CDCh): 6 = 4.76 (s, 2H), 3.75-3.70 (m, 6H), 3.70-3.65 (m, 6H), 3.63-3.60 (m, 2H), 3.58-3.55 (m, 2H), 3.39 (s, 3H), 2.39 ppm (t, J = 6.3 Hz, 1 H);13C NMR (126 MHz, CDCh): 6 = 95.8, 72.6, 71 .9, 70.8, 70.7, 70.6, 67.0, 67.0, 61 .9, 59.1 .

[0308] 2, 5, 7,10-tetraoxadodecan-12-ol (36).

[0309] Follow General Procedure F, using diethylene glycol (34) and MEMCI. Purified by flash column chromatography (24 g silica column) using a linear gradient from 0% to 6% MeOH in DCM. Yield: 615 mg (40%);1H NMR (500 MHz, CDCb): 6 = 4.76 (s, 2H), 3.76-3.70 (m, 6H), 3.70-3.67 (m, 2H), 3.61 (dd, J = 4.6, 4.6 Hz, 2H), 3.56 (dd, J = 4.7, 4.7 Hz, 2H), 3.39 (3H, s), 2.31 ppm (dt, J = 2.3, 6.3 Hz, 1 H);

[0310] 13C NMR (126 MHz, CDCb): 6 = 95.8, 72.5, 72.0, 70.6, 67.2, 67.1 , 62.0, 59.1.

[0311] 2, 4, 7,10-tetraoxadodecan-12-ol (37).

[0312] Follow General Procedure F, using triethylene glycol (33) and MOMBr. Purified by flash column chromatography (80 g silica column) using a linear gradient from 0% to 8% MeOH in DCM. Yield: 2.86 g (74%);1H NMR (500 MHz, CDCb): 6 = 4.66 (s, 2H), 3.75-3.66 (m, 10H), 3.61 (dd, J = 4.5, 4.5 Hz, 2H), 3.37 (s, 3H), 2.44 ppm (t, J = 6.3 Hz, 1 H);13C NMR (126 MHz, CDCb): 6 = 96.7, 72.6, 70.8, 70.7, 70.6, 66.9, 61.9, 55.4.

[0313] 2, 5, 7,10,13-pentaoxapentadecan-15-yl methanesulfonate (38).

[0314] Follow General Procedure G, using alcohol 35. Yield: 729 mg (37%);1H NMR (400 MHz, CDCb): 6 = 4.75 (s, 2H), 4.39-4.36 (m, 2H), 3.78-3.75 (m, 2H), 3.73-3.63 (m, 10H), 3.57-3.54 (m, 2H), 3.39 (s, 3H), 3.07 ppm (s, 3H);13C NMR (101 MHz, CDCb): 6 = 95.8, 71 .9, 70.8, 70.7, 69.3, 69.2, 67.0, 59.1 , 37.9.

[0315] 2.5.7.10-tetraoxadodecan-12-yl methanesulfonate (39).

[0316] Follow General Procedure G, using alcohol 36. Yield: 659 mg (77%);1H NMR (500 MHz, CDCb): 6 = 4.74 (s, 2H), 4.39-4.37 (m, 2H), 3.79-3.76 (m, 2H), 3.75-3.66 (m, 6H), 3.57-3.54 (m, 2H), 3.39 (s, 3H), 3.06 ppm (s, 3H);13C NMR (126 MHz, CDCb): 6 = 95.8, 71 .9, 70.8, 69.22, 69.16, 67.1 , 67.0, 59.2, 37.8.

[0317] 2.4.7.10-tetraoxadodecan-12-yl methanesulfonate (40).

[0318] Follow General Procedure G, using alcohol 37. Yield: 1.14 g (81 %);1H NMR (500 MHz, CDCb): 6 = 4.65 (s, 2H), 4.39-4.37 (m, 2H), 3.79-3.76 (m, 2H), 3.71-3.63 (m, 8H), 3.37 (s, 3H), 3.07 ppm (s, 3H);13C NMR (126 MHz, CDCb): 6 = 96.7, 70.9, 70.8, 70.7, 69.3, 69.2, 66.9, 55.4, 37.9.

[0319] 3-(allyloxy)-2-((2-(2-(2-azidoethoxy)ethoxy)ethoxy)methyl)-2-methylpropan-1-ol (41).

[0320] Follow General Procedure A, using 1.0 eq. diol 5, 1.2 eq. of NaH and 1.0 eq. of 2-(2-(2- azidoethoxy)ethoxy)ethyl methanesulfonate (6). Purified by reverse phase flash column chromatography (50 g C18 gold column) using a linear gradient over 11 min from 0% to 100% MeCN in 0.1 % HCOOH in water. Yield: 315 mg (60%);1H NMR (500 MHz, CDCb): 6 = 5.93-5.84 (m, 1 H), 5.26 (qd, J = 1.7, 17.4 Hz, 1 H), 5.16 (qd, J = 1.4, 10.6 Hz, 1 H), 3.97 (td, J = 1.3, 5.3 Hz, 2H), 3.69-3.59 (m, 11 H), 3.56 (s, 2H), 3.51 (d, J = 9.0 Hz, 1 H), 3.44-3.38 (m, 5H), 2.99 (br. s, 1 H), 0.88 ppm (s, 3H);13C NMR (126 MHz, CDCb): 6 = 135.0, 116.7, 76.0, 74.7, 72.6, 71 .1 , 70.9, 70.8, 70.6, 70.2, 69.2, 50.9, 40.8, 17.7. 3-(allyloxy)-2-((2-(2-azidoethoxy)ethoxy)methyl)-2-methylpropan-1-ol (42).

[0321] Follow General Procedure A, using 1.0 eq. diol 5, 1.2 eq. of NaH and 1.0 eq. of 2-(2-azidoethoxy)ethyl methanesulfonate (7). Purified by reverse phase flash column chromatography (50 g C18 gold column) using a linear gradient over 10 min from 0% to 100% MeCN in 0.1 % HCOOH in water. Yield: 244 mg (33%);1H NMR (400 MHz, CDCh): 6 = 5.95-5.84 (m, 1 H), 5.26 (dd, J = 1.3, 17.2 Hz, 1 H), 5.16 (d, J = 10.3 Hz, 1 H), 3.97 (d, J = 5.3 Hz, 2H), 3.70-3.59 (m, 6H), 3.57 (s, 2H), 3.53 (d, J = 9.1 Hz, 1 H), 3.47- 3.35 (m, 5H), 2.91 (br. s, 1 H), 0.88 ppm (s, 3H);13C NMR (101 MHz, CDCh): 6 = 134.9, 116.8, 76.0, 74.9, 72.6, 71.2, 70.6, 70.2, 69.3, 50.9, 40.8, 17.7.

[0322] 15-((allyloxy)methyl)-25-azido-15-methyl-2,4,7,10,13,17,20,23-octaoxapentacosane (43).

[0323] Follow General Procedure A, using 1.0 eq of alcohol 41 , 1.5 eq. of NaH and 1.5 eq. of mesylate 40. Purified by reverse phase flash column chromatography (15.5 g C18 gold column) using a linear gradient over 10 min from 0% to 100% MeCN in 0.1 % HCOOH in water. Yield: 78 mg (50%);1H NMR (500 MHz, CDCh): 6 = 5.92-5.83 (m, 1 H), 5.24 (dd, J = 1.5, 17.3 Hz, 1 H), 5.13 (dd, J = 1.2, 10.5 Hz, 1 H), 4.65 (s, 2H), 3.94 (d, J = 5.4 Hz, 2H), 3.70-3.60 (m, 18H), 3.58-3.53 (m, 4H), 3.40-3.36 (m, 5H), 3.33 (s, 4H), 3.29 (s, 2H), 0.94 ppm (s, 3H);13C NMR (126 MHz, CDCh): 6 = 135.5, 116.2, 96.7, 74.1 , 73.2, 72.4, 71.24, 71.22, 71.0, 70.9, 70.85, 70.82, 70.7, 70.6, 70.2, 67.0, 55.3, 50.9, 41.1 , 17.5.

[0324] 15-((allyloxy)methyl)-25-azido-15-methyl-2,5,7,10,13,17,20,23-octaoxapentacosane (44).

[0325] Follow General Procedure A, using 1.0 eq of alcohol 40, 1.5 eq. of NaH and 1.5 eq. of mesylate 39. Purified by reverse phase flash column chromatography (15.5 g C18 gold column) using a linear gradient over 10 min from 0% to 100% MeCN in 0.1 % HCOOH in water. Yield: 82 mg (53%);1H NMR (500 MHz, CDCh): 6 = 5.92-5.84 (m, 1 H), 5.24 (dd, J = 1.6, 17.2 Hz, 1 H), 5.13 (dd, J = 1.1 , 10.4 Hz, 1 H), 4.75 (s, 2H), 3.94 (d, J = 5.3 Hz, 2H), 3.72-3.60 (m, 16H), 3.58-3.54 (m, 6H), 3.40-3.36 (m, 5H), 3.33 (s, 4H), 3.29 (s, 2H), 0.94 ppm (s, 3H); );13C NMR (126 MHz, CDCh): 6 = 135.5, 1 16.2, 95.8, 74.1 , 73.2, 72.4, 72.0, 71.2, 71.0, 70.9, 70.7, 70.65, 70.58, 70.2, 67.2, 67.0, 59.1 , 50.9, 41.1 , 17.6.

[0326] 15-((allyloxy)methyl)-22-azido-15-methyl-2,4,7,10,13,17,20-heptaoxadocosane (45).

[0327] Follow General Procedure A, using 1.0 eq of alcohol 42, 1.5 eq. of NaH and 1.5 eq. of mesylate 40. Purified by reverse phase flash column chromatography (30 g C18 gold column) using a linear gradient over 10 min from 0% to 100% MeCN in 0.1 % HCOOH in water. Yield: 130 mg (52%);1H NMR (400 MHz, CDCh): 6 = 5.94-5.83 (m, 1 H), 5.25 (dd, J = 1.6, 17.3 Hz, 1 H), 5.14 (dd, J = 1.4, 10.3 Hz, 1 H), 3.94 (d, J = 5.3 Hz, 2H), 3.71-3.53 (m, 18H), 3.40-3.29 (m, 1 1 H), 0.96 ppm (s, 3H);13C NMR (101 MHz, CDCh): 6 = 135.5, 1 16.2, 96.7, 74.2, 74.1 , 73.2, 72.4, 71 .3, 71.2, 70.9, 70.8, 70.7, 70.6, 70.2, 67.0, 55.3, 51.0, 41.1 , 17.6.

[0328] 15-((allyloxy)methyl)-22-azido-15-methyl-2,5,7,10,13,17,20-heptaoxadocosane (46).

[0329] Follow General Procedure A, using 1.0 eq of alcohol 42, 1.5 eq. of NaH and 1.5 eq. of mesylate 39. Purified by reverse phase flash column chromatography (30 g C18 gold column) using a linear gradient over 10 min from 0% to 100% MeCN in 0.1 % HCOOH in water. Yield: 11 1 mg (56%);1H NMR (400 MHz, CDCh): 6 = 5.94-5.84 (m, 1 H), 5.25 (dd, J = 1.5, 17.2 Hz, 1 H), 5.13 (dd, J = 1.1 , 10.5 Hz, 1 H), 3.94 (d, J = 5.5 Hz, 2H), 3.73-3.55 (m, 18H), 3.40-3.34 (m, 9H), 3.30 (s, 2H), 0.95 ppm (s, 3H);13C NMR (101 MHz, CDCh): 6 = 135.5, 1 16.2, 95.8, 74.2, 74.1 , 73.2, 72.4, 72.0, 71.3, 71.2, 70.7, 70.65, 70.59, 70.2, 67.2, 67.0, 59.1 , 51.0, 41.1 , 17.6.

[0330] 18-((allyloxy)methyl)-18-methyl-2, 5, 7,10,13,16,20,23,26,29,31 ,34-dodecaoxapentatriacontane (47).

[0331] Follow General Procedure A, using 1 .0 eq of diol 5, 4 eq. of NaH and 3 eq. of mesylate 38. Purified by reverse phase flash column chromatography (50 g C18 gold column) using a linear gradient over 11 min from 0% to 100% MeCN in 0.1 % HCOOH in water. Yield: 205 mg (55%);1H NMR (400 MHz, CDCh): 6 = 5.93-5.83 (m, 1 H), 5.24 (qd, J = 1.7, 17.2 Hz, 1 H), 5.13 (qd, J = 1.5, 10.4 Hz, 1 H), 4.75 (s, 4H), 3.94 (td, J = 1.5, 5.4 Hz, 2H), 3.74-3.60 (m, 24H), 3.57-3.53 (m, 8H), 3.39 (s, 6H), 3.32 (s, 4H), 3.29 (s, 2H), 0.94 ppm (s, 3H);13C NMR (101 MHz, CDCh): 6 = 135.5, 116.2, 95.8, 74.1 , 73.2, 72.4, 72.0, 71.2, 70.84, 70.81 , 70.7, 70.6, 67.1 , 67.0, 59.1 , 41.1 , 17.6.

[0332] 15-((2-(2-(2-azidoethoxy)ethoxy)ethoxy)methyl)-15-methyl-2,4,7,10,13,17-hexaoxanonadecan-

[0333] 19-al (48).

[0334] Follow General Procedure B, using alkene 43. Yield: 200 mg (89%);1H NMR (500 MHz, CDCh): 6 = 9.71 (s, 1 H), 4.63 (s, 2H), 4.00 (d, J = 0.8 Hz, 2H), 3.70-3.28 (m, 32H), 0.95 ppm (s, 3H);13C NMR (126 MHz, CDCh): 6 = 202.2, 96.7, 77.0, 74.7, 73.9, 71 .22, 71 .20, 70.9, 70.83, 70.81 , 70.7, 70.6, 70.2, 67.0, 55.3, 50.9, 41.3, 17.5.

[0335] 15-((2-(2-(2-azidoethoxy)ethoxy)ethoxy)methyl)-15-methyl-2,5,7,10,13,17-hexaoxanonadecan- 19-al (49).

[0336] Follow General Procedure B, using alkene 44. Yield: 62 mg (76%);1H NMR (500 MHz, CDCh): 6 = 9.71 (s, 1 H), 4.72 (s, 2H), 4.00 (s, 2H), 3.73-3.29 (m, 33H), 0.95 ppm (s, 3H);13C NMR (126 MHz, CDCh): 202.1 , 95.8, 77.0, 74.7, 73.90, 73.86, 71.9, 71.2, 70.9, 70.8, 70.7, 70.65, 70.57, 70.2, 67.1 , 67.0, 59.1 , 50.9, 41.3, 17.5.

[0337] 15-((2-(2-azidoethoxy)ethoxy)methyl)-15-methyl-2,4,7,10,13,17-hexaoxanonadecan-19-al (50).

[0338] Follow General Procedure B, using alkene 45. Yield: 62 mg (76%);1H NMR (400 MHz, CDCh): 6 = 9.74 (s, 1 H), 4.66 (s, 2H), 4.02 (s, 2H), 3.72-3.30 (m, 29H), 0.99 ppm (s, 3H);13C NMR (101 MHz, CDCh): 6 = 202.1 , 96.7, 77.0, 74.7, 74.0, 73.9, 71 .25, 71 .21 , 70.84, 70.81 , 70.75, 70.7, 70.6, 70.2, 67.0, 55.3, 51.0, 41.3, 17.5.

[0339] 15-((2-(2-azidoethoxy)ethoxy)methyl)-15-methyl-2,5,7,10,13,17-hexaoxanonadecan-19-al (51).

[0340] Follow General Procedure B, using alkene 46. Yield: 97 mg (90%);1H NMR (400 MHz, CDCh): 6 = 9.74 (s, 1 H), 4.75 (s, 2H), 4.02 (s, 2H), 3.72-3.31 (m, 29H), 0.98 ppm (s, 3H);13C NMR (126 MHz, CDCh): 6 = 202.1 , 95.8, 74.7, 74.0, 73.9, 72.0, 71 .25, 71 .22, 70.8, 70.7, 70.6, 70.2, 67.1 , 67.0, 59.1 , 51 .0, 41 .3, 17.5. 18-(2,5,7,10,13,16-hexaoxaheptadecan-17-y l)-18-methyl-2,5,7,10,13,16,20-heptaoxadocosan-22- al (52).

[0341] Follow General Procedure B, using alkene 47. Yield: 170 mg (87%);1H NMR (500 MHz, CDCh): 6 = 9.73 (t, J = 1 .0 Hz, 1 H), 4.75 (s, 4H), 4.02 (d, J = 1.1 Hz, 2H), 3.73-3.55 (m, 32H), 3.43-3.31 (m, 12H), 0.97 ppm (s, 3H);13C NMR (126 MHz, CDCh): 6 = 202.1 , 95.8, 77.1 , 74.7, 73.9, 72.0, 71.2, 70.82, 70.80, 70.7, 70.6, 67.1 , 67.0, 59.1 , 41.3, 17.5.

[0342] 15-((2-(2-(2-azidoethoxy)ethoxy)ethoxy)methyl)-15-methyl-2,4,7,10,13,17-hexaoxanonadecan-

[0343] 19-oic acid (53).

[0344] Follow General Procedure C, using aldehyde 48. Yield: 199 mg (98%);1H NMR (500 MHz, CDCh): 6 =

[0345] 4.63 (s, 2H), 4.02 (s, 2H), 3.68-3.52 (m, 22H), 3.43-3.33 (m, 11 H), 0.92 ppm (s, 3H);13C NMR (126 MHz, CDCh): 6 = 172.3, 96.6, 75.2, 74.60, 74.55, 71.3, 71.2, 70.8, 70.7, 70.65, 70.58, 70.42, 70.36,

[0346] 70.1. 66.9, 55.3, 50.8, 40.8, 17.8.

[0347] 15-((2-(2-(2-azidoethoxy)ethoxy)ethoxy)methyl)-15-methyl-2,5,7,10,13,17-hexaoxanonadecan- 19-oic acid (54).

[0348] Follow General Procedure C, using aldehyde 49. Yield: 64 mg (99%);1H NMR (500 MHz, CDCh): 6 =

[0349] 4.72 (s, 2H), 3.95 (s, 2H), 3.72-3.51 (m, 22H), 3.42-3.23 (m, 11 H), 0.90 ppm (s, 3H);13C NMR (126 MHz, CDCh): 6 = 173.7, 95.7, 75.3, 74.6, 71.9, 71.1 , 70.8, 70.6, 70.5, 70.4, 70.3, 70.1 , 67.0, 66.91 , 66.88, 59.0, 50.8, 40.9, 17.8.

[0350] 15-((2-(2-azidoethoxy)ethoxy)methyl)-15-methyl-2,4,7,10,13,17-hexaoxanonadecan-19-oic acid

[0351] (55).

[0352] Follow General Procedure C, using aldehyde 50. Yield: 88 mg (95%);1H NMR (400 MHz, CDCh): 6 =

[0353] 4.64 (s, 2H), 4.03 (s, 2H), 3.71-3.50 (m, 18H), 3.43-3.27 (m, 11 H), 0.94 ppm (s, 3H);13C NMR (101 MHz, CDCh): 6 = 172.3, 96.6, 75.3, 74.8, 74.5, 71.3, 71.2, 70.70, 70.65, 70.6, 70.5, 70.4, 70.1 , 68.8,

[0354] 66.9, 55.3, 50.9, 40.8, 17.8.

[0355] 15-((2-(2-azidoethoxy)ethoxy)methyl)-15-methyl-2,5,7,10,13,17-hexaoxanonadecan-19-oic acid

[0356] (56).

[0357] Follow General Procedure C, using aldehyde 51. Yield: 62 mg (63%);1H NMR (400 MHz, CDCh): 6 =

[0358] 4.73 (s, 2H), 4.01 (s, 2H), 3.72-3.51 (m, 18H), 3.42-3.30 (m, 11 H), 0.93 ppm (s, 3H);13C NMR (101 MHz, CDCh): 6 = 173.0, 95.7, 75.5, 74.9, 74.8, 71 .9, 71 .3, 71 .2, 70.5, 70.5, 70.2, 70.1 , 69.5, 67.0, 66.9,

[0359] 59.1. 50.9, 40.8, 17.9.

[0360] 18-(2,5,7,10,13,16-hexaoxaheptadecan-17-y l)-18-methyl-2,5,7,10,13,16,20-heptaoxadocosan-22- oic acid (57).

[0361] Follow General Procedure C, using aldehyde 52. Yield: 147 mg (91%);1H NMR (500 MHz, CDCh): 6 = 4.75 (s, 4H), 4.05 (s, 2H), 3.74-3.55 (m, 32H), 3.44 (s, 2H), 3.42 (d, J = 9.0 Hz, 2H), 3.39 (s, 6H), 3.36 (d, J = 9.1 Hz, 2H), 0.95 ppm (s, 3H):13C NMR (126 MHz, CDCh): 5 = 171 .9, 95.7, 75.2, 74.7, 71 .9,

[0362] 71.3, 70.8, 70.7, 70.6, 70.4, 68.8, 67.0, 66.9, 59.1 , 40.7, 18.0.

[0363] (2S,4R)-1 -((21 S)-15-((2-(2-(2-azidoethoxy)ethoxy)ethoxy)methyl)-21 -(tert-butyl)-l 5-methyl-19- oxo-2, 4, 7,10,13,17-hexaoxa-20-azadocosan-22-oyl)-4-hydroxy-W-(4-(4-methylthiazol-5- yl)benzyl)pyrrolidine-2 -carboxamide (59).

[0364] Follow General Procedure D, using carboxylic acid 53 and VH032-amine (14, synthesised through literature procedures2 5). Yield: 64 mg (59%); Contains a mixture of two diastereomers;1H NMR (500 MHz, CDCh): 6 = 8.65 (s, 1 H), 7.39 (t, J = 6.0 Hz, 1 H), 7.34 (d, J = 8.4 Hz, 2H), 7.31 (d, J = 8.5 Hz, 2H), 7.13 (d, J = 8.9 Hz, 1 H), 4.69 (t, J = 7.8 Hz, 1 H), 4.62 (s, 2H), 4.56-4.47 (m, 3H), 4.32 (dd, J = 5.3, 15.0 Hz, 1 H), 4.01 (d, J = 11.1 Hz, 1 H), 3.92 (d, J = 15.9 Hz, 1 H), 3.88 (d, J = 15.8 Hz, 1 H), 3.68-3.50 (m, 23H), 3.41 (d, J = 9.0 Hz, 1 H), 3.38 (d, J = 9.6 Hz, 1 H), 3.31 (t, J = 18.7 Hz, 9H), 2.51-2.45 (m, 4H), 2.33 ppm (br. s, 1 H), 2.09 (dd, J = 7.9, 13.6 Hz, 1 H), 0.95 (s, 3H), 0.93 ppm (s, 9H);13C NMR (126 MHz, CDCh): 6 = 171.3, 170.9, 170.4, 150.3, 148.5, 138.3, 131.7, 131.0, 129.5, 128.2, 96.6, 74.6, 73.9, 73.8, 71 .1 , 71 .1 , 70.8, 70.71 , 70.69, 70.66, 70.6, 70.54, 70.45, 70.1 , 66.9, 58.6, 56.9, 56.7, 55.2, 50.8, 43.3, 41.1 , 36.1 , 35.2, 26.5, 17.5, 16.1 ; LC-MS m / z calc, for C43H70N7O13S [M+H]+924.5, found: 924.8.

[0365] (2S,4R)-1 -((21 S)-15-((2-(2-(2-azidoethoxy)ethoxy)ethoxy)methyl)-21 -(tert-butyl)-l 5-methyl-19- oxo-2, 4, 7,10,13,17-hexaoxa-20-azadocosan-22-oyl)-4-hydroxy-W-((S)-1 -(4-(4-methylthiazol-5- yl)phenyl)ethyl)pyrrolidine-2 -carboxamide (60).

[0366] Follow General Procedure D, using carboxylic acid 53 and Me-VH032-amine (58, synthesised through literature procedure6). Yield: 89 mg (66%); Contains a mixture of two diastereomers;1H NMR (500 MHz, CDCh): 6 = 8.66 (s, 1 H), 7.46 (d, J = 7.8 Hz, 1 H), 7.38 (d, J = 8.3 Hz, 2H), 7.34 (d, J = 8.2 Hz, 2H), 7.17 (d, J = 8.5 Hz, 1 H), 5.05 (dq, J = 7.1 , 7.2 Hz, 1 H), 4.71 (t, J = 7.7 Hz, 1 H), 4.63 (s, 2H), 4.52 (d, J = 8.8 Hz, 1 H), 4.48 (br. s, 1 H), 4.03 (d, J = 11.9 Hz, 1 H), 3.92 (s, 2H), 3.68-3.51 (m, 23H), 3.43 (d, J = 9.0 Hz, 1 H), 3.39 (d, J = 8.9 Hz, 1 H), 3.38-3.27 (m, 9H), 2.53-2.45 (m, 4H), 2.35 (br. s, 1 H), 2.03 (dd, J =

[0367] 8.3, 13.1 Hz, 1 H), 1.45 (d, J = 7.0 Hz, 3H), 1.04 (s, 9H), 0.97 ppm (s, 3H);13C NMR (101 MHz, CDCh): 6 = 171.6, 170.6, 169.8, 150.4, 148.6, 143.3, 131.7, 131.0, 129.7, 126.5, 96.7, 74.7, 73.94, 73.87, 71 .2, 71 .1 , 70.9, 70.8, 70.7, 70.65, 70.60, 70.5, 70.1 , 66.9, 58.4, 57.1 , 56.6, 55.3, 50.8, 49.0, 41 .1 , 35.5, 35.1 , 26.6, 22.3, 17.6, 16.2; LC-MS m / z calc, for C44H72N7O13S [M+H]+938.5, found: 938.8.

[0368] (2S,4R)-1 -((21 S)-15-((2-(2-(2-azidoethoxy)ethoxy)ethoxy)methyl)-21 -(tert-butyl)-l 5-methyl-19- oxo-2, 5, 7,10,13,17-hexaoxa-20-azadocosan-22-oyl)-4-hydroxy-JV-(4-(4-methylthiazol-5- yl)benzyl)pyrrolidine-2 -carboxamide (61).

[0369] Follow General Procedure D, using carboxylic acid 54 and VH032-amine (14, synthesised through literature procedures2 5). Yield: 58 mg (50%); Contains a mixture of two diastereomers;1H NMR (500 MHz, CDCh): 6 = 8.65 (s, 1 H), 7.38 (t, J = 5.9 Hz, 1 H), 7.33 (d, J = 8.5 Hz, 2H), 7.32 (d, J = 8.6 Hz, 2H), 7.13 (d, J = 9.0 Hz, 1 H), 4.71-4.67 (m, 3H), 4.55-4.46 (m, 3H), 4.32 (dd, J = 5.3, 15.0 Hz, 1 H), 4.01 (d, J = 11 .3 Hz, 1 H), 3.90 (s, 2H), 3.68-3.51 (m, 23H), 3.40 (d, J = 8.8 Hz, 1 H), 3.38 (d, J = 9.0 Hz, 1 H), 3.32 (d, J = 34.6 Hz, 9H), 2.50-2.44 (m, 4H), 2.30 (br. s, 1 H), 2.08 (dd, J = 7.7, 13.5 Hz, 1 H), 0.95 (s, 3H), 0.92 ppm (s, 9H);13C NMR (126 MHz, CDCb): 6 = 171 .3, 171.0, 170.4, 150.3, 148.5, 138.3, 131.7, 131.0, 129.5, 128.1 , 95.7, 74.6, 73.9, 73.8, 71.8, 71.12, 71.09, 70.8, 70.7, 70.5, 70.4, 70.1 , 67.0, 66.9, 59.0, 58.6, 56.9, 56.7, 50.8, 43.3, 41 .1 , 36.1 , 35.2, 26.4, 17.5, 16.1 ; LC-MS m / z calc, for C43H70N7O13S [M+H]+924.5, found: 924.8.

[0370] (2S,4R)-1 -((21 S)-15-((2-(2-azidoethoxy)ethoxy)methyl)-21 -(tert-butyl)-l 5-methyl-19-oxo-

[0371] 2.4.7.10.13.17-hexaoxa-20-azadocosan-22-oyl)-4-hydroxy-W-(4-(4-methylthiazol-5- yl)benzyl)pyrrolidine-2 -carboxamide (62).

[0372] Follow General Procedure D, using carboxylic acid 55 and VH032-amine (14, synthesised through literature procedures2 5). Yield: 51 mg (61%); Contains a mixture of two diastereomers;1H NMR (400 MHz, CDCb): 6 = 8.65 (s, 1 H), 7.39 (t, J = 5.5 Hz, 1 H), 7.36-7.28 (m, 4H), 7.15 (d, J = 8.6 Hz, 1 H), 4.70 (t, J = 7.7 Hz, 1 H), 4.62 (s, 2H), 4.57-4.46 (m, 3H), 4.32 (dd, J = 5.1 , 15.1 Hz, 1 H), 4.02 (d, J = 11.1 Hz, 1 H), 3.90 (s, 2H), 3.68-3.47 (m, 19H), 3.42 (d, J = 9.3 Hz, 1 H), 3.38 (d, J = 9.2 Hz, 1 H), 3.36-3.26 (m, 9H), 2.50-2.42 (m, 4H), 2.13-2.03 (m, 1 H), 0.96 (s, 3H), 0.94 ppm (s, 9H);13C NMR (101 MHz, CDCb): 6 = 171.3, 171.0, 170.4, 150.4, 148.5, 138.3, 131.7, 131.0, 129.5, 128.1 , 96.6, 74.6, 74.0, 73.9, 73.84, 73.78, 71.15, 71.08, 70.8, 70.69, 70.66, 70.6, 70.5, 70.1 , 66.9, 58.7, 56.9, 56.7, 55.2, 50.8, 43.3, 41.1 , 36.1 , 35.2, 26.5, 17.5, 16.1 ; LC-MS m / z calc, for C41H64N7O12S [M-H]- 878.4, found: 878.2.

[0373] (2S,4R)-1 -((21 S)-15-((2-(2-azidoethoxy)ethoxy)methyl)-21 -(tert-butyl)-l 5-methyl-19-oxo-

[0374] 2.5.7.10.13.17-hexaoxa-20-azadocosan-22-oyl)-4-hydroxy-W-(4-(4-methylthiazol-5- yl)benzyl)pyrrolidine-2 -carboxamide (63).

[0375] Follow General Procedure D, using carboxylic acid 56 and VH032-amine (14, synthesised through literature procedures2 5). Yield: 45 mg (78%); Contains a mixture of two diastereomers;1H NMR (400 MHz, CDCb): 6 = 8.66 (s, 1 H), 7.40-7.29 (m, 5H), 7.13 (d, J = 8.7 Hz, 1 H), 4.75-4.66 (m, 3H), 4.58- 4.45 (m, 3H), 4.32 (dd, J = 5.3, 15.0 Hz, 1 H), 4.05 (d, J = 10.8 Hz, 1 H), 3.92 (s, 2H), 3.71-3.49 (m, 19H), 3.45-3.27 (m, 11 H), 2.56-2.45 (m, 4H), 2.14-2.04 ppm (m, 1 H);13C NMR (101 MHz, CDCb): 6 = 171.4, 170.9, 170.5, 150.4, 148.6, 138.3, 131.7, 131.0, 129.6, 128.2, 95.7, 74.6, 74.0, 73.93, 73.91 , 73.8, 71 .9, 71 .2, 71 .1 , 70.8, 70.63, 70.57, 70.5, 70.2, 67.1 , 66.9, 59.1 , 58.6, 57.0, 56.7, 50.9, 43.3, 41 .1 , 36.0, 35.1 , 26.5, 17.6, 16.1 ; LC-MS m / z calc, for C41H66N7O12S [M+H]+880.4, found: 880.7.

[0376] (2S,4R)-1 -((S)-24-(tert-butyl)-18-(2,5,7,10,13,16-hexaoxaheptadecan-17-y l)-18-methyl-22-oxo- 2, 5, 7,10,13,16,20-heptaoxa-23-azapentacosan-25-oyl)-4-hydroxy-JV-(4-(4-methylthiazol-5- yl)benzyl)pyrrolidine-2 -carboxamide (64).

[0377] Follow General Procedure D, using carboxylic acid 57 and VH032-amine (14, synthesised through literature procedures2 5). Yield: 179 mg (73%);1H NMR (400 MHz, CDCb): 6 = 8.67 (s, 1 H), 7.40-7.29 (m, 5H), 7.13 (d, J = 8.9 Hz, 1 H), 4.73-4.67 (m, 5H), 4.58-4.46 (m, 3H), 4.32 (dd, J = 5.3, 15.0 Hz, 1 H), 4.03 (d, J = 11.3 Hz, 1 H), 3.93 (d, J = 15.4 Hz, 1 H), 3.87 (d, J = 15.5 Hz, 1 H), 3.71-3.49 (m, 33H), 3.43-3.26 (m, 12H), 2.55-2.45 (m, 4H), 2.09 (dd, J = 8.0, 13.2 Hz, 1 H), 0.95 (s, 3H), 0.94 ppm (s, 9H);13C NMR (101 MHz, CDCb): 6 = 171.4, 170.9, 170.4, 150.4, 148.5, 138.3, 131.7, 131.0, 129.6, 128.2, 95.7, 74.6, 73.9, 73.8, 71 .9, 71 .1 , 70.8, 70.71 , 70.68, 70.6, 70.5, 70.2, 67.0, 66.9, 59.1 , 58.6, 57.0, 56.7,

[0378] 43.3, 41.1 , 36.1 , 35.2, 26.5, 17.6, 16.1.

[0379] (2S,4 / ?)-1-((21S)-21-(tert-butyl)-15-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4- yl)amino)ethoxy)ethoxy)ethoxy)methyl)-15-methyl-19-oxo-2,4,7,10, 13,17-hexaoxa-20- azadocosan-22-oyl)-4-hydroxy-W-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2 -carboxamide (66).

[0380] Follow General Procedure H, using azide 59 and 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1 ,3- dione (19). Yield: 6 mg (47%); Contains a mixture of four diastereomers;1H NMR (500 MHz, CDCh): 6 = 9.34-9.09 (m, 1 H), 8.68 (s, 1 H), 7.51-7.29 (m, 6H), 7.17-7.12 (m, 1 H), 7.09 (d, J = 7.3 Hz, 1 H), 6.91 (dd, J = 6.5, 8.1 Hz, 1 H), 6.53-6.49 (m, 1 H), 4.95-4.81 (m, 1 H), 4.74-4.69 (m, 1 H), 4.64 (s, 2H), 4.62- 4.45 (m, 3H), 4.36-4.26 (m, 1 H), 4.12 (d, J = 11.0 Hz, 1 H), 3.97-3.89 (m, 2H), 3.78-3.50 (m, 23H), 3.48-3.25 (m, 11 H), 2.88-2.64 (m, 3H), 2.56-2.49 (m, 4H), 2.14-2.05 (m, 2H), 0.97-0.93 ppm (m, 12H); LC-MS m / z calc, for CseHsoNyOvS [M+H]+1154.5, found: 1155.1.

[0381] (2S,4R)-1-((21S)-21-(tert-butyl)-15-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4- yl)amino)ethoxy)ethoxy)ethoxy)methyl)-15-methyl-19-oxo-2,4,7,10, 13,17-hexaoxa-20- azadocosan-22-oyl)-4-hydroxy-W-((S)-1 -(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2- carboxamide (67).

[0382] Follow General Procedure H, using azide 60 and 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1 ,3- dione (19). Yield: 8 mg (43%); Contains a mixture of four diastereomers;1H NMR (500 MHz, CDCh): 6 = 9.26-9.01 (m, 1 H), 8.68 (s, 1 H), 7.53-7.44 (m, 2H), 7.42-7.35 (m, 4H), 7.22-7.15 (m, 1 H), 7.09 (d, J = 6.7 Hz, 1 H), 6.90 (dd, J = 2.9, 8.6 Hz, 1 H), 6.54-6.48 (m, 1 H), 5.08 (dq, J = 7.1 , 7.1 Hz, 1 H), 4.94- 4.87 (m, 1 H), 4.75-4.71 (m, 1 H), 4.65 (s, 2H), 4.57-4.47 (m, 2H), 4.13 (d, J = 11.7 Hz, 1 H), 3.99-3.91 (m, 2H), 3.77-3.51 (m, 23H), 3.48-3.28 (m, 11 H), 2.89-2.69 (m, 3H), 2.56-2.48 (m, 4H), 2.14-2.04 (m, 2H), 1.47 (d, J = 6.7 Hz, 3H), 1.05 (s, 9H), 0.98-0.95 ppm (m, 3H);13C NMR (126 MHz, CDCh): 6 = 171.9, 171.7, 171.6, 170.90, 170.88, 170.87, 170.8, 169.9, 169.8, 169.41 , 169.40, 168.81 , 168.79,

[0383] 168.78, 167.81 , 167.80, 150.4, 148.6, 147.0, 143.4, 136.2, 132.7, 131.8, 131.0, 129.7, 126.6, 116.9,

[0384] 111.78, 111.76, 110.50, 110.49, 96.7, 74.5, 74.1 , 73.9, 73.8, 71.32, 71.26, 71.2, 71.1 , 71.01 , 70.99, 70.97, 70.9, 70.82, 70.76, 70.73, 70.71 , 70.65, 70.53, 70.52, 70.3, 69.59, 69.57, 69.5, 66.9, 58.5, 57.2, 57.1 , 56.8, 55.3, 49.07, 49.05, 49.0, 42.5, 41 .1 , 35.7, 35.6, 35.1 , 35.1 , 35.0, 31 .6, 29.8, 26.6, 22.9, 22.4,

[0385] 22.3, 17.6, 16.2; LC-MS m / z calc, for C57H82N7O17S [M+H]+1168.5, found: 1169.2.

[0386] (2S,4 / ?)-1-((21S)-21-(tert-butyl)-15-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4- yl)amino)ethoxy)ethoxy)ethoxy)methyl)-15-methyl-19-0X0-2,5,7,10, 13,17-hexaoxa-20- azadocosan-22-oyl)-4-hydroxy-W-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2 -carboxamide (68).

[0387] Follow General Procedure H, using azide 61 and 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1 ,3- dione (19). Yield: 5 mg (32%); Contains a mixture of four diastereomers;1H NMR (500 MHz, CDCh): 6 = 9.33-9.08 (m, 1 H), 8.68 (s, 1 H), 7.51-7.40 (m, 2H), 7.39-7.33 (m, 4H), 7.18-7.12 (m, 1 H), 7.10 (d, J = 7.0 Hz, 1 H), 6.93-6.88 (m, 1 H), 6.54-6.48 (m, 1 H), 4.95-4.81 (m, 1 H), 4.74-4.70 (m, 3H), 4.64-4.45 (m, 3H), 4.36-4.27 (m, 1 H), 4.12 (d, J = 10.8 Hz, 1 H), 3.98-3.88 (m, 2H), 3.78-3.49 (m, 23H), 3.48- 3.26 (m, 11 H), 2.86-2.65 (m, 3H), 2.57-2.49 (m, 4H), 2.14-2.05 (m, 2H), 0.97-0.91 ppm (m, 12H);13C NMR (126 MHz, CDCb): 6 = 171.83, 171.79, 171.5, 171.4, 171.0, 170.9, 170.8, 169.4, 169.4, 168.8,

[0388] 167.8, 150.4, 148.6, 148.6, 147.0, 146.9, 138.5, 138.40, 138.38, 136.1 , 132.7, 131.8, 131.0, 129.59, 129.56, 128.34, 128.28, 116.9, 116.8, 111 .8, 111 .7, 1 10.5, 110.5, 95.7, 74.4, 74.0, 73.9, 73.8, 71.9,

[0389] 71.3, 71.23, 71.15, 71 .1 , 71.02, 70.96, 70.89, 70.86, 70.81 , 70.77, 70.7, 70.59, 70.57, 70.5, 70.39, 70.36, 69.6, 69.5, 67.1 , 66.9, 59.1 , 58.7, 58.6, 57.1 , 57.0, 56.9, 56.8, 49.3, 49.05, 49.00, 48.97, 43.4,

[0390] 42.6, 42.5, 41.1 , 36.2, 36.1 , 35.1 , 35.0, 31 .6, 26.5, 22.9, 17.6, 16.2; LC-MS m / z calc, for CseHsoNyOvS [M+H]+1154.5, found: 1155.2.

[0391] (2S,4 / ?)-1-((21 S)-21-(tert-butyl)-15-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1 ,3- dioxoisoindolin-5-yl)amino)ethoxy)ethoxy)ethoxy)methyl)-15-methyl-19-0X0-2,4,7,10,13,17- hexaoxa-20-azadocosan-22-oyl)-4-hydroxy-W-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2- carboxamide (69).

[0392] Follow General Procedure H, using azide 59 and 2-(2,6-dioxopiperidin-3-yl)-5,6-difluoroisoindoline-1 ,3- dione (65). Yield: 8 mg (62%); Contains a mixture of four diastereomers;1H NMR (500 MHz, CDCb): 6 = 8.68 (s, 1 H), 8.58 (d, J = 14.0 Hz, 1 H), 7.43-7.34 (m, 6H), 7.13-7.12 (m, 2H), 5.22-5.20 (m, 1 H), 4.90 (dd, J = 4.8, 12.0 Hz, 1 H), 4.72 (t, J = 7.9 Hz, 1 H), 4.64 (s, 2H), 4.58 (dd, J = 6.6, 14.9 Hz, 1 H), 4.54 (br. s, 1 H), 4.47 (d, J = 8.1 Hz, 1 H), 4.34 (dd, J = 4.3, 14.7 Hz, 1 H), 4.11 (d, J = 11.3 Hz, 1 H), 3.95-3.87 (m, 2H), 3.75 (t, J = 5.0 Hz, 2H), 3.70-3.50 (m, 21 H), 3.48-3.42 (m, 2H), 3.42-3.26 (m, 9H), 2.88-2.67 (m, 3H), 2.59-2.51 (m, 4H), 2.16-2.10 (m, 2H), 0.96-0.90 ppm (m, 12H);13C NMR (126 MHz, CDCb): 6 = 171.53, 171.50, 171 .48, 171.40, 171.38, 170.83, 170.82, 170.73, 170.71 , 168.49, 168.47,

[0393] 167.6, 167.05, 167.03, 153.98 (d, J C-F = 248.6 Hz), 150.4, 148.6, 143.2, 142.87 (d, J C-F = 12.6 Hz),

[0394] 138.3, 131.7, 131.0, 130.18, 130.16, 129.61 , 129.60, 128.3, 118.72 (d, J C-F = 7.4 Hz), 110.31 (d, J C- = 22.5 Hz), 105.99 (d, J C-F = 4.8 Hz), 96.7, 74.50, 74.48, 74.4, 73.9, 73.8, 71.2, 71.12, 71.10, 70.9,

[0395] 70.8, 70.75, 70.71 , 70.66, 70.6, 70.5, 70.33, 70.32, 69.2, 69.13, 69.10, 66.9, 58.6, 58.5, 57.1 1 , 57.08,

[0396] 56.8, 55.3, 49.4, 43.4, 43.1 , 41 .1 , 36.03, 36.00, 34.9, 31.6, 26.5, 22.9, 17.6, 16.2;19F NMR (471 MHz, CDCb): 6 = -127.33—127.44 (m, 1 F); LC-MS m / z calc, for C56H79FN7O17S [M+H]+1172.5, found: 1173.1.

[0397] (2S,4 / ?)-1-((21S)-21-(tert-butyl)-15-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1 ,3- dioxoisoindolin-5-yl)amino)ethoxy)ethoxy)ethoxy)methyl)-15-methyl-19-0X0-2,4,7,10,13,17- hexaoxa-20-azadocosan-22-oyl)-4-hydroxy-W-((S)-1 -(4-(4-methylthiazol-5- yl)phenyl)ethyl)pyrrolidine-2 -carboxamide (70).

[0398] Follow General Procedure H, using azide (60) and 2-(2,6-dioxopiperidin-3-yl)-5,6-difluoroisoindoline- 1 ,3-dione (65). Yield: 9 mg (47%); Contains a mixture of four diastereomers;1H NMR (500 MHz, CDCb): 6 = 8.67 (s, 1 H), 8.62-8.55 (m, 1 H), 7.46 (d, J = 7.3 Hz, 1 H), 7.42-7.39 (m, 3H), 7.36 (d, J = 8.3 Hz, 2H), 7.17 (d, J H-F = 8.7 Hz, 1 H), 7.13 (d, J = 6.9 Hz, 1 H), 5.25-5.20 (m, 1 H), 5.08 (dq, J = 7.0, 7.1 Hz, 1 H), 4.90 (dd, J = 5.3, 12.4 Hz, 1 H), 4.73 (t, J = 7.4 Hz, 1 H), 4.65 (s, 2H), 4.53-4.49 (m, 2H), 4.12 (d, J = 11 .2 Hz, 1 H), 3.93 (s, 2H), 3.75 (t, J = 4.9 Hz, 2H), 3.70-3.55 (m, 21 H), 3.48-3.29 (m, 1 1 H), 2.99 (br. s, 1 H), 2.91-2.69 (m, 3H), 2.58-2.53 (m, 4H), 2.16-2.09 (m, 1 H), 2.09-2.04 (m, 1 H), 1.49-1.45 (m, 3H), 1.05 (s, 9H), 0.97-0.96 ppm (m, 3H);13C NMR (126 MHz, CDCb): 5 = 171.71 , 171.68, 171.3, 170.8, 169.8, 168.50, 168.45, 167.6, 167.04, 167.01 , 153.98 (d, J C-F = 248.7 Hz), 150.4, 148.6, 143.3, 142.86 (d, J C-F = 12.7 Hz), 131.7, 131.0, 130.19 (d, J C-F = 1.9 Hz), 129.7, 126.6, 118.73 (d, J C-F = 8.8 Hz), 110.29 (d, J c-F = 22.3 Hz), 105.96 (d, J C-F = 5.2 Hz), 105.97, 96.7, 74.5, 74.0, 73.9, 73.8, 71 .2, 71.1 , 70.9, 70.78, 70.75, 70.73, 70.66, 70.6, 70.5, 70.3, 69.14, 69.09, 66.9, 58.5, 58.4, 57.2, 57.1 , 56.7, 55.3, 49.4, 49.0, 43.1 , 41 .1 , 35.5, 35.0, 31.6, 26.6, 22.9, 22.4, 17.6, 16.2;19F NMR (471 MHz, CDCb): 6 = -127.34— 127.44 (m, 1 F); LC-MS m / z calc, for C57H81FN7O17S [M+H]+1186.5, found: 1187.2.

[0399] (2S,4 / ?)-1-((21S)-21-(tert-butyl)-15-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3- dioxoisoindolin-5-yl)amino)ethoxy)ethoxy)ethoxy)methyl)-15-methyl-19-0X0-2,5,7,10,13,17- hexaoxa-20-azadocosan-22-oyl)-4-hydroxy-W-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2- carboxamide (71).

[0400] Follow General Procedure H, using azide 61 and 2-(2,6-dioxopiperidin-3-yl)-5,6-difluoroisoindoline-1 ,3- dione (65). Yield: 9 mg (57%); Contains a mixture of four diastereomers;1H NMR (500 MHz, CDCb): 6 = 8.68 (s, 1 H), 8.65-8.60 (m, 1 H), 7.43-7.33 (m, 6H), 7.13-711 (m, 2H), 5.24-5.18 (m, 1 H), 4.89 (dd, J = 4.5, 12.1 Hz, 1 H), 4.74-4.71 (m, 3H), 4.58 (dd, J = 6.6, 14.8 Hz, 1 H), 4.55-4.51 (m, 1 H), 4.47 (d, J = 8.6 Hz, 1 H), 4.34 (dd, J = 4.6, 15.5 Hz, 1 H), 4.10 (d, J = 11 .3 Hz, 1 H), 3.93 (d, J = 17.1 Hz, 1 H), 3.89 (d, J = 16.5 Hz, 1 H), 3.77-3.72 (m, 2H), 3.71-3.50 (m, 21 H), 3.48-3.42 (m, 2H), 3.42-3.34 (m, 5H), 3.31-3.26 (m, 4H), 2.90-2.67 (m, 3H), 2.58-2.51 (m, 4H), 2.16-2.10 (m, 2H), 0.96-0.91 ppm (m, 12H);13C NMR (126 MHz, CDCb): 6 = 171.5, 171.43, 171 .41 , 170.9, 170.70, 170.69, 168.52, 168.50, 167.05, 167.03, 153.98 (d, J C-F = 249.2 Hz), 150.4, 148.6, 142.85 (d, J C-F = 11.6 Hz), 138.35, 138.34, 131.7, 131.0, 130.17 (d, J C-F = 2.3 Hz), 129.60, 129.59, 128.3, 118.71 (d, J C-F = 9.3 Hz), 110.29 (d, J C-F = 22.4 Hz), 105.99 (d, J C-F = 4.5 Hz), 95.7, 74.5, 73.91 , 73.85, 73.8, 71 .9, 71 .2, 71 .1 , 70.9, 70.79, 70.78, 70.77, 70.74, 70.73, 70.69, 70.60, 70.59, 70.5, 70.32, 70.31 , 69.2, 69.12, 69.08, 67.1 , 66.9, 59.1 , 58.6,

[0401] 58.5, 57.10, 57.08, 57.06, 57.0, 56.8, 49.4, 43.4, 43.1 , 41 .1 , 36.0, 35.0, 31.6, 26.5, 22.9, 17.6, 16.2;19F NMR (471 MHz, CDCb): 6 = -127.32—127.44 (m, 1 F); LC-MS m / z calc, for C56H79FN7O17S [M+H]+

[0402] 1172.5, found: 1173.1.

[0403] (2S,4 / ?)-1-((21S)-21-(tert-butyl)-15-((2-(2-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3- dioxoisoindolin-5-yl)amino)ethoxy)ethoxy)methyl)-15-methyl-19-0X0-2,4,7,10, 13,17-hexaoxa-20- azadocosan-22-oyl)-4-hydroxy-W-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2 -carboxamide (72).

[0404] Follow General Procedure H, using azide 62 and 2-(2,6-dioxopiperidin-3-yl)-5,6-difluoroisoindoline-1 ,3- dione (65). Yield: 9 mg (47%); Contains a mixture of four diastereomers;1H NMR (500 MHz, CDCb): 6 = 8.97-8.92 (m, 1 H), 8.67 (s, 1 H), 7.47-7.42 (m, 1 H), 7.41-7.39 (m, 1 H), 7.36-7.31 (m, 4H), 7.15 (d, J = 8.7 Hz, 1 H), 7.12-7.09 (m, 1 H), 5.22-5.19 (m, 1 H), 4.91-4.86 (m, 1 H), 4.69 (t, J = 8.1 Hz, 1 H), 4.63 (s, 2H), 4.59-4.48 (m, 3H), 4.35-4.30 (m, 1 H), 4.07 (d, J = 11.3 Hz, 1 H), 3.94-3.85 (m, 2H), 3.71 (t, J = 4.8 Hz, 2H), 3.68-3.50 (m, 17H), 3.44 (d, J = 5.2 Hz, 1 H), 3.42 (d, J = 5.6 Hz, 1 H), 3.39-3.25 (m, 9H), 2.87-2.66 (m, 3H), 2.50-2.45 (m, 4H), 2.14-2.08 (m, 2H), 0.95 (s, 9H), 0.92-0.92 ppm (m, 3H);13C NMR (126 MHz, CDCb): 6 = 171.60, 171.56, 171.55, 171.34, 171.31 , 171.01 , 170.99, 170.98, 170.6, 168.7, 167.58, 167.56, 167.09, 167.06, 153.92 (d, J C-F = 249.5 Hz), 150.4, 148.6, 142.79 (d, J C-F = 12.7 Hz), 138.4, 138.4, 131 .74, 131.73, 130.96, 130.95, 130.1 , 129.5, 129.5, 128.2, 118.65 (d, J C-F = 8.2 Hz), 110.34 (d, J C-F = 22.3 Hz), 106.04-105.91 (m), 96.6, 74.52, 74.48, 74.4, 73.8, 73.74, 73.69, 73.67, 71.3, 71.21 , 71.16, 71.09, 71 .06, 70.89, 70.87, 70.71 , 70.68, 70.68, 70.6, 70.52, 70.48, 70.46, 70.3, 69.1 , 69.02, 69.00, 66.9, 58.73, 58.71 , 58.69, 58.67, 57.02, 57.00, 56.97, 56.8, 55.3, 49.4, 43.3, 43.1 , 41 .11 , 41 .09, 41 .07, 36.2, 36.2, 36.1 , 35.13, 35.11 , 35.1 , 31.6, 26.5, 22.8, 17.53, 17.51 , 17.50, 16.2;19F{1H} NMR (471 MHz, CDCb): 6 = -127.39—127.44 (m, 1 F); LC-MS m / z calc, for C54H75FN7O16S [M+H]+1128.5, found: 1128.4.

[0405] (2S,4 / ?)-1-((21 S)-21-(tert-butyl)-15-((2-(2-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1 ,3- dioxoisoindolin-5-yl)amino)ethoxy)ethoxy)methyl)-15-methyl-19-0X0-2,5,7,10,13,17-hexaoxa-20- azadocosan-22-oyl)-4-hydroxy-W-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2 -carboxamide (73).

[0406] Follow General Procedure H, using azide 63 and 2-(2,6-dioxopiperidin-3-yl)-5,6-difluoroisoindoline-1 ,3- dione (65). Yield: 6 mg (32%); Contains a mixture of four diastereomers;1H NMR (500 MHz, CDCb): 6 = 8.87-8.78 (m, 1 H), 8.67 (s, 1 H), 7.48-7.38 (m, 2H), 7.38-7.32 (m, 4H), 7.17-7.09 (m, 2H), 5.23-5.17 (m, 1 H), 4.92-4.87 (m, 1 H), 4.73 (s, 2H), 4.70 (t, J = 8.0 Hz, 1 H), 4.61-4.47 (m, 3H), 4.37-4.31 (m, 1 H), 4.10 (d, J = 9.8 Hz, 1 H), 3.94-3.86 (m, 2H), 3.74-3.50 (m, 19H), 3.48-3.27 (m, 11 H), 2.89-2.64 (m, 3H), 2.55-2.46 (m, 4H), 2.16-2.07 (m, 2H), 0.95 (s, 9H), 0.93-0.91 ppm (m, 3H);13C NMR (126 MHz, CDCb): 6 = 171.53, 171.48, 171.40, 171.39, 171.36, 171.0, 170.95, 170.93, 170.92, 170.7, 168.60, 168.59, 167.59, 167.58, 167.56, 167.56, 167.1 , 153.93 (d, J C-F = 248.2 Hz), 150.4, 148.6, 142.80 (d, J C-F = 13.1 Hz), 138.39, 138.38, 138.37, 138.36, 131.75, 131.73, 130.99, 130.98, 130.13 (d, C-F = 1.8 Hz), 129.57, 129.56, 129.56, 129.5, 128.2, 118.66 (d, J C-F = 8.9 Hz), 110.34 (d, J C-F = 23.0 Hz), 106.08- 105.98 (m), 95.7, 74.54, 74.49, 74.4, 73.9, 73.8, 73.7, 73.7, 71.9, 71.12, 71.11 , 71.09, 70.91 , 70.88, 70.57, 70.56, 70.5, 70.4, 70.31 , 70.30, 70.28, 69.14, 69.12, 69.11 , 69.04, 69.02, 69.01 , 67.04, 67.04, 66.9, 59.1 , 58.69, 58.67, 58.6, 58.6, 57.08, 57.06, 57.05, 57.0, 56.8, 56.80, 56.79, 56.78, 49.43, 49.42, 43.33, 43.32, 43.31 , 43.1 1 , 43.10, 43.09, 41.12, 41 .10, 41.08, 35.07, 35.06, 35.04, 35.02, 31.6, 26.5, 22.8, 17.54, 17.52, 17.50, 16.2;19F{1H} NMR (471 MHz, CDCb): 6 = -127.41— 127.45 (m, 1 F); LC-MS m / z calc, for C54H75FN7O16S [M+H]+1128.5, found: 1128.4.

[0407] (17S)-17-((2S,4 / ?)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1 - carbonyl)-11 -((2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)methyl)-11 ,18,18-trimethyl-15-oxo-3,6,9,13- tetraoxa-16-azanonadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2- f] [1 ,2,4]triazolo[4,3-a][1 ,4]diazepin-6-yl)acetate (74).

[0408] Follow General Procedure E, using 1.0 eq. of (+)-JQ1-acid (22) and 1.2 eq. of di-MEM protected compound 64. Yield: 40 mg (40%); Contains a mixture of two diastereomers;1H NMR (500 MHz, CDCb): 6 = 8.67 (s, 1 H), 7.42-7.38 (m, 3H), 7.36 (s, 4H), 7.32 (d, J = 8.5 Hz, 2H), 7.19 (d, J = 8.6 Hz, 1 H), 4.72 (t, J = 8.0 Hz, 1 H), 4.62-4.50 (m, 4H), 4.40-4.26 (m, 3H), 4.08 (d, J = 11 .1 Hz, 1 H), 3.99 (d, J = 15.4 Hz, 1 H), 3.92 (d, J = 15.4 Hz, 1 H), 3.74 (t, J = 4.7 Hz, 2H), 3.72-3.53 (m, 23H), 3.46-3.40 (m, 2H), 3.39-3.28 (m, 4H), 2.66 (s, 3H), 2.53-2.46 (m, 4H), 2.41 (s, 3H), 2.16 (dd, J = 8.1 , 13.3 Hz, 1 H), 1 .69 (s, 3H), 0.98 (s, 3H), 0.96 ppm (s, 9H);13C NMR (126 MHz, CDCb): 6 = 171 .7, 171 .4, 171 .1 , 170.6, 164.0, 155.5, 150.4, 150.0, 148.6, 138.4, 136.9, 136.8, 132.4, 131.8, 131.0, 130.9, 130.6, 130.0, 129.6, 128.8, 128.3, 74.4, 74.1 , 74.0, 73.8, 73.7, 72.8, 71.2, 71.10, 71.07, 71.0, 70.9, 70.7, 70.5, 70.2, 69.2,

[0409] 64.2, 61.8, 58.7, 57.0, 56.9, 53.9, 43.4, 41.2, 36.9, 36.3, 35.3, 26.5, 17.7, 16.2, 14.5, 13.2, 11.9; LC- MS m / z calc, for CeoH83CIN8Oi4S2 [M+2H]2+619.3, found: 619.7.

[0410] (17S)-17-((2S,4 / ?)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1 - carbonyl)-11 ,18,18-trimethyl-11 -((2-(2-(2-((methylsulfonyl)oxy)ethoxy)ethoxy)ethoxy)methyl)- 15-oxo-3, 6, 9, 13-tetraoxa-16-azanonadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H- thieno[3,2-f][1 ,2,4]triazolo[4,3-a][1 ,4]diazepin-6-yl)acetate (75).

[0411] Alcohol 74 (40 mg, 32.3 pmol) was dissolved in DCM (380 pL) before the addition of DIPEA (16.9 pL, 96.9 pmol) and cooling to 0°C. MsCI (2.5 pL, 32.3 pmol) was then added and the reaction was left to stir at 0°C for 20 min before stirring at r.t. for 1 h. LC-MS showed 1 :1 ratio of starting material to product, with no change after an additional 1 h of stirring. The flask was cooled to 0°C and additional MsCI (1 .3 pL, 16.2 pmol) was added. The flask was left to stir at 0°C for 20 min before stirring at r.t. for 30 min. Careful addition of MsCI is required due to the formation of di-mesyl product. The reaction was concentrated in vacuo and the residue purified by reverse phase flash column chromatography (50 g C18 gold column) using a linear gradient from 30% to 100% MeCN in 0.1 % HCOOH in water over 11 min to afford compound 75 as a mixture of two diastereomers. Yield: 19 mg (44%);1H NMR (500 MHz, CDCh): 6 = 8.67 (s, 1 H), 7.41-7.36 (m, 3H), 7.35 (s, 4H), 7.32 (d, J = 8.6 Hz, 2H), 7.17-7.13 (m, 1 H), 4.72 (t, J = 7.9 Hz, 1 H), 4.62-4.50 (m, 4H), 4.40-4.26 (m, 5H), 4.06 (d, J = 11 .2 Hz, 1 H), 3.95 (d, J = 15.2 Hz, 1 H), 3.90 (d, J = 15.3 Hz, 1 H), 3.76-3.71 (m, 4H), 3.70-3.53 (m, 19H), 3.42 (d, J = 9.0 Hz, 1 H), 3.40 (d, J = 9.3 Hz, 1 H), 3.37-3.28 (m, 4H), 3.05 (s, 3H), 2.66 (s, 3H), 2.53-2.46 (m, 4H), 2.41 (s, 3H), 2.16 (dd, J = 8.6, 13.2 Hz, 1 H), 1.68 (s, 3H), 0.99-0.96 (m, 3H), 0.95 ppm (s, 9H);13C NMR (126 MHz, CDCh): 6 = 171.6, 171.4, 171.1 , 170.4, 164.0, 155.5, 150.4, 150.0, 148.6, 138.4, 137.0, 136.7, 132.3, 131 .8, 131.04, 130.99, 130.6, 130.0, 129.6, 128.8, 128.3, 74.6, 74.0, 73.9, 73.8, 71.2, 71.1 , 70.93, 70.85, 70.72, 70.69, 70.53, 70.51 , 70.2, 69.4, 69.21 , 69.16, 64.2, 58.7, 57.0, 56.8, 53.9, 43.3,

[0412] 41.2, 37.8, 36.9, 36.3, 35.3, 26.5, 17.6, 16.1 , 14.5, 13.2, 11.9; LC-MS m / z calc, for CBI HSSCINSOIBSS [M+2H]2+658.3, found: 658.7. tert-butyl 4-(2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxoisoindolin-4-yl)piperazine-1 -carboxylate (76).

[0413] 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1 ,3-dione (19) (50 mg, 18.1 pmol) and 1-Boc-piperazine (37 mg, 20.0 pmol) were dissolved in DMSO (1.1 mL). DIPEA (126.7 pL, 72.4 pmol) was then added and the reaction was stirred and heated to 90°C in a closed microwave vial for 16 h. The mixture was then purified by reverse phase flash column chromatography (15.5 g C18 gold column) using a linear gradient from 0% to 100% MeCN in 0.1 % HCOOH in water over 8 min to afford compound 76 as a yellow / orange solid. Yield: 58 mg (73 %); Analytics were consistent with literature7;1H NMR (500 MHz, DMSO): 6 = 11 .06 (s, 1 H), 7.72 (dd, J = 7.4, 8.2 Hz, 1 H), 7.39 (d, J = 7.1 Hz, 1 H), 7.35 (d, J = 8.4 Hz, 1 H), 5.10 (dd, J = 5.5, 12.8 Hz, 1 H), 3.54-3.49 (m, 4H), 3.27-3.23 (m, 4H), 2.92-2.84 (m, 1 H), 2.63- 2.51 (m, 2H), 2.05-2.01 (m, 1 H), 1.43 ppm (s, 9H); LC-MS m / z calc, for C18H18N4O6 [M-(C(CH3)3)+H]+386.1 , found: 386.9. tert-butyl 4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1 ,3-dioxoisoindolin-5-yl)piperazine-1 - carboxylate (77).

[0414] 2-(2,6-dioxopiperidin-3-yl)-5,6-difluoroisoindoline-1 ,3-dione (65) (50 mg, 17.0 pmol) and 1-Boc- piperazine (35 mg, 18.7 pmol) were dissolved in DMSO (1.1 mL). DIPEA (118.5 pL, 68.0 pmol) was then added and the reaction was stirred and heated to 90°C in a closed microwave vial for 16 h. The mixture was then purified by reverse phase flash column chromatography (15.5 g C18 gold column) using a linear gradient from 0% to 100% MeCN in 0.1 % HCOOH in water over 8 min to afford compound 77 as a pale-yellow solid. Yield: 72 mg (91 %); Analytics were consistent with literature8;1H NMR (500 MHz, CDCh): 6 = 8.60 (br. s, 1 H), 7.47 (d, J H-F = 10.8 Hz, 1 H), 7.37 (d, H-F = 7.3 Hz, 1 H), 4.93 (dd, J = 5.6, 12.2 Hz, 1 H), 3.59 (dd, J = 4.9, 4.9 Hz, 4H), 3.20 (dd, J = 4.8, 4.8 Hz, 4H), 2.89-2.67 (m, 3H), 2.13-2.07 (m, 1 H), 1 .47 ppm (s, 9H);19F NMR (471 MHz, CDCh): 6 = -111 .01 (dd, J F-H = 7.4, 10.8 Hz, 1 F); LC-MS m / z calc, for C18H17FN4O6 [M-(C(CH3)3)+H]+404.1 , found: 404.9.

[0415] 2-((allyloxy)methyl)-2-(hydroxymethyl)propane-1 ,3-diol (79).

[0416] Pentaerythritol (78) (3.0 g, 22.0 mmol) was dissolved / suspended in DMF (44 mL) and cooled 0°C. 60% NaH in oil (1 .32 g, 33.0 mmol) was then added and the reaction was left to stir at 0°C for 15 min. Allyl bromide (2.23 mL, 26.4 mmol) was added dropwise and the reaction was left to stir at r.t. for 16 h. The mixture was then filtered through celite and evaporated to dryness. The residue was purified by flash column chromatography (80 g silica column) using a linear gradient from 0% to 20% MeOH in DCM to afford 79 as a colourless oil. Yield: 1.364 g (35%);1H NMR (400 MHz, CDCh): 6 = 5.93-5.83 (m, 1 H), 5.26 (qd, J = 1.6, 17.2 Hz, 1 H), 5.21 (qd, J = 1.3, 10.4 Hz, 1 H), 3.99 (td, J = 1.4, 5.6 Hz, 2H), 3.74 (d, J = 5.6 Hz, 6H), 3.50 (s, 2H), 2.38 ppm (t, J = 5.6 Hz, 3H);13C NMR (101 MHz, CDCh): 6 = 134.3, 117.6, 72.8, 72.6, 65.2, 45.1.

[0417] 2 -((allyloxy)methyl)-2-((2-(2-(2-azidoethoxy)ethoxy)ethoxy)methyl)propane-1 ,3-diol (80).

[0418] Follow General Procedure A, using 1.0 eq. triol 79, 1.2 eq. of NaH and 1 .0 eq. of mesylate 2-(2-(2- azidoethoxy)ethoxy)ethyl methanesulfonate (6). Purified by reverse phase flash column chromatography (50 g C18 gold column) using a linear gradient over 12 min from 0% to 100% MeCN in 0.1 % HCOOH in water. Yield: 155 mg (39%);1H NMR (400 MHz, CDCh): 6 = 5.94-5.82 (m, 1 H), 5.25 (dd, J = 1.5, 17.2 Hz, 1 H), 5.19 (dd, J = 1.2, 10.4 Hz, 1 H), 3.98 (d, J = 5.3 Hz, 2H), 3.70-3.62 (m, 14H), 3.59 (s, 2H), 3.48 (s, 2H), 3.42-3.36 (m, 2H), 2.76 ppm (br. s, 2H);13C NMR (101 MHz, CDCh): 6 = 134.5, 1 17.3, 72.7, 72.3, 70.88, 70.87, 70.7, 70.5, 70.2, 65.1 , 50.9, 45.2.

[0419] 15-((allyloxy)methyl)-15-((2-(2-(2-azidoethoxy)ethoxy)ethoxy)methyl)-2,4,7,10,13,17,20,23,26,28- decaoxanonacosane (81).

[0420] Follow General Procedure A, using 1.0 eq. diol 80, 4.0 eq. of NaH and 3.0 eq. of MOM mesylate 40. Purified by reverse phase flash column chromatography (30 g C18 gold column) using a linear gradient over 10 min from 0% to 100% MeCN in 0.1 % HCOOH in water. Yield: 191 mg (62%);1H NMR (400 MHz, CDCh): 6 = 5.93-5.83 (m, 1 H), 5.24 (dd, J = 1.6, 17.3 Hz, 1 H), 5.12 (d, J = 10.4 Hz, 1 H), 4.66 (s, 4H), 3.93 (d, J = 5.2 Hz, 2H), 3.72-3.52 (m, 34H), 3.46-3.36 ppm (m, 16H);13C NMR (101 MHz, CDCh): 5 = 135.5, 116.1 , 96.7, 72.4, 71.2, 71.0, 70.84, 70.78, 70.72, 70.66, 70.6, 70.3, 70.2, 69.4, 67.0, 55.3, 50.9, 45.7.

[0421] 15-((2-(2-(2-azidoethoxy)ethoxy)ethoxy)methyl)-15-(2,4,7,10,13-pentaoxatetradecan-14-yl)-

[0422] 2.4.7.10.13.17-hexaoxanonadecan-19-al (82).

[0423] Follow General Procedure B, using alkene 81. Yield: 154 mg (81 %);1H NMR (400 MHz, CDCh): 6 = 9.73 (s, 1 H), 4.65 (s, 4H), 4.01 (s, 2H), 3.72-3.53 (m, 36H), 3.48-3.35 ppm (m, 14H);13C NMR (101 MHz, CDCh): 6 = 202.4, 96.7, 71.2, 70.9, 70.82, 70.77, 70.72, 70.65, 70.6, 70.2, 70.0, 67.0, 55.3, 50.9, 45.8.

[0424] 15-((2-(2-(2-azidoethoxy)ethoxy)ethoxy)methyl)-15-(2,4,7,10,13-pentaoxatetradecan-14-yl)-

[0425] 2.4.7.10.13.17-hexaoxanonadecan-19-oic acid (83).

[0426] Follow General Procedure C, using aldehyde 82. Yield: 155 mg (quant.);1H NMR (400 MHz, CDCh): 6 = 4.65 (s, 4H), 3.98 (s, 2H), 3.72-3.54 (m, 36H), 3.49-3.45 (m, 6H), 3.42-3.35 ppm (m, 8H);13C NMR (101 MHz, CDCh): 6 = 173.8, 96.5, 72.3, 71.2, 71.1 , 71.0, 70.9, 70.63, 70.60, 70.5, 70.41 , 70.37, 70.3, 70.1 , 70.0, 66.7, 55.2, 50.7, 45.1 .

[0427] (2S,4R)-1 -((S)-15-((2-(2-(2-azidoethoxy)ethoxy)ethoxy)methyl)-21 -(tert-butyl)-l 9-oxo-15- (2, 4, 7,10,13-pentaoxatetradecan-14-y l)-2 ,4,7 ,10,13,17-hexaoxa-20-azadocosan-22-oyl)-4- hydroxy-W-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2 -carboxamide (84).

[0428] Follow General Procedure D, using carboxylic acid 83 and VH032-amine (14, synthesised through literature procedures2 5). Yield: 51 mg (64%);1H NMR (400 MHz, CDCh): 6 = 8.65 (s, 1 H), 7.41-7.28 (m, 5H), 7.13 (d, J = 8.8 Hz, 1 H), 4.68 (t, J = 7.5 Hz, 1 H), 4.62 (s, 4H), 4.58-4.48 (m, 3H), 4.32 (dd, J = 5.2, 15.0 Hz, 1 H), 4.00 (d, J = 11 .1 Hz, 1 H), 3.93 (d, J = 15.3 Hz, 1 H), 3.88 (d, J = 15.0 Hz, 1 H), 3.68- 3.45 (m, 37H), 3.42 (s, 6H), 3.38-3.32 (m, 8H), 2.54-2.44 (m, 4H), 2.29 (br. s, 1 H), 2.09 (dd, J = 8.3, 13.0 Hz, 1 H), 0.93 ppm (s, 9H);13C NMR (101 MHz, CDCh): 6 = 171.3, 170.9, 170.3, 150.3, 148.5, 138.3, 131.7, 131.0, 129.5, 128.2, 96.6, 71.2, 71 .1 , 71 .03, 70.98, 70.8, 70.7, 70.6, 70.5, 70.4, 70.09, 70.07, 66.9, 58.6, 56.9, 56.7, 55.2, 50.8, 45.6, 43.3, 36.0, 35.2, 26.5, 16.1 ; LC-MS m / z calc, for CsiHseCINyOisS [M+H]+1 116.6, found: 1116.4.

[0429] (2S,4 / ?)-1-((21 S)-21-(tert-butyl)-15-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1 ,3- dioxoisoindolin-5-yl)amino)ethoxy)ethoxy)ethoxy)methyl)-19-oxo-15-(2,4,7,10,13- pentaoxatetradecan-14-yl)-2,4,7,10,13,17-hexaoxa-20-azadocosan-22-oyl)-4-hydroxy-W-(4-(4- methylthiazol-5-yl)benzyl)pyrrolidine-2 -carboxamide (85).

[0430] Follow General Procedure H, using azide 84 and 2-(2,6-dioxopiperidin-3-yl)-5,6-difluoroisoindoline-1 ,3- dione (65). Purified by HPLC using a linear gradient of 5% to 95% MeCN in 0.1 % HCOOH in water over 15 min gradient. Yield: 27 mg (55%); Contains a mixture of two diastereomers;1H NMR (500 MHz, CDCh): 6 = 8.68 (s, 1 H), 8.66-8.61 (m, 1 H), 7.45-7.38 (m, 2H), 7.38-7.32 (m, 4H), 7.14-7.11 (m, 2H), 5.28-5.22 (m, 1 H), 4.90 (dd, J = 5.2, 12.0 Hz, 1 H), 4.71 (t, J = 7.4 Hz, 1 H), 4.64 (s, 4H), 4.57 (dd, J = 6.6, 14.9 Hz, 1 H), 4.53 (s, 1 H), 4.49 (d, J = 8.8 Hz, 1 H), 4.35 (dd, J = 5.1 , 14.7 Hz, 1 H), 4.08 (d, J = 11 .3 Hz, 1 H), 3.94 (d, J = 15.4 Hz, 1 H), 3.88 (d, J = 15.3 Hz, 1 H), 3.75 (t, J = 5.1 Hz, 2H), 3.70-3.35 (m, 49H), 2.90-2.66 (m, 3H), 2.56-2.48 (m, 4H), 2.16-2.10 (m, 2H), 1.81 (br. s, 1 H), 0.94 ppm (s, 9H);13C NMR (126 MHz, CDCb): 6 = 171.5, 171.42, 171.36, 170.9, 170.6, 168.53, 168.49, 167.5, 167.04, 167.02, 153.96 (d, J C-F = 248.1 Hz), 150.4, 148.6, 142.84 (d, J C-F = 12.5 Hz), 138.37, 138.35, 131.7, 131.0, 130.16 (d, J C-F = 1.8 Hz), 129.60, 129.58, 128.3, 118.68 (d, J C-F = 8.9 Hz), 110.30 (d, C-F = 21.3 Hz), 106.01-105.96 (m), 96.7, 71.13, 71.05, 71.0, 70.7, 70.6, 70.5, 70.4, 70.3, 70.0, 69.2, 69.1 ,

[0431] 66.9, 58.6, 58.6, 57.02, 56.99, 56.8, 55.3, 49.4, 45.7, 43.3, 43.1 , 43.0, 36.10, 36.06, 35.1 , 31.6, 26.5,

[0432] 22.9, 16.2;19F NMR (471 MHz, CDCb): 6 = -127.24—127.33 (m, 1 F); LC-MS m / z calc, for C64H95FN7O22S [M+H]+1364.6, found: 1365.0.

[0433] 11 -((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1 ,3-dioxoisoindolin-5- yl)amino)ethoxy)ethoxy)ethoxy)methyl)-11-((2-(((S)-1 -((2S,4 / ?)-4-hydroxy-2-((4-(4-methylthiazol- 5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1 -oxobutan-2-yl)amino)-2- oxoethoxy)methyl)-3,6,9,13,16,19-hexaoxahenicosane-1 ,21 -diyl bis(2-((S)-4-(4-chlorophenyl)- 2,3,9-trimethyl-6H-thieno[3,2-f][1 ,2,4]triazolo[4,3-a][1 ,4]diazepin-6-yl)acetate) (AB3124) (86).

[0434] Follow General Procedure E, using compound 85 and 3.0 eq of JQ1-acid (22). Purified by HPLC using a linear gradient from 20% to 95% MeCN in 0.1 % HCOOH in water over 15 min. Yield: 8.9 mg (22%); Contains a mixture of two diastereomers;1H NMR (500 MHz, CDCb): 6 = 8.68 (s, 1 H), 8.60 (s, 1 H),

[0435] 7.49-7.44 (m, 1 H), 7.41-7.30 (m, 13H), 7.18 (d, J = 8.8 Hz, 1 H), 7.10 (d, J H-F = 7.2 Hz, 1 H), 5.35-5.29 (m, 1 H), 4.89 (dd, J = 5.2, 12.0 Hz, 1 H), 4.71 (t, J = 8.0 Hz, 1 H), 4.60 (t, J = 7.0 Hz, 2H), 4.58-4.53 (m, 3H), 4.38 (dd, J = 5.4, 14.9 Hz, 1 H), 4.35-4.24 (m, 4H), 4.04 (d, J = 11.1 Hz, 1 H), 3.95 (d, J = 15.4 Hz, 1 H), 3.90 (d, J = 15.2 Hz, 1 H), 3.77-3.70 (m, 6H), 3.70-3.41 (m, 40H), 2.88-2.66 (m, 9H), 2.50 (s, 3H),

[0436] 2.49-2.40 (m, 7H), 2.20 (dd, J = 7.8, 13.0 Hz, 1 H), 2.14-2.07 (m, 1 H), 1.68 (s, 6H), 0.96 ppm (s, 9H);13C NMR (126 MHz, CDCb): 6 = 171 .7, 171.4, 171.35, 171.28, 171.18, 171.15, 170.2, 168.51 , 168.47, 167.5, 167.03, 167.01 , 164.0, 162.8, 155.4, 153.94 (d, J C-F = 248.6 Hz), 150.4, 150.1 , 148.5, 142.88 (d, J C-F = 12.8 Hz), 138.5, 136.9, 136.7, 132.3, 131.8, 131.02, 130.98, 130.9, 130.5, 130.16 (d, J C-F = 1.8 Hz), 130.0, 129.54, 129.53, 128.8, 128.2, 118.58 (d, J C-F = 8.9 Hz), 1 10.27 (d, J C-F = 21.9 Hz), 105.96 (d, J C-F = 5.5 Hz), 71.2, 71.1 , 70.8, 70.7, 70.6, 70.5, 70.4, 70.2, 70.0, 69.2, 69.14, 69.09, 64.1 ,

[0437] 58.9, 56.9, 56.8, 53.8, 49.4, 45.7, 36.9, 36.6, 35.6, 31.6, 26.5, 22.9, 16.2, 14.6, 13.2, 1 1.9;19F{1H} NMR (471 MHz, CDCb): 6 = -127.22*, -127.26* (1 F); HRMS m / z calc, for C98H117CI2FN15O22S3 [M+H]+2040.7015, found: 2040.6797.

[0438] 5,6-difluoro-2-(1 -methyl-2,6-dioxopiperidin-3-yl)isoindoline-1 ,3-dione (87).

[0439] 2-(2,6-dioxopiperidin-3-yl)-5,6-difluoroisoindoline-1 ,3-dione (65) (50 mg, 17.0 pmol) was dissolved in DMF (500 pL). K2CO3 (47 mg, 34.0 pmol) was then added, and the flask was cooled to 0°C under N2. Methyl iodide (29 mg, 20.4 pmol) was then added, and the reaction was stirred vigorously at r.t. for 5.5 h. The reaction was filtered with PTFE syringe filters before concentrating under vacuum. The residue was purified by reverse phase flash column chromatography (15.5 g C18 gold column) using a linear gradient over 9 min from 0% to 70% MeCN in 0.1 % HCOOH in water to afford 87 as a white solid. Yield: 42 mg (80%);1H NMR (500 MHz, CDCb): 6 = 7.69 (dd, J H-H = 7.2, J H-F = 7.2 Hz, 2H), 4.99-4.94 (m, 1 H), 3.18 (s, 3H), 3.05-2.91 (m, 1 H), 2.83-2.73 (m, 2H), 2.15-2.06 ppm (m, 1 H);13C NMR (126 MHz, CDCb): 6 = 171.0, 168.5, 165.5, 154.76 (dd, J C-F = 15.6, 262.3 Hz), 128.71 (dd, J C-F = 5.6, 5.6 Hz), 113.78 (dt, J C-F = 10.1 , 16.5 Hz), 50.6, 31.9, 27.4, 22.0;19F NMR (471 MHz, CDCb): 6 = -124.58 (dd, J F-F = 7.3, J F-H = 7.3, 2F). LC-MS m / z calc, for C14H11F2N2O4 [M+H]+309.1 , found: 309.0.

[0440] (2S,4S)-1 -((21 S)-15-((2-(2-(2-azidoethoxy)ethoxy)ethoxy)methyl)-21 -(tert-butyl)-l 5-methyl-19- oxo-2, 4, 7,10,13,17-hexaoxa-20-azadocosan-22-oyl)-4-hydroxy-W-((S)-1 -(4-(4-methylthiazol-5- yl)phenyl)ethyl)pyrrolidine-2 -carboxamide (89).

[0441] Follow General Procedure D, using carboxylic acid 53 and c / s-Me-VH032-amine (88, synthesised according to literature procedures6). Yield: 50 mg (56%); Contains a mixture of two diastereomers;1H NMR (500 MHz, CDCb): 6 = 8.79 (s, 1 H), 7.64 (d, J = 7.9 Hz, 1 H), 7.40 (d, J = 8.3 Hz, 2H), 7.37 (d, J = 8.3 Hz, 2H), 7.09 (d, J = 9.1 Hz, 1 H), 5.06 (dq, J = 7.1 , 7.1 Hz, 1 H), 4.72 (d, J = 9.0 Hz, 1 H), 4.62 (s, 2H), 4.53 (d, J = 9.2 Hz, 1 H), 4.46-4.42 (m, 1 H), 3.97-3.89 (m, 3H), 3.79 (d, J = 11.1 Hz, 1 H), 3.68- 3.52 (m, 22H), 3.43 (d, J = 9.0 Hz, 1 H), 3.39 (d, J = 8.9 Hz, 1 H), 3.38-3.29 (m, 9H), 2.54 (s, 3H), 2.31 (d, J = 14.0 Hz, 1 H), 2.13 (ddd, J = 5.0, 9.2, 14.2 Hz, 1 H), 1.48 (d, J = 6.8 Hz, 3H), 1.04 (s, 9H), 0.98 ppm (s, 3H);13C NMR (126 MHz, CDCb): 6 = 171.9, 171.7, 169.9, 150.7, 147.9, 142.8, 132.0, 130.8,

[0442] 129.7, 126.6, 96.6, 74.6, 73.9, 73.8, 71.12, 71.09, 71.07, 70.9, 70.8, 70.72, 70.68, 70.6, 70.55, 70.47, 70.1 , 66.8, 59.9, 58.7, 56.4, 55.2, 50.7, 49.3, 41.1 , 35.3, 34.8, 26.5, 22.0, 17.5, 15.8; LC-MS m / z calc, for C44H70N7O13S [M-H]- 936.5, found: 936.3.

[0443] (2S,4R)-1 -((21 S)-21 -(tert-butyl)-l 5-((2-(2-(2-((6-f I uoro-2-(1 -methyl-2,6-dioxopiperidin-3-yl)-1 ,3- dioxoisoindolin-5-yl)amino)ethoxy)ethoxy)ethoxy)methyl)-15-methyl-19-0X0-2,4,7,10,13,17- hexaoxa-20-azadocosan-22-oyl)-4-hydroxy-W-((S)-1 -(4-(4-methylthiazol-5- yl)phenyl)ethyl)pyrrolidine-2 -carboxamide (90).

[0444] Follow General Procedure H, using azide 60 and thalidomide derivative 87. Yield: 13 mg (27%); Contains a mixture of four diastereomers;1H NMR (500 MHz, CDCb): 6 = 8.68 (s, 1 H), 7.44 (d, J = 7.7 Hz, 1 H), 7.42-7.38 (m, 3H), 7.36 (d, J = 8.3 Hz, 2H), 7.18 (d, J = 8.6 Hz, 1 H), 7.08 (d, J H-F = 7.1 Hz, 1 H), 5.31-5.24 (m, 1 H), 5.07 (dq, J = 7.0, 7.1 Hz, 1 H), 4.93-4.88 (m, 1 H), 4.73 (t, J = 7.6 Hz, 1 H), 4.64 (s, 2H), 4.54-4.48 (m, 2H), 4.10 (d, J = 11.7 Hz, 1 H), 3.95 (d, J = 15.9 Hz, 1 H), 3.92 (d, J = 16.2 Hz, 1 H), 3.75 (t, J = 5.0 Hz, 2H), 3.70-3.53 (m, 21 H), 3.46-3.38 (m, 4H), 3.38-3.31 (m, 7H), 3.19 (s, 3H), 3.01-2.92 (m, 1 H), 2.82-2.70 (m, 2H), 2.56-2.47 (m, 4H), 2.12-2.04 (m, 2H), 1.47 (d, J = 6.9 Hz, 3H), 1.05 (s, 9H), 0.98 ppm (s, 3H);13C NMR (126 MHz, CDCb): 6 = 171.6, 171.3, 170.7, 169.8, 169.1 ,

[0445] 167.7, 167.2, 162.8, 154.0 (d, J C-F = 249.0 Hz), 150.5, 148.5, 143.3, 142.73 (d, J C-F = 12.7 Hz), 131.7, 130.9, 130.2, 129.7, 126.6, 118.79 (d, C-F = 9.0 Hz), 110.24 (d, C-F = 22.7 Hz), 105.81 (d, C-F = 5.2 Hz), 96.6, 74.5, 73.9, 71.2, 71.1 , 70.9, 70.7, 70.64, 70.57, 70.5, 70.2, 68.9, 66.9, 58.4, 57.1 , 56.7, 55.3, 50.2, 49.0, 43.0, 41.1 , 35.5, 35.1 , 32.1 , 27.4, 26.6, 22.4, 22.2, 17.6, 16.2;19F NMR (471 MHz, CDCb): 6 = -127.29— 127.35 (m, 1 F); LC-MS m / z calc, for C58H83N7O17S [M+H]+1200.6, found: 1200.4. (25.45)-1-((21S)-21-(tert-butyl)-15-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3- dioxoisoindolin-5-yl)amino)ethoxy)ethoxy)ethoxy)methyl)-15-methyl-19-0X0-2,4,7,10,13,17- hexaoxa-20-azadocosan-22-oyl)-4-hydroxy-W-((S)-1 -(4-(4-methylthiazol-5- yl)phenyl)ethyl)pyrrolidine-2 -carboxamide (91).

[0446] Follow General Procedure H, using azide 89 and 2-(2,6-dioxopiperidin-3-yl)-5,6-difluoroisoindoline-1 ,3- dione (65). Yield: 11 mg (34%); Contains a mixture of four diastereomers;1H NMR (500 MHz, CDCh): 6 = 8.89-8.65 (m, 2H), 7.76-7.69 (m, 1 H), 7.44-7.40 (m, 3H), 7.38 (d, J = 8.3 Hz, 2H), 7.14-7.09 (m, 2H), 5.62-5.57 (m, 1 H), 5.26-5.20 (m, 1 H), 5.08 (dq, J = 7.0, 7.1 Hz, 1 H), 4.93-4.87 (m, 1 H), 4.72 (d, J = 8.4 Hz, 1 H), 4.64 (s, 2H), 4.58-4.53 (m, 1 H), 4.49-4.43 (m, 1 H), 3.97-3.90 (m, 3H), 3.86-3.81 (m, 1 H), 3.77-3.74 (m, 2H), 3.70-3.51 (m, 20H), 3.48-3.25 (m, 11 H), 2.91-2.66 (m, 3H), 2.53 (s, 3H), 2.30 (d, J = 14.3 Hz, 1 H), 2.19-2.09 (m, 2H), 1.52-1.47 (m, 3H), 1.06 (s, 9H), 0.97-0.93 ppm (m, 3H);13C NMR (126 MHz, CDCh): 6 = 171.99, 171.94, 171.73, 171.71 , 171.51 , 171.45, 171.4, 170.1 , 168.5, 168.4, 167.5, 167.0, 153.98 (d, J C-F = 248.7 Hz), 150.5, 148.7, 142.85 (d, J C-F = 12.4 Hz), 142.60, 142.57, 131.6, 131.3, 130.2, 129.8, 126.6, 118.75 (d, J C-F = 8.6 Hz), 110.30 (d, J C-F = 22.6 Hz), 105.97- 105.91 (m), 96.7, 74.5, 73.9, 71.21 , 71.19, 71.1 , 71.0, 70.8, 70.74, 70.65, 70.6, 70.5, 69.1 , 69.0, 66.9,

[0447] 60.2, 60.1 , 58.8, 56.5, 55.3, 49.4, 49.4, 43.0, 41 .1 , 35.3, 35.05, 35.01 , 31 .6, 26.5, 22.9, 22.0, 17.5, 16.2;19F NMR (471 MHz, CDCh): 6 = -127.22— 127.38 (m, 1 F); LC-MS m / z calc, for C57H81FN7O17S [M+H]+1186.5, found: 1186.4.

[0448] (25.45)-1 -((21 S)-21 -(tert-butyl)-l 5-((2-(2-(2-((6-f I uoro-2-(1 -methyl-2,6-dioxopiperidin-3-yl)-1 ,3- dioxoisoindolin-5-yl)amino)ethoxy)ethoxy)ethoxy)methyl)-15-methyl-19-0X0-2,4,7,10,13,17- hexaoxa-20-azadocosan-22-oyl)-4-hydroxy-W-((S)-1 -(4-(4-methylthiazol-5- yl)phenyl)ethyl)pyrrolidine-2 -carboxamide (92).

[0449] Follow General Procedure H, using azide 89 and thalidomide derivative 87. Yield: 9.5 mg (30%); Contains a mixture of four diastereomers;1H NMR (500 MHz, CDCh): 6 = 8.68 (s, 1 H), 7.62 (d, J = 7.8 Hz, 1 H), 7.44-7.39 (m, 3H), 7.37 (d, J = 8.3 Hz, 2H), 7.12-7.07 (m, 2H), 5.45 (d, J = 8.9 Hz, 1 H), 5.23 (dd, J = 4.8, 8.4 Hz, 1 H), 5.08 (dq, J = 7.1 , 7.2 Hz, 1 H), 4.93-4.87 (m, 1 H), 4.74 (d, J = 9.0 Hz, 1 H), 4.64 (s, 2H), 4.56 (d, J = 9.2 Hz, 1 H), 4.49-4.44 (m, 1 H), 3.98-3.91 (m, 3H), 3.82 (d, J = 10.8 Hz, 1 H), 3.75 (t, J = 4.9 Hz, 2H), 3.70-3.54 (m, 20H), 3.46-3.39 (m, 4H), 3.38-3.32 (m, 7H), 3.19 (s, 3H), 3.01- 2.92 (m, 1 H), 2.82-2.70 (m, 2H), 2.53 (s, 3H), 2.34 (d, J = 14.4 Hz, 1 H), 2.17-2.06 (m, 2H), 1.50 (d, J = 6.8 Hz, 3H), 1.07 (s, 9H), 0.99 ppm (s, 3H);13C NMR (126 MHz, CDCh): 6 = 172.0, 171.7, 171.3, 170.0, 169.1 , 167.7, 167.2, 154.01 (d, J C-F = 248.1 Hz), 150.5, 148.7, 142.71 (d, C-F = 12.9 Hz), 142.5, 131 .6, 131 .3, 130.2, 118.89 (d, J C-F = 8.9 Hz), 110.29 (d, J C-F = 22.4 Hz), 105.79 (d, J C-F = 4.9 Hz), 96.7, 74.6, 73.95, 73.91 , 71 .22, 71 .16, 71 .0, 70.8, 70.7, 70.61 , 70.55, 68.9, 66.9, 60.0, 58.9, 56.5, 55.3,

[0450] 50.2, 49.4, 43.0, 41.2, 35.4, 34.9, 32.1 , 27.4, 26.5, 22.2, 22.0, 17.6, 16.2;19F NMR (471 MHz, CDCh): 6 = -127.38— 127.42 (m, 1 F); LC-MS m / z calc, for C58H83N7O17S [M+H]+1200.6, found: 1200.8. (17S)-11 -((2-(2-(2-((6-f I uoro-2-(1 -methyl-2,6-dioxopiperidin-3-yl)-1 ,3-dioxoisoindolin-5- yl)amino)ethoxy)ethoxy)ethoxy)methyl)-17-((2S,4 / ?)-4-hydroxy-2-(((S)-1 -(4-(4-methylthiazol-5- yl)phenyl)ethyl)carbamoyl)pyrrolidine-1 -carbonyl)-11 ,18,18-trimethyl-15-oxo-3,6,9,13-tetraoxa- 16-azanonadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f|[1 ,2,4]triazolo[4,3- a][1 ,4]diazepin-6-yl)acetate neg-AB3067 (93).

[0451] Follow General Procedure E, using compound 90 and 1.5 eq of JQ1-acid (22). Purified by HPLC using a linear gradient over 10 min from 30% to 95% MeCN in 0.1 % HCOOH in water. Yield: 2.2 mg (13%); Contains a mixture of four diastereomers;1H NMR (500 MHz, CDCh): 6 = 8.67 (s, 1 H), 7.44 (d, J = 7.9 Hz, 1 H), 7.42-7.34 (m, 7H), 7.32 (d, J = 8.6 Hz, 2H), 7.18 (d, J = 8.4 Hz, 1 H), 7.08 (d, J H-F = 7.0 Hz, 1 H), 5.30-5.25 (m, 1 H), 5.08 (dq, J = 7.2, 7.2 Hz, 1 H), 4.90 (dd, J = 5.5, 12.5 Hz, 1 H), 4.74 (t, J = 7.9 Hz, 1 H), 4.60 (dd, J = 6.2, 7.9 Hz, 1 H), 4.55-4.49 (m, 2H), 4.36-4.26 (m, 2H), 4.11 (d, J = 1 1 .3 Hz, 1 H), 3.98-3.90 (m, 2H), 3.77-3.73 (m, 4H), 3.68-3.56 (m, 19H), 3.47-3.40 (m, 4H), 3.39-3.31 (m, 4H), 3.19 (s, 3H), 2.98-2.93 (m, 1 H), 2.82-2.70 (m, 2H), 2.66 (s, 3H), 2.55-2.48 (m, 4H), 2.41 (s, 3H), 2.12-2.06 (m, 2H), 1 .68 (s, 3H), 1 .48 (d, J = 7.0 Hz, 3H), 1 .06 (s, 9H), 1 .00-0.98 ppm (m, 3H);19F{1H} NMR (471 MHz, CDCh): 6 = -127.31*, -127.31*, -127.34*, -127.34* (1 F); HRMS m / z calc. for C75H94CIFNiiOi7S2[M+H]+1538.5938, found: 1538.6122.

[0452] (17S)-11 -((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1 ,3-dioxoisoindolin-5- yl)amino)ethoxy)ethoxy)ethoxy)methyl)-17-((2S,4S)-4-hydroxy-2-(((S)-1 -(4-(4-methylthiazol-5- yl)phenyl)ethyl)carbamoyl)pyrrolidine-1 -carbonyl)-11 ,18,18-trimethyl-15-oxo-3,6,9,13-tetraoxa- 16-azanonadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f|[1 ,2,4]triazolo[4,3- a][1 ,4]diazepin-6-yl)acetate C / S-AB3067 (94).

[0453] Follow General Procedure E, using compound 91 and 1.5 eq of JQ1-acid (22). Purified by HPLC using a linear gradient over 10 min from 30% to 95% MeCN in 0.1 % HCOOH in water. Yield: 1.2 mg (8%); Contains a mixture of four diastereomers;1H NMR (500 MHz, CDCh): 6 = 8.74-8.55 (m, 2H), 7.76- 7.71 (m, 1 H), 7.43-7.36 (m, 7H), 7.32 (d, J = 8.6 Hz, 2H), 7.14-7.09 (m, 2H), 5.60-5.56 (m, 1 H), 5.28- 5.24 (m, 1 H), 5.09 (dq, J = 7.1 , 7.2 Hz, 1 H), 4.93-4.87 (m, 1 H), 4.73 (d, J = 9.0 Hz, 1 H), 4.60 (dd, J = 6.1 , 7.9 Hz, 1 H), 4.56 (t, J = 8.0 Hz, 1 H), 4.48-4.43 (m, 1 H), 4.33-4.29 (m, 2H), 3.96-3.88 (m, 3H), 3.86-3.82 (m, 1 H), 3.77-3.73 (m, 4H), 3.68-3.53 (m, 18H), 3.48-3.29 (m, 8H), 2.90-2.70 (m, 3H), 2.66 (s, 3H), 2.53 (s, 3H), 2.41 (s, 3H), 2.31 (d, J = 14.0 Hz, 1 H), 2.18-2.10 (m, 2H), 1.68 (s, 3H), 1.52-1.47 (m, 3H), 1 .07 (s, 9H), 0.98-0.94 ppm (m, 3H);19F{1H} NMR (471 MHz, CDCh): 6 = -127.24*, -127.28*, -127.32*, -127.35* (1 F); HRMS m / z calc, for C74H92CIFN11O17S2 [M+H]+1524.5781 , found: 1524.7015.

[0454] (17S)-11 -((2-(2-(2-((6-f I uoro-2-(1 -methyl-2,6-dioxopiperidin-3-yl)-1 ,3-dioxoisoindolin-5- yl)amino)ethoxy)ethoxy)ethoxy)methyl)-17-((2S,4S)-4-hydroxy-2-(((S)-1 -(4-(4-methylthiazol-5- yl)phenyl)ethyl)carbamoyl)pyrrolidine-1 -carbonyl)-11 ,18,18-trimethyl-15-oxo-3,6,9,13-tetraoxa- 16-azanonadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f|[1,2,4]triazolo[4,3- a][1 ,4]diazepin-6-yl)acetate neg-c / s-AB3067 (95).

[0455] Follow General Procedure E, using compound 92 and 1.5 eq of JQ1-acid (22). Purified by HPLC using a linear gradient over 10 min from 30% to 95% MeCN in 0.1 % HCOOH in water. Yield: 0.7 mg (9%); Contains a mixture of four diastereomers;1H NMR (500 MHz, CDCh): 6 = 8.68 (s, 1 H), 7.65 (d, J = 8.1 Hz, 1 H), 7.39 (q, J = 9.9 Hz, 7H), 7.32 (d, J = 8.7 Hz, 2H), 7.11 (d, J = 9.2 Hz, 1 H), 7.08 (d, J H-F = 7.1 Hz, 1 H), 5.48 (d, J = 9.1 Hz, 1 H), 5.29-5.24 (m, 1 H), 5.08 (dq, J = 7.2, 7.2 Hz, 1 H), 4.90 (dd, J = 5.2, 12.3 Hz, 1 H), 4.75 (d, J = 9.0 Hz, 1 H), 4.60 (dd, J = 6.2, 7.9 Hz, 1 H), 4.56 (d, J = 9.3 Hz, 1 H), 4.48- 4.43 (m, 1 H), 4.35-4.27 (m, 2H), 3.98-3.92 (m, 3H), 3.82 (d, J = 10.9 Hz, 1 H), 3.77-3.73 (m, 4H), 3.70- 3.56 (m, 19H), 3.47-3.40 (m, 4H), 3.38-3.33 (m, 4H), 3.19 (s, 3H), 3.01-2.93 (m, 1 H), 2.82-2.70 (m, 2H), 2.66 (s, 3H), 2.53 (s, 3H), 2.41 (s, 3H), 2.33 (d, J = 14.2 Hz, 1 H), 2.17-2.07 (m, 2H), 1.68 (s, 3H), 1 .50 (d, J = 6.9 Hz, 3H), 1 .07 (s, 9H), 1 .00 ppm (s, 3H);19F{1H} NMR (471 MHz, CDCh): 6 = -127.37*, -127.37*, -127.37*, -127.37* (1 F); HRMS m / z calc, for C75H94CIFN11 O17S2 [M+H]+1538.5938, found: 1538.6201.

[0456] (17S)-11 -((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1 ,3-dioxoisoindolin-5- yl)amino)ethoxy)ethoxy)ethoxy)methyl)-17-((2S,4 / ?)-4-hydroxy-2-(((S)-1 -(4-(4-methylthiazol-5- yl)phenyl)ethyl)carbamoyl)pyrrolidine-1 -carbonyl)-11 ,18,18-trimethyl-15-oxo-3,6,9,13-tetraoxa- 16-azanonadecyl (2 / ?)-2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2- f][1 ,2,4]triazolo[4,3-a][1 ,4]diazepin-6-yl)butanoate (AB3145) (97).

[0457] Follow General Procedure E, using compound 70 and 1.5 eq of ET-JQ1-OH (96, synthesised through literature procedures46). Purified by HPLC using a linear gradient over 10 min from 30% to 95% MeCN in 0.1 % HCOOH in water. Yield: 2.2 mg (16%); Contains a mixture of four diastereomers;1H NMR (500 MHz, CDCh): 6 = 8.67 (s, 1 H), 8.53-8.48 (m, 1 H), 7.48 (d, J = 7.8 Hz, 1 H), 7.42-7.35 (m, 5H), 7.35- 7.29 (m, 4H), 7.19 (d, J = 9.0 Hz, 1 H), 7.12 (d, J H-F = 7.1 Hz, 1 H), 5.31-5.26 (m, 1 H), 5.08 (dq, J = 7.1 , 7.2 Hz, 1 H), 4.90 (dd, J = 5.3, 12.0 Hz, 1 H), 4.73 (dd, J = 7.8, 7.8 Hz, 1 H), 4.55-4.49 (m, 2H), 4.47- 4.41 (m, 1 H), 4.37-4.33 (m, 1 H), 4.24 (d, J = 10.9 Hz, 1 H), 4.12 (d, J = 11.1 Hz, 1 H), 4.01-3.88 (m, 3H), 3.82-3.72 (m, 4H), 3.70-3.53 (m, 17H), 3.48-3.28 (m, 8H), 2.91-2.68 (m, 3H), 2.66 (s, 3H), 2.53- 2.47 (m, 4H), 2.41 (s, 3H), 2.17-2.06 (m, 3H), 1 .73-1.57 (m, 4H), 1.47 (dd, J = 2.4, 6.9 Hz, 3H), 1.06- 0.99 (m, 12H), 0.98-0.94 ppm (m, 3H);19F{1H} NMR (471 MHz, CDCh) 6 = -127.23*, -127.26*, -127.26*, -127.30* (1 F); LC-MS m / z calc, for C76H9637CIFNiiOi7S2[M(37CI)+H]+1554.6, found: 1554.0.

[0458] References

[0459] 1. Pettersson, M.; Crews, C. M., PROteolysis TArgeting Chimeras (PROTACs) — Past, present and future. Drug Discov Today Technol. 2019, 31, 15-27.

[0460] 2. Bekes, M.; Langley, D. R.; Crews, C. M., PROTAC targeted protein degraders: the past is prologue. Nat Rev Drug Discov. 2022, 27 (3), 181-200.

[0461] 3. Cromm, P. M.; Crews, C. M., Targeted protein degradation: From chemical biology to drug discovery. Cell Chem Biol. 2017, 24 (9), 1181-1190.

[0462] 4. Adjei, A. A., What is the right dose? The elusive optimal biologic dose in Phase I clinical trials. J Clin Oncol. 2006, 24 (25), 4054-4055.

[0463] 5. Holohan, C.; Van Schaeybroeck, S.; Longley, D. B.; Johnston, P. G., Cancer drug resistance: an evolving paradigm. Nat Rev. Cancer 2013, 73 (10), 714-726.

[0464] 6. Samarasinghe, K. T. G.; Crews, C. M., Targeted protein degradation: A promise for undruggable proteins. Cell Chem Biol. 2021, 28 (7), 934-951.

[0465] 7. Longley, D.; Johnston, P., Molecular mechanisms of drug resistance. J Pathol. 2005, 205 (2), 275-292.

[0466] 8. Mares, A.; Miah, A. H.; Smith, I. E. D.; Rackham, M.; Thawani, A. R.; Cryan, J.; Haile, P. A.; Votta, B. J.; Beal, A. M.; Capriotti, C.; Reilly, M. A.; Fisher, D. T.; Zinn, N.; Bantscheff, M.; MacDonald, T. T.; Vossenkamper, A.; Dace, P.; Churcher, I.; Benowitz, A. B.; Watt, G.; Denyer, J.; Scott-Stevens, P.; Hading, J. D., Extended pharmacodynamic responses observed upon PROTAC- mediated degradation of RIPK2. Commun Biol. 2020, 3 (1), 140.

[0467] 9. Burke, M. R.; Smith, A. R.; Zheng, G., Overcoming cancer drug resistance utilizing PROTAC technology. Front Cell Dev Biol. 2022, 10.

[0468] 10. Passirani, C.; Vessieres, A.; La Regina, G.; Link, W.; Silvestri, R., Modulating undruggable targets to overcome cancer therapy resistance. Drug Resist Updat. 2022, 60, This article is a preprint and has not been certified by peer review.

[0469] 11. Chan, K.-H.; Zengerle, M.; Testa, A.; Ciulli, A., Impact of target warhead and linkage vector on inducing protein degradation: comparison of bromodomain and extra-terminal (BET) degraders derived from triazolodiazepine (JQ1) and tetrahydroquinoline (I-BET726) BET inhibitor scaffolds. J Med Chem. 2018, 67 (2), 504-513.

[0470] 12. Gadd, M. S.; Testa, A.; Lucas, X.; Chan, K.-H.; Chen, W.; Lamont, D. J.; Zengerle, M.; Ciulli, A., Structural basis of PROTAC cooperative recognition for selective protein degradation. Nat Chem Biol. 2017, 73 (5), 514-521.

[0471] 13. Nowak, R. P.; DeAngelo, S. L.; Buckley, D.; He, Z.; Donovan, K. A.; An, J.; Safaee, N.; Jedrychowski, M. P.; Ponthier, C. M.; Ishoey, M.; Zhang, T.; Mancias, J. D.; Gray, N. S.; Bradner, J. E.; Fischer, E. S., Plasticity in binding confers selectivity in ligand-induced protein degradation. Nat Chem Biol. 2018, 14 (7), 706-714.

[0472] 14. Farnaby, W.; Koegl, M.; Roy, M. J.; Whitworth, C.; Diers, E.; Trainor, N.; Zollman, D.; Steurer, S.; Karolyi-Oezguer, J.; Riedmueller, C.; Gmaschitz, T.; Wachter, J.; Dank, C.; Galant, M.; Sharps, B.; Rumpel, K.; Traxler, E.; Gerstberger, T.; Schnitzer, R.; Petermann, O.; Greb, P.; Weinstabl, H.; Bader, G.; Zoephel, A.; Weiss-Puxbaum, A.; Ehrenhofer-Wolfer, K.; Wohrle, S.; Boehmelt, G.; Rinnenthal, J.; Arnhof, H.; Wiechens, N.; Wu, M.-Y.; Owen-Hughes, T.; Ettmayer, P.; Pearson, M.; McConnell, D. B.; Ciulli, A., BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design. Nat Chem Biol. 2019, 75 (7), 672-680.

[0473] 15. Roy, M. J.; Winkler, S.; Hughes, S. J.; Whitworth, C.; Galant, M.; Farnaby, W.; Rumpel, K.; Ciulli, A., SPR-Measured dissociation kinetics of PROTAC ternary complexes influence target degradation rate. ACS Chem Biol. 2019, 14 (3), 361-368.

[0474] 16. Ottis, P.; Palladino, C.; Thienger, P.; Britschgi, A.; Heichinger, C.; Berrera, M.; Julien- Laferriere, A.; Roudnicky, F.; Kam-Thong, T.; Bischoff, J. R.; Martoglio, B.; Pettazzoni, P., Cellular resistance mechanisms to targeted protein degradation converge toward impairment of the engaged ubiquitin transfer pathway. ACS Chem Biol. 2019, 14 (10), 2215-2223.

[0475] 17. Shirasaki, R.; Matthews, G. M.; Gandolfi, S.; de Matos Simoes, R.; Buckley, D. L.; Raja Vora, J.; Sievers, Q. L.; Bruggenthies, J. B.; Dashevsky, O.; Poarch, H.; Tang, H.; Bariteau, M. A.; Sheffer, M.; Hu, Y.; Downey-Kopyscinski, S. L.; Hengeveld, P. J.; Glassner, B. J.; Dhimolea, E.; Ott, C. J.; Zhang, T.; Kwiatkowski, N. P.; Laubach, J. P.; Schlossman, R. L.; Richardson, P. G.; Culhane, A. C.; Groen, R. W. J.; Fischer, E. S.; Vazquez, F.; Tsherniak, A.; Hahn, W. C.; Levy, J.; Auclair, D.; Licht, J. D.; Keats, J. J.; Boise, L. H.; Ebert, B. L.; Bradner, J. E.; Gray, N. S.; Mitsiades, C. S., Functional genomics identify distinct and overlapping genes mediating resistance to different classes of heterobifunctional degraders of oncoproteins. Cell Rep. 2021, 34 (1). 18. Mayor-Ruiz, C.; Jaeger, M. G.; Bauer, S.; Brand, M.; Sin, C.; Hanzl, A.; Mueller, A. C.; Menche, J.; Winter, G. E., Plasticity of the Cullin-RING Ligase repertoire shapes sensitivity to ligand- induced protein degradation. Mol. Cell 2019, 75 (4), 849-858. e8.

[0476] 19. Zhang, L.; Riley-Gillis, B.; Vijay, P.; Shen, Y., Acquired resistance to BET-PROTACs (proteolysis-targeting chimeras) caused by genomic alterations in core components of E3 ligase complexes. Mol Cancer Ther. 2019, 18 (7), 1302-1311 .

[0477] 20. Winter, G. E.; Mayer, A.; Buckley, D. L.; Erb, M. A.; Roderick, J. E.; Vittori, S.; Reyes, J. M.; di lulio, J.; Souza, A.; Ott, C. J.; Roberts, J. M.; Zeid, R.; Scott, T. G.; Paulk, J.; Lachance, K.; Olson, C. M.; Dastjerdi, S.; Bauer, S.; Lin, C. Y.; Gray, N. S.; Kelliher, M. A.; Churchman, L. S.; Bradner, J. E., BET Bromodomain proteins function as master transcription elongation factors independent of CDK9 recruitment. Mol. Cell 2017, 67 (1), 5-18. e19.

[0478] 21 . Zengerle, M.; Chan, K.-H.; Ciulli, A., Selective small molecule induced degradation of the BET bromodomain protein BRD4. ACS Chem Biol. 2015, 10 (8), 1770-1777.

[0479] 22. Raina, K.; Lu, J.; Qian, Y.; Altieri, M.; Gordon, D.; Rossi, A. M. K.; Wang, J.; Chen, X.; Dong, H.; Siu, K.; Winkler, J. D.; Crew, A. P.; Crews, C. M.; Coleman, K. G., PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer. PNAS 2016, 113 (26), 7124- 7129.

[0480] 23. Imaide, S.; Riching, K. M.; Makukhin, N.; Vetma, V.; Whitworth, C.; Hughes, S. J.; Trainor, N.; Mahan, S. D.; Murphy, N.; Cowan, A. D.; Chan, K.-H.; Craigon, C.; Testa, A.; Maniaci, C.; Urh, M.; Daniels, D. L.; Ciulli, A., Trivalent PROTACs enhance protein degradation via combined avidity and cooperativity. Nat Chem Biol. 2021, 17 (11), 1157-1167.

[0481] 24. Bradner, J.; Buckley, D.; Winter, G. E. Methods to induce targeted protein degradation through bifunctional molecules. WO / 2017 / 007612, 2017.

[0482] 25. Girardini, M.; Maniaci, C.; Hughes, S. J.; Testa, A.; Ciulli, A., Cereblon versus VHL: Hijacking E3 ligases against each other using PROTACs. Bioorg Med Chem. 2019, 27 (12), 2466-2479.

[0483] 26. Powell, C. E.; Du, G.; Bushman, J. W.; He, Z.; Zhang, T.; Fischer, E. S.; Gray, N. S., Selective degradation-inducing probes for studying cereblon (CRBN) biology. RSC Med Chem. 2021, 72 (8), 1381-1390.

[0484] 27. Steinebach, C.; Kehm, H.; Lindner, S.; Vu, L. P.; Kbpff, S.; Lopez Marmol, A.; Weiler, C.; Wagner, K. G.; Reichenzeller, M.; Krbnke, J.; Gutschow, M., PROTAC-mediated crosstalk between E3 ligases. Chem Commun. 2019, 55 (12), 1821-1824.

[0485] 28. Galdeano, C.; Gadd, M. S.; Soares, P.; Scaffidi, S.; Van Molle, I.; Birced, I.; Hewitt, S.; Dias, D. M.; Ciulli, A., Structure-guided design and optimization of small molecules targeting the proteinprotein interaction between the von Hippel-Lindau (VHL) E3 ubiquitin ligase and the hypoxia inducible factor (HIF) alpha subunit with in vitro nanomolar affinities. J Med Chem. 2014, 57 (20), 8657-8663.

[0486] 29. Steinebach, C.; Voell, S. A.; Vu, L. P.; Bricelj, A.; Sosic, I.; Schnakenburg, G.; Gutschow, M., A facile synthesis of ligands for the von Hippel-Lindau E3 ligase. Synthesis 2020, 52 (17), 2521- 2527.

[0487] 30. Riching, K. M.; Mahan, S.; Corona, C. R.; McDougall, M.; Vasta, J. D.; Robers, M. B.; Urh, M.; Daniels, D. L., Quantitative live-cell kinetic degradation and mechanistic profiling of PROTAC mode of action. ACS Chem Biol. 2018, 13 (9), 2758-2770.

[0488] 31. Lopez-Girona, A.; Mendy, D.; Ito, T.; Miller, K.; Gandhi, A. K.; Kang, J.; Karasawa, S.; Carmel, G.; Jackson, P.; Abbasian, M.; Mahmoudi, A.; Gathers, B.; Rychak, E.; Gaidarova, S.; Chen, R.; Schafer, P. H.; Handa, H.; Daniel, T. O.; Evans, J. F.; Chopra, R., Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 2012, 26 (11), 2326-2335.

[0489] 32. Soares, P.; Gadd, M. S.; Frost, J.; Galdeano, C.; Ellis, L.; Epemolu, O.; Rocha, S.; Read, K. D.; Ciulli, A., Group-based optimization of potent and cell-Active inhibitors of the von Hippel-Lindau (VHL) E3 ubiquitin ligase: structure-activity relationships leading to the chemical probe (2S,4R)-1-((S)- 2-(1-cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5- yl)benzyl)pyrrolidine-2-carboxamide (VH298). J Med Chem. 2018, 61 (2), 599-618.

[0490] 33. Klein, V. G.; Bond, A. G.; Craigon, C.; Lokey, R. S.; Ciulli, A., Amide-to-ester substitution as a strategy for optimizing PROTAC permeability and cellular activity. J Med Chem. 2021, 64 (24), 18082- 18101.

[0491] 34. Bond, A. G.; Craigon, C.; Chan, K.-H.; Testa, A.; Karapetsas, A.; Fasimoye, R.; Macartney, T.; Blow, J. J.; Alessi, D. R.; Ciulli, A., Development of BromoTag: A “bump-and-hole”-PROTAC system to induce potent, rapid, and selective degradation of tagged target proteins. J Med Chem. 2021, 64 (20), 15477-15502.

[0492] 35. Hu, J.; Hu, B.; Wang, M.; Xu, F.; Miao, B.; Yang, C.-Y.; Wang, M.; Liu, Z.; Hayes, D. F.; Chinnaswamy, K.; Delproposto, J.; Stuckey, J.; Wang, S., Discovery of ERD-308 as a highly potent proteolysis targeting chimera (PROTAC) degrader of estrogen receptor (ER). J Med Chem. 2019, 62 (3), 1420-1442.

[0493] 36. Buhimschi, A. D.; Armstrong, H. A.; Toure, M.; Jaime-Figueroa, S.; Chen, T. L.; Lehman, A. M.; Woyach. J. A.; Johnson, A. J.; Byrd, J. C.; Crews, C. M., Targeting the C481 S Ibrutinib-resistance mutation in Bruton’s Tyrosine Kinase using PROTAC-mediated degradation. Biochemistry 2018, 57 (26), 3564-3575.

[0494] 37. Petrylak, D. P.; Gao, X.; Vogelzang, N. J.; Garfield, M. H.; Taylor, I.; Dougan Moore, M.; Peck, R. A.; Burris, H. A., First-in-human phase I study of ARV-110, an androgen receptor (AR) PROTAC degrader in patients (pts) with metastatic castrate- resista nt prostate cancer (mCRPC) following enzalutamide (ENZ) and / or abiraterone (ABI). J Clin Oncol. 2020, 38 (15_suppl), 3500-3500.

[0495] 38. Lin, X.; Xiang, H.; Luo, G., Targeting estrogen receptor a for degradation with PROTACs: A promising approach to overcome endocrine resistance. EurJ Med Chem. 2020, 206, 112689.

[0496] 39. Burslem, G. M.; Ottis, P.; Jaime-Figueroa, S.; Morgan, A.; Cromm, P. M.; Toure, M.; Crews, C. M., Efficient synthesis of immunomodulatory drug analogues enables exploration of structuredegradation relationships. ChemMedChem 2018, 73 (15), 1508-1512.

[0497] 40. Degorce, S. L.; Tavana, O.; Banks, E.; Crafter, C.; Gingipalli, L.; Kouvchinov, D.; Mao, Y.; Paehl, F.; Solanki, A.; Valge-Archer, V.; Yang, B.; Edmondson, S. D., Discovery of proteolysistargeting chimera molecules that selectively degrade the IRAK3 pseudokinase. J Med Chem. 2020, 63 (18), 10460-10473.

[0498] 41. Zhou, Z.; Long, J.; Wang, Y.; Li, Y.; Zhang, X.; Tang, L.; Chang, Q.; Chen, Z.; Hu, G.; Hu, S.; Li, Q.; Peng, C.; Chen, X., Targeted degradation of CD147 proteins in melanoma. Bioorganic Chemistry 2020, 105, 104453.

[0499] 42. Posternak, G.; Tang, X.; Maisonneuve, P.; Jin, T.; Lavoie, H.; Daou, S.; Orlicky, S.; Goullet de Rugy, T.; Caldwell, L.; Chan, K.; Aman, A.; Prakesch, M.; Poda, G.; Mader, P.; Wong, C.; Maier, S.; Kitaygorodsky, J.; Larsen, B.; Colwill, K.; Yin, Z.; Ceccarelli, D. F.; Batey, R. A.; Taipale, M.; Kurinov, I.; Uehling, D.; Wrana, J.; Durocher, D.; Gingras, A.-C.; Al-Awar, R.; Therrien, M.; Sicheri, F., Functional characterization of a PROTAC directed against BRAF mutant V600E. Nat Chem Biol. 2020, 76 (11), 1170-1178.

[0500] 43. Machleidt, T.; Woodroofe, C. C.; Schwinn, M. K.; Mendez, J.; Robers, M. B.; Zimmerman, K.; Otto, P.; Daniels, D. L.; Kirkland, T. A.; Wood, K. V., NanoBRET — A novel BRET platform for the analysis of protein-protein interactions. ACS Chem Biol. 2015, 10 (8), 1797-1804.

[0501] 44. Rock, K. L.; Gramm, C.; Rothstein, L.; Clark, K.; Stein, R.; Dick, L.; Hwang, D.; Goldberg, A. L., Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 1994, 78 (5), 761-771.

[0502] 45. Nabet, B.; Roberts, J. M.; Buckley, D. L.; Paulk, J.; Dastjerdi, S.; Yang, A.; Leggett, A. L.; Erb, M. A.; Lawlor, M. A.; Souza, A.; Scott, T. G.; Vittori, S.; Perry, J. A.; Qi, J.; Winter, G. E.; Wong, K.-K.; Gray, N. S.; Bradner, J. E., The dTAG system for immediate and target-specific protein degradation. Nat Chem Biol. 2018, 14 (5), 431-441 .

[0503] 46. Bond, A. G.; Testa, A.; Ciulli, A., Stereoselective synthesis of allele-specific BET inhibitors. Organic & Biomolecular Chemistry 2020, 78 (38), 7533-7539.

Claims

Claims1. A compound of formula (I) :wherein m, n and 0 are each independently selected from 0, 1 , 2, 3, 4, 5 and 6; wherein R is selected from H, Me; wherein G is selected from H, Me; wherein W is selected fromwherein X is selected fromwherein Z is selected from H, F; wherein Y is selected from -NH- and -O-; wherein U is selected from H, Me, Et, Pr, and iPr; wherein Ti and T2 are each independently selected from H and OH; and wherein X is attached to the thalidomide-derivative of the compound at the 3-C or 4-C position; or a pharmaceutically acceptable, salt, enantiomer, stereoisomer, hydrate, solvate, or polymorph thereof.

2. A compound of formula (I) according to claim 1 , wherein the compound of formula (I) has a formula (IA):wherein m, n and o are each independently selected from 0, 1 , 2, 3, 4, 5 and 6; wherein R is selected from H, Me; wherein W is selected fromwherein X is selected fromwherein Z is selected from H, F; wherein Y is selected from -NH- and-O-; wherein U is selected from H, Me, Et, Pr, and iPr; wherein Ti and T2 are each independently selected from H and OH; and wherein X is attached to the thalidomide-derivative of the compound at the 3-C or 4-C position; or a pharmaceutically acceptable, salt, enantiomer, stereoisomer, hydrate, solvate, or polymorph thereof.

3. A compound of (I) according to claims 1 or 2, the compound having a formula (IB):wherein m, and n are each independently selected from 0, 1 , 2, 3, 4, 5 and 6; wherein X is selected fromwherein R is selected from H and Me; wherein Z is selected from H and F; wherein Y is selected from -NH- and-O-; wherein U is selected from H, Me, Et, Pr, and iPr; wherein Ti and T2 are each independently selected from H and OH; and wherein X is attached to the thalidomide-derivative of the compound at the 3-C or 4-C position; or a pharmaceutically acceptable, salt, enantiomer, stereoisomer, hydrate, solvate, or polymorph thereof.

4. A compound of (I) according to claims 1 or 2, the compound having a formula (IC):wherein m, n and 0 are each independently selected from 0, 1 , 2, 3, 4, 5 and 6; wherein X is selected fromwherein R is selected from H and Me; wherein Z is selected from H and F; wherein Y is selected from -NH- and-O-; wherein U is selected from H, Me, Et, Pr, and iPr; wherein T1 and T2 are each independently selected from H and OH; and wherein X is attached to the thalidomide-derivative of the compound at the 3-C or 4-C position; or a pharmaceutically acceptable, salt, enantiomer, stereoisomer, hydrate, solvate, or polymorph thereof.

5. A compound according to any preceding claim, wherein X is attached to the thalidomide- derivative of the compound at the 3-C position; or wherein X is attached to the thalidomide-derivative of the compound at the 4-C position.

6. A compound according to any preceding claim, wherein Ti and T2 are each independently selected from H and OH, optionally wherein T1 is OH and T2 is H7. A compound according to any preceding claim, wherein m and n are each independently selected from 2 or 3, optionally wherein one of:(i) Both m and n are 3;(ii) m is 3 and n is 2;(iii) m is 2 and n is 3;(iv) both m and n are 2;(v) both m and n are 1 ; further optionally, wherein both m and n are 3.

8. A compound according to any preceding claim, wherein U is selected from H, Me, Et, Pr, and iPr, optionally wherein U is selected from H and Et.

9. A compound according to any preceding claim, wherein Y is -O-orwherein Y is -NH-, optionally wherein Y is -NH-.

10. A compound according to any preceding claim, wherein R is H.11 . A compound according to any one of claims 1 to 9, wherein R is Me.

12. A compound according to any preceding claim, wherein X is13. A compound according to any one of claims 1 to 11 , wherein X is14. A compound according to claim 1 , 2 or 4 to 13, when depending from claims 1 , 2 or 4, wherein o is selected from 2 or 3, optionally wherein o is 3.

15. A compound according to any preceding claim, wherein the compound is selected from:or a pharmaceutically acceptable, salt, enantiomer, stereoisomer, hydrate, solvate, or polymorph thereof.

16. A compound according to any preceding claim, wherein the compound is selected from:or a pharmaceutically acceptable, salt, enantiomer, stereoisomer, hydrate, solvate, or polymorph thereof.

17. A compound according to claim 15 or 16, wherein the compound is selected from:or a pharmaceutically acceptable, salt, enantiomer, stereoisomer, hydrate, solvate, or polymorph thereof.

18. A compound according to any one of claims 15 to 17, wherein the compound is selected from:or a pharmaceutically acceptable, salt, enantiomer, stereoisomer, hydrate, solvate, or polymorph thereof.

19. A pharmaceutical composition comprising a compound as defined in any preceding claim and a pharmaceutically acceptable vehicle or diluent therefor.

20. A compound according to any one of claims 1 to 18 for use as a medicament.A compound according to any one of claims 1 to 18, or a pharmaceutical composition as defined in claim 19, for the prophylaxis or treatment of one of: a. a disease or condition associated with deregulation of protein activity of one or more proteins within the Bromo- and Extra-terminal (BET) family of proteins BRD2, BRD3 and BRD4; or b. a disease or condition associated with selective degradation of the BRD4 protein within the bromodomain of the BET family of proteins; c. a disease or condition associated with deregulation of BET protein activity.

Citation Information

Patent Citations

  • Methods to induce targeted protein degradation through bifunctional molecules

    WO2017007612A1

  • Antibody protac conjugates

    WO2019140003A1

  • Improved small molecules

    WO2022101603A1

Cited By

  • Protac compounds binding keap1 ubiquitin ligase for targeted protein degradation

    WO2025083472A3